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DISSERTATION ABSTRACT 
 
Steven A. Romero 
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
December 2014 
 
Title:  Sustained Post-exercise Vasodilation: Histaminergic Mechanisms and 
Adaptations 
 
 Blood flow to the previously active skeletal muscle remains elevated for several 
hours following an acute bout of aerobic exercise and is dependent on activation of H1 
and H2 histamine receptors. Many questions remain unanswered in humans regarding the 
mechanisms mediating this sustained post-exercise vasodilation and what benefits come 
of this physiological phenomenon. The studies detailed in this dissertation were designed 
to examine the upstream mechanisms and explore a potential benefit associated with 
sustained post-exercise vasodilation. 
In chapter IV, we examined if oxidative stress is the upstream exercise-related 
factor mediating sustained post-exercise vasodilation. Intravenously infusing the 
antioxidant ascorbate blunted sustained post-exercise vasodilation, and this reduction was 
similar in magnitude to that observed with H1\H2 blockade. However, ascorbate may 
directly degrade histamine and may also inhibit its formation. Therefore, we conducted a 
follow-up study to verify the findings in study 1. In this study, we intravenously infused 
n-acetylcysteine, a potent antioxidant with no known histaminergic interactions. We 
found that n-acetylcysteine had no effect on sustained post-exercise vasodilation, 
indicating that exercise-induced oxidative stress is not the exercise related factor 
mediating sustained post-exercise vasodilation.  
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In chapter V, we attempted to measure interstitial histamine in an effort to 
demonstrate that exercise induces the local formation of histamine in previously active 
skeletal muscle. We found that histamine is increased in the interstitial fluid within 
skeletal muscle during and after exercise. Additionally, we determined that de novo 
synthesis via histidine decarboxylase contributes to the rise in histamine during and 
following exercise. We also demonstrated a possible role of mast cells as an additional 
mechanism augmenting histamine in skeletal muscle. Collectively, these studies 
demonstrate that histamine is the ligand activating histamine receptors and activation is 
due to the induction of histidine decarboxylase and mast cell activation.  
In chapter VI, we attempted to determine if histamine receptor activation 
contributes to the expression of pro- and anti-angiogenic growth factors during the 
recovery from exercise. Our preliminary findings indicate that activation of histamine 
receptors may play a role in the expression of pro-angiogenic growth factors during the 
recovery from acute aerobic exercise.   
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CHAPTER I 
INTRODUCTION 
BACKGROUND 
An acute bout of aerobic exercise elicits profound changes in the cardiovascular 
and metabolic systems of the human body. These changes ensure that the essential 
cardiovascular and metabolic demands of exercise are met, and that the overall function 
of these systems is never compromised. But what happens after exercise? Do these 
systems function at levels observed prior to exercise or are there more prolonged 
alterations that subserve some regulatory mechanism or phenotypic adaptation? These are 
fundamental questions that are often overlooked in human integrative physiology.  
For over a decade our laboratory has studied cardiovascular regulation during the 
recovery from aerobic exercise. Original studies examined the mechanisms regulating the 
known blood pressure lowering effect of exercise, post-exercise hypotension (74, 77, 78, 
80). Research on post-exercise hypotension has evolved over the past several decades 
from Fitzgerlad’s personal account of hypotension following exercise (57) to studies 
describing the alterations in cardiac output and vascular resistance, and more recently to 
mechanistic studies describing how and why these changes occur. 
Arterial blood pressure is equal to cardiac output multiplied by peripheral 
vascular resistance. Thus, alterations in cardiac output and/or peripheral vascular 
resistance can drive the reduction in blood pressure observed following aerobic exercise. 
Studies investigating the mechanisms regulating cardiac output and peripheral vascular 
resistance gave rise to a phenomenon termed sustained post-exercise vasodilation. As one 
can imagine, it is this physiological phenomenon that reduces peripheral vascular 
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resistance during the recovery from exercise. Thus, without an equal and opposite rise in 
cardiac output to compensate for the robust peripheral vasodilation, arterial blood 
pressure will fall. Recently, our laboratory has focused its efforts on exploring the 
mechanisms and potential adaptations related to sustained post-exercise vasodilation, but 
we still acknowledge that it is a component of the larger hemodynamic pattern that occurs 
during the recovery from exercise. 
Both neural and local vascular mechanisms contribute to sustained post-exercise 
vasodilation. Central resetting of the arterial baroreflex and reduced sympathetic vascular 
transduction  comprise the neural component of sustained post-exercise vasodilation (78), 
whereas the local vascular component is entirely dependent on H1 and H2 histamine 
receptor activation. McCord and colleagues were the first to demonstrate that sustained 
post-exercise vasodilation is reduced by ~80% following 60 min cycling exercise using 
systemic H1/H2 histamine receptor blockade (119, 125, 126). More recently our 
laboratory has demonstrated that systemic H1/H2 histamine receptor blockade abolishes 
post-exercise vasodilation following unilateral dynamic knee extension exercise, 
suggesting that vasodilation following small muscle mass exercise is entirely histamine 
receptor dependent (16). Unpublished data from our laboratory supports this conclusion 
as the arterial baroreflex and sympathetic vascular transduction appear unchanged 
following dynamic knee extension exercise.  
 Aside from the contribution to post-exercise hypotension, does histamine receptor 
mediated sustained post-exercise vasodilation subserve any cardio-metabolic adaptations 
within the skeletal muscle? Data collected recently from our laboratory demonstrated that 
systemic H1/H2 histamine receptor blockade reduces oxygen consumption across the 
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previously exercised leg, and occurred in the absence of changes in arteriovenous oxygen 
difference or oxygen extraction. This suggests that an unknown metabolically active 
process is exquisitely linked to activation of histamine receptors during the recovery from 
exercise. Presently, it is unclear what this process is, but it was recently suggested that 
histamine receptor mediated sustained post-exercise vasodilation may contribute to 
microvascular remodeling through induction of pro-angiogenic growth factors (74). This 
and other potential adaptations associated with histamine receptor activation and 
sustained post-exercise vasodilation have not been examined thoroughly.   
STATEMENT OF PROBLEM 
The underlying mechanisms mediating sustained post-exercise vasodilation 
remain unresolved. The findings using H1/H2 histamine receptor blockade suggest that 
sustained post-exercise vasodilation is linked inherently to histaminergic signaling 
pathways. The logical assumption is that exercise induces the release and/or formation of 
histamine where it can then activate histamine receptors thus driving sustained post-
exercise vasodilation. However, histamine concentrations in both plasma and whole-
blood are unchanged following exercise (119, 125, 126) suggesting that histamine may be 
released locally in the previously active skeletal muscle without spillover into the 
circulation. This notion is supported by the observation that the vasodilation occurs only 
within the previously exercise skeletal muscles using the unilateral dynamic knee 
extension exercise model (16). To date, intramuscular histamine has never been measured 
during or following acute aerobic exercise in humans.  
If histamine is the ligand activating histamine receptors during the recovery from 
exercise, where is it coming from? Histamine can be formed locally within skeletal 
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muscle through mast cell activation (129, 201) or formed de novo via the inducible 
enzyme, histidine decarboxylase (55). Thus, several competing or perhaps complimentary 
mechanisms may increase histamine formation in skeletal muscle during the recovery 
from exercise.  
The question regarding the origins of histamine formation within skeletal muscle 
can be taken one step further; what upstream exercise related factor might be driving 
post-exercise histamine formation? Oxidative stress, increased temperature, and the local 
release of myokines have been proposed as mediators of sustained post-exercise 
vasodilation through histamine dependent mechanisms (74).  
Sustained post-exercise vasodilation is a robust phenomenon. Acutely, it 
contributes to post-exercise hypotension and increases glucose delivery to the previously 
active skeletal muscle. Moreover, several recent studies have demonstrated that the 
magnitude of post-exercise hypotension is related to the long-term blood pressure 
reductions observed with chronic exercise training in pre-hypertensives (84, 115).  These 
observations reveal that repeated activation of histamine receptors and subsequent 
vasodilation associated with acute aerobic exercise may contribute to various cardio-
metabolic adaptations associated with chronic exercise training.  
It is well known that chronic exercise induces microvascular growth and 
remodeling within skeletal muscle (50, 161). This expansion of the skeletal muscle 
microvasculature, also known as angiogenesis, is dependent on the acute release of pro-
and anti-angiogenic growth factors within the previously exercise skeletal muscle (150). 
Interestingly, histamine contributes to angiogenesis in conditions such as wound healing 
(143) and cancer growth (59). Furthermore, histamine has been shown to upregulate pro-
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angiogenic growth factors such as vascular endothelial growth factor (64, 65) and matrix 
metalloproteinase 2 (45). Thus, it is plausible that the angiogenesis associated with 
exercise training may result from recurring activation of histamine receptors and 
upregulation of pro-angiogenic growth factors.  
The studies detailed in this dissertation were designed to answer several lines of 
inquiry relating to the histaminergic mechanisms and potential adaptations of post-
exercise histamine receptor activation and sustained post-exercise vasodilation. In chapter 
IV, we examined if oxidative stress is the exercise-related factor mediating sustained 
post-exercise vasodilation. In chapter V, we attempted to measure interstitial histamine in 
an effort to demonstrate that exercise induces the local formation of histamine in 
previously active skeletal muscle. Additionally, we wanted to determine if the source of 
histamine was mast cells or de novo synthesis via histidine decarboxylase. In chapter VI, 
we attempted to determine if histamine receptor activation contributes to the expression 
of pro- and anti-angiogenic growth factors during the recovery from exercise.  
HYPOTHESES 
This dissertation was conducted in order to test the following hypothesis: 
 
1. In chapter IV, study 1, we hypothesized that intravenous administration of the 
potent antioxidant ascorbate would blunt sustained post-exercise vasodilation. 
Moreover, this reduction would be similar in magnitude to that observed with 
H1/H2 histamine receptor blockade. In the follow-up study, we hypothesized that 
intravenous n-acetylcysteine administration would similarly inhibit sustained 
post-exercise vasodilation. 
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2. In chapter V, we hypothesized that interstitial histamine would be augmented in 
skeletal muscle during and after 1 hr of unilateral dynamic knee extension 
exercise. Additionally, we hypothesized that this observed increase was the result 
of de novo synthesis via histidine decarboxylase and not mast cell activation.  
3. In chapter VI, we hypothesized that compared with control subjects, the mRNA 
expression of pro-angiogenic growth factors would be blunted during the recovery 
from exercise in subjects who received H1/H2 histamine receptor blockade. 
SIGNIFICANCE  
 The primary goal of this dissertation is to examine the mechanisms and potential 
adaptations associated with post-exercise histamine receptor activation and sustained 
post-exercise vasodilation. Delineating the underlying mechanisms and potential 
adaptations will set the stage for future investigations that can determine if this 
phenomenon that occurs acutely during the recovery from exercise contributes to the 
phenotypic changes observed with chronic exercise training. We can then develop 
physiological and pharmacological interventions designed to exploit the histaminergic 
signaling pathway and related adaptations. These interventions could then be used to 
improve vascular health in patients suffering from vascular diseases such as peripheral 
artery disease.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
INTRODUCTION 
Two distinct vasodilatory phenomenon occur during the recovery from an acute 
bout of exercise (74, 77, 114). The first, known as immediate post-exercise vasodilation, 
occurs during the initial seconds of recovery and can last upwards of 20 mins. The 
second, sustained post-exercise vasodilation, is more prolonged that its immediate 
counterpart, lasting upwards of two hours into the recovery period. While these 
phenomena both occur during the recovery from exercise, each has unique and 
independent regulatory mechanisms.    
Immediate Post-exercise Vasodilation 
Immediate post-exercise vasodilation occurs following both isometric and 
dynamic exercise. The primary variable influencing immediate post-exercise vasodilation 
is the duration of exercise but the type and intensity of the exercise are also important. 
For example, by using varying intensities and duration of isometric contractions of the 
quadriceps muscle, Wesche (195) documented that immediate post-exercise vasodilation 
was more pronounced and longer in duration following exercise that is more sustained 
and that requires a greater effort. The elevation in blood flow observed by Wesche was 
transient, lasting ~10 sec following low intensity, short duration exercise and lasting 
upwards of only ~22 sec following more severe isometric exercise. Walløe and Wesche 
later conducted a similar study in which they used intermittent isometric contractions of 
the quadriceps muscle performed at varying levels of intensity and duration (190). The 
post-exercise vasodilation reported in this study was longer than previously observed but 
     
 8
was still quite transient lasting ~150 sec following the highest workloads performed for 6 
min. These findings are relatively universal with respect to isometric exercise as several 
other studies have reported similar findings. The immediate post-exercise vasodilation 
observed following short duration dynamic exercise is longer lived and more pronounced 
than isometric exercise. For example, Bangsbo and colleagues reported that blood flow 
remained elevated for 20 mins following exhaustive unilateral dynamic knee extension 
exercise lasting 3 min in duration (13). Together, these studies demonstrate that a 
relationship exists between the time, type, and intensity of exercise performed and the 
duration and magnitude of immediate post-exercise vasodilation.  
The mechanisms contributing to immediate post-exercise vasodilation are 
multifactorial and complex. It should be noted that this vasodilatory response is not 
mediated by mechanisms related to oxygen consumption within the previously active 
skeletal muscle (13, 133).  
As observed with the onset of exercise, the muscle pump may also contribute to 
immediate post-exercise vasodilation. Mechanical compression of the arterial blood 
supply by contracting skeletal muscles may induce inherently a reactive hyperemic 
response. This is the most likely mechanism mediating immediate post-exercise 
vasodilation following prolonged isometric exercise, but may contribute to the rapid 
(seconds) vasodilation following rhythmic isometric exercise or dynamic exercise.    
Much of the immediate vasodilatory response can be attributed to alterations in 
the neural control of the vasculature and local vasodilator signals. During exercise 
sympathetic outflow is elevated but is reduced during the immediate recovery period. 
Direct neural recordings of muscle sympathetic outflow in humans via 
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microneurography, indicate that nerve activity is reduced rapidly following isometric 
handgrip exercise, thus attenuating vascular resistance and increasing blood flow to the 
previously active skeletal muscle (180). Numerous local vasodilators have been 
implicated as potential mediators of immediate post-exercise vasodilation (14). For 
example, adenosine uptake inhibition via dipyridamole administration augmented post-
isometric contraction hyperemia whereas inhibiting adenosine formation via ecto-5-
nucleotidase adenine reduced it, suggesting that adenosine contributes to immediate post-
exercise vasodilation (110). Additionally, nitric oxide has been suggested to contribute to 
immediate post-exercise vasodilation. Using intra-arterial infusions of the nitric oxide 
synthase inhibitor NG-monomethyl-L-arginine, Rådegran and Saltin, documented a 34% 
reduction in femoral blood flow following short duration high intensity dynamic knee 
extension exercise (165). Prostanoids and histamine may also contribute to immediate 
post-exercise vasodilation. Using an experimental model that consisted of prolonged 
isometric exercise and blood flow restriction, Morganroth et al. documented that 
immediate post-exercise vasodilation was reduced via prostanoid synthesis inhibition or 
via H1 and H2 histamine receptor antagonism (134). However, using a similar 
experimental approach but with a lesser exercise intensity to that of Morganroth et al., 
Honig and Daniel demonstrated that immediate post-exercise vasodilation was unaffected 
by antagonism of H1 and H2 histamine receptors (39). The discrepancy between these two 
studies is unclear but Honig and Daniel contend that the findings by Morganroth et al. 
may be related to an inflammatory response associated with vascular injury induced by 
the use of a more intense exercise protocol coupled with blood flow restriction.  
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Taken together, these investigations clearly indicate that the mechanisms 
governing immediate post-exercise vasodilation are indeed multifactorial. Reductions in 
sympathetically mediated vasomotor tone and the numerous local vasodilators associated 
with immediate post-exercise vasodilation point towards a possible “carry-over” effect 
from the preceding exercise bout. More specifically, the multiple and redundant 
vasodilatory mechanisms thought to contribute to exercise hyperemia may carry-over into 
the early recovery period.     
Sustained Post-exercise Vasodilation 
Unlike its short-lived counterpart, sustained post-exercise vasodilation can last 
upwards of several hours into the recovery period. In humans, sustained post-exercise 
occurs following prolonged aerobic exercise but is absent following short duration 
resistance exercise (16). Post-exercise hypotension has been observed following 
moderate duration whole body resistance exercise, but appears to be mediated by 
reductions in cardiac output as vascular resistance is usually unchanged or even elevated 
(21, 121, 169, 187). Interestingly, sex appears to be an important determinant of sustained 
post-exercise vasodilation following resistance exercise as it is more often observed in 
females (163).   
The majority of studies investigating sustained post-exercise vasodilation have 
utilized large muscle-mass dynamic exercise (e.g. cycling) ranging from 30 to 60 min in 
duration. Similar to the dependence of immediate post-exercise vasodilation on the 
duration and intensity of exercise, sustained post-exercise vasodilation is consistently 
observed and greater in magnitude following moderate intensity (50% - 60% VO2peak), 
prolonged (30 - 60 min) exercise (80). Recently, our laboratory has shown that a 
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unilateral dynamic knee extension exercise model also induces sustained post-exercise 
vasodilation. While smaller in magnitude compared with large muscle-mass exercise, the 
vasodilation observed following 1hr of knee extension exercise at 60% peak power is 
reproducible and is quite robust (16).  
 During exercise, there are well known vascular changes that occur within and 
beyond the active skeletal muscle (114). Likewise, regional vasomotor changes also 
occur during the recovery from exercise. Sustained post-exercise vasodilation occurs 
primarily within the vascular beds perfusing previously active skeletal muscle, but also 
occurs, to a lesser extent, in the inactive skeletal muscle following large muscle-mass 
exercise (76, 125). However, our laboratory has recently demonstrated that 60 min of 
moderate intensity unilateral dynamic knee extension exercise induces sustained post-
exercise vasodilation in only the previously active leg (16). Blood flow was similar to 
pre-exercise levels in the contralateral leg. This divergence from the typical vascular 
changes following large muscle-mass exercise is likely related to the amount of active 
skeletal muscle and afferent nerve activation during exercise, as will be discussed in a 
subsequent section.  
A series of papers from our laboratory have also provided evidence regarding 
blood flow in the splanchnic, renal, and cutaneous circulations during sustained post-
exercise vasodilation. Pricher and colleagues reported that both splanchnic and renal 
vascular conductance was reduced during exercise as expected, but returned to pre-
exercise levels following 60 min cycling exercise (160). Wilkins et al. reported that 
cutaneous vascular conductance was elevated early in the recovery period but returned to 
pre-exercise levels thereafter. To my knowledge, only one study has examined the 
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cerebral circulation during the recovery from exercise when arterial blood pressure was 
reduced and skeletal muscle blood was presumably elevated. Willie et al. documented 
that cerebral blood velocity and autoregulation are unchanged following  60 min 
moderate intensity cycling exercise (199). This finding is not surprising considering the 
ability of the cerebral vasculature to maintain blood flow during modest, non-syncopal 
hypotension.   
MECHANISMS OF SUSTAINED POST-EXERCISE VASODILATION 
Several investigators have laid the physiological groundwork with respect to the 
mechanisms regulating sustained post-exercise vasodilation. These investigators and their 
elegant studies have together constructed the framework that integrates the various 
mechanistic components mediating sustained post-exercise vasodilation. However, some 
of the inner workings currently remain unclear. The current evidence suggests that 
critical changes occur within the central baroreflex network and locally within the 
skeletal muscle vasculature and are referred to as the neural and local vascular 
components of sustained post-exercise vasodilation.  
Neural Component: Arterial Baroreflex Resetting and Reduced Vascular Transduction 
 A number of early investigations reported that neurovascular regulation is altered 
during the recovery from aerobic exercise. It was not until recently that these post-
exercise changes were found to be related to the well-known neural changes that occur 
during exercise. Floras and colleagues were the first to provide direct evidence of the 
discreet neurovascular changes that occur during the recovery from exercise in humans 
(58). Using microneurography, they documented a 34% reduction in muscle sympathetic 
nerve activity following 45 min of moderate treadmill running. The absence of reflex 
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tachycardia and augmented sympathetic outflow despite a clear reduction in arterial 
blood pressure was suggestive of an exercise-induced sympathoinhibition via altered 
baroreflex regulation and/or reduced sympathetic vascular transduction. Along these 
lines, Halliwill and colleagues later demonstrated in humans that the arterial baroreflex is 
indeed reset following large muscle-mass aerobic exercise (78). Specifically, they 
documented a 29% reduction in muscle sympathetic nerve activity following 60 min of 
cycle exercise at 60% VO2peak. This dramatic reduction in baseline sympathetic outflow 
was due to a downward and leftward shift of the arterial baroreflex stimulus response 
curve and occurred without changes in sympathetic baroreflex gain. However, in a 
different study, Halliwill and colleagues showed that carotid-cardiac baroreflex gain is 
augmented during the recovery from aerobic exercise, possibly as mechanism to restrain 
the reduction in arterial blood pressure (79). This exercise-induced sympathoinhibition 
via altered sympathetic baroreflex regulation has also been documented in normotensive 
(130) and spontaneously hypertensive rats (107, 112). However, in contrast to the 
findings in humans, sympathetic baroreflex gain is attenuated in rats (107, 130).  
Unraveling the central pathways that mediate resetting of the baroreflex during 
and following exercise has been a central focus of research within the last decade. It was 
not until recently that we developed a clear understanding of these central pathways in 
the medulla and their interactions during and after exercise. Much of our understanding 
regarding resetting of the baroreflex during exercise was due to the elegant work of Jeff 
Potts (158). The central theme of this research focused on the inhibition of second order 
barosensitive neurons by afferent input from active skeletal muscle. The afferent neurons 
project from skeletal muscle to the nucleus tractus solitarii where they release substance 
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P which then activates neurokinin 1 receptors on γ-aminobutyric acid (GABA) inhibitory 
interneurons. Upregulation of GABAergic interneuron activity inhibits increased 
baroreceptor afferent input to the nucleus tractus solitarii. This inhibition normalizes 
nucleus tractus solitarii activity output to the caudal ventrolateral medulla, thus reducing 
inhibitory input to the rostral ventrolateral medulla and increasing sympathetic outflow.  
Chen and colleagues built upon these observations regarding muscle afferents and 
baroinhibition in the nucleus tractus solitarii, but focused their efforts on the exercise 
recovery period (31). Their work also centers on the GABAergic inhibition of 
barosensitive neurons via substance P release by skeletal muscle afferents and neurokinin 
1 receptor activation. Chen and colleagues first demonstrated an obligatory role for 
substance P and neurokinin 1 receptors by reducing post-exercise hypotension by 37% 
via nucleus tractus solitarii microinjection of a neurokinin 1 receptor antagonist (32). As 
expected, antagonism of neurokinin 1 receptors also blocked the exercise pressor 
response, but had no effect on pre-exercise blood pressure. To further delineate the 
mechanisms underlying the baroinhibition in the nucleus tractus solitarii, they recorded 
GABAergic inhibitory post-synaptic currents and documented a large reduction in 
spontaneous activity in second order barosensitive neurons following aerobic exercise 
(30), which is suggestive of a reduced GABA inhibitory input. Interestingly, antagonism 
of neurokinin 1 receptors reduced the inhibitory post-synaptic currents on second order 
barosensitive neurons following sham exercise, but had no effect following aerobic 
exercise, suggesting that the neural response to endogenously released substance P and 
neurokinin 1 receptor activation is inhibited during the recovery from exercise. Because 
substance P has been shown to cause neurokinin 1 receptor internalization in the spinal 
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cord of rats (124), Chen and colleagues proposed that this may be the mechanism 
preventing GABAergic inhibition of second order barosensitive neurons following 
exercise. They confirmed this hypothesis by immunofluorescence labeling of neurokinin 
1 receptors located on GABA inhibitory neurons within the nucleus tractus solitarii and 
visually confirming receptor internalization following aerobic exercise, but not sham 
exercise (30). Taken together, the arterial baroreflex is reset during the recovery from 
exercise by increased afferent input from active skeletal muscle which then increases the 
release of substance P and subsequent activation of neurokinin 1 receptors located on 
GABA inhibitory neurons. Prolonged activation of neurokinin 1 receptors causes receptor 
internalization and blunted GABAergic inhibition of second order barosensitive neurons 
during the recovery from exercise. In turn, nucleus tractus solitarii activity output to the 
caudal ventrolateral medulla in increased, thus augmenting inhibitory input to the rostral 
ventrolateral medulla and reducing sympathetic outflow to the peripheral vasculature. 
In addition to resetting of the arterial baroreflex, Halliwill and colleagues also 
documented in humans, a reduced capacity to transduce sympathetic outflow into 
vasoconstriction following exercise (78). A reduction in sympathetic vascular 
transduction can be mediated by pre-synaptic inhibition, changes in the synaptic cleft, 
and post-junctional inhibition. In humans, it appears that the reduction in sympathetic 
vascular reduction is not mediated post-junctionally as the vasoconstrictor response to the 
intra-arterial infusion of the α1-agonist phenylephrine and the α2-agonist clonidine is 
intact during the recovery from 60 min cycle exercise (75). This suggests that the 
reduction in sympathetic vascular transduction is likely mediated by pre-synaptic 
inhibition or through a mechanism in the synaptic cleft that increases norepinephrine 
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metabolism or reuptake. In contrast to the findings in humans, DiCarlo and co-workers 
demonstrated that the vascular responsiveness to the intravenous infusion of 
phenylephrine is attenuated following aerobic exercise, using an isolated aortic ring 
preparation (94) and in several intact animal models (95, 154, 168). The inconsistency 
between the human and non-human investigations is unclear, but may be related to the 
local vascular mechanisms thought to mediate sustained post-exercise vasodilation as will 
be discussed in a subsequent section.  
  Taken together, resetting of the arterial baroreflex due to discreet changes in the 
cardiovascular control centers in medulla induce sustained post-exercise vasodilation 
through reductions in sympathetic vasoconstrictor tone. Additional sympathoinhibition is 
mediated through the inability to transduce sympathetic outflow into vasoconstriction. 
Thus, these two neural changes that occur during the recovery from aerobic exercise 
compromise the “neural component” of sustained post-exercise vasodilation. These post-
exercise changes have been reviewed recently by our laboratory (74) and are summarized 
in Figure 2.1. 
 
Figure 2.1. Neural Component of Sustained Post-exercise Vasodilation.  
Baroreflex resetting via discreet changes in the nucleus tractus solitarii of the medulla 
and reduced sympathetic vascular transduction are highlighted as mediators of sustained 
post-exercise vasodilation. From (74). 
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Local Vascular Component: Histamine Receptor Activation 
In 2001, Halliwill presented a “laundry list” of local vasodilators that could 
mediate sustained post-exercise vasodilation (80). Potential candidates included in this 
list were nitric oxide, prostanoids, adenosine, and several others. As presented elegantly 
by the late John T. Shepard, a proposed mediator of hyperemia must meet the following 
criteria: 1) the substance(s) or its precursor(s) should be present in skeletal muscle; 2) the 
substance(s) should have access to the muscle resistance vessels; 3) the concentration in 
the interstitial fluid must be capable of causing and maintaining vasodilation, and there 
should be a close relationship between the interstitial fluid concentration and the blood 
flow; and, 4) the substance(s) should be capable of producing dilatation of arterioles on 
topical application. Each of the candidate vasodilator substances meets these 
requirements and has also been implicated as a mediator of exercise hyperemia. Since 
Halliwill’s “laundry list,” we have developed a better understanding of the local 
vasodilator mechanisms that have no role in mediating sustained post-exercise 
vasodilation, but have also identified a principal mechanism. This section will summarize 
the investigations that have attempted, without success, to identify the local vascular 
mechanism and will present the current view of the local vascular component mediating 
sustained post-exercise vasodilation.  
 One of the most studied local vasodilator substances is nitric oxide which is 
formed through the actions of several nitric oxide synthase isoforms (185). Endothelial 
nitric oxide synthase is thought to be primarily responsible for nitric oxide formation 
within the vascular endothelium in response to acute exercise (114). Exercising 
hemodynamic factors such as shear stress, circumferential stretch, and paracrine factors 
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are thought to increase endothelial nitric oxide synthase activity during exercise. Nitric 
oxide has been implicated in mediating exercise hyperemia, but its role remains 
controversial (34, 175). Is nitric oxide formation augmented following exercise? 
Jungersten et al. documented that plasma nitrate, a major stable end product of nitric 
oxide metabolism was augmented for 2 hrs following prolonged cycle exercise (106). 
This finding coupled with those in animal models suggesting that nitric oxide blunts α-
adrenergic responsiveness during the recovery from exercise (154, 168) lead Halliwill 
and colleagues to examine the contribution of nitric oxide to sustained post-exercise 
vasodilation (76). Using NG-monomethyl-L-arginine to inhibit systemic nitric oxide 
formation, Halliwill and colleagues demonstrated in healthy humans that peripheral 
vasodilation persisted during the recovery from 60 min cycle exercise. Thus, it does not 
appear that nitric oxide contributes to sustained post-exercise vasodilation. 
 Next on the laundry list of local vasodilators to be examined were the prostanoids. 
Enzymatic breakdown of membrane bound arachidonic acid via cyclooxygenase-1 
induces prostanoid formation within the vascular endothelium. Exercise and the 
immediate recovery period increases sheer stress along the vascular tree within the 
skeletal muscle and is a potent stimulus for the endothelial formation of prostanoids 
(111). Moreover, Cowley et al. inhibited cyclooxygenase-1 via ingestion of 1800 mg of 
aspirin and reduced both calf and forearm blood flood early into the exercise recovery 
period (36). Further, 6-keto-PGF1α , the stable metabolite of prostacyclin hydrolysis, is 
elevated early in the recovery period following short duration high intensity aerobic 
exercise (171). Given these prior findings, the prostanoids were an ideal candidate to 
mediate sustained post-exercise vasodilation. However, Lockwood and co-workers 
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demonstrated that the systemic inhibition of cyclooxygenase-1 via 10 mg kg-1 oral 
ibuprofen had no effect on femoral vascular conductance through 90 min of exercise 
recovery (118). Thus, it does not appear that the exercise-induced formation of 
prostanoids contributes to sustained post-exercise vasodilation. 
 In 2005, our understanding of the local vascular component was significantly 
advanced with the finding that a histaminergic mechanism was responsible for sustained 
post-exercise vasodilation. This was quite unexpected given that it was not on Halliwill’s 
original laundry list of potential vasodilators. According to laboratory folklore, the initial 
experimental endeavors regarding a histaminergic mechanism were purely serendipitous.  
 The initial evidence in humans regarding a histaminergic mechanism was 
provided by Lockwood and colleagues (119). They demonstrated that systemic blockade 
of histamine H1 receptors via high dose (500 mg) fexofenadine significantly blunted the 
rise in femoral vascular conductance through 90 min of recovery from 60 min moderate 
intensity cycle exercise. Moreover, blockade of histamine H2 receptors via high dose 
ranitidine (300mg), also significantly blunted the rise in femoral vascular conductance 
through 90 min of recovery following cycle exercise (125). Combined blockade of H1 
and H2 histamine receptors reduces sustained post-exercise vasodilation by ~80% 
following 60 min cycling exercise in both sedentary and trained individuals (74, 126). 
More recently, our laboratory has demonstrated that combined H1/H2 histamine receptor 
blockade abolishes sustained post-exercise vasodilation following 60 min of unilateral 
dynamic knee extension exercise and that the vasodilation occurs only in the vascular 
beds perfusing the previously active skeletal muscl
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An explanation for the discrepant findings regarding histamine receptor mediated 
sustained post-exercise vasodilation following large muscle mass exercise versus small 
muscle mass exercise is lacking, but the divergence is likely related to the active muscle 
required to perform exercise. As previously discussed, muscle afferent activation during 
exercise mediates resetting of the arterial baroreflex and associated sympathoinhibition 
during the recovery from large muscle mass exercise. Presumably, there would be less 
afferent feedback during small muscle mass exercise and therefore resetting of the arterial 
baroreflex and associated sympathoinhibition would be limited. Recent unpublished 
observations from our laboratory support this conclusion as the arterial baroreflex and 
sympathetic vascular transduction appear unchanged following 60 min unilateral 
dynamic knee extension exercise. Additionally, sustained post-exercise vasodilation is 
observed only in the vasculature of the previously active leg following unilateral dynamic 
knee extension exercise, whereas blood flow to active and non-active regions is elevated 
following cycling exercise in the absence of elevated circulating histamine 
concentrations. This suggests that there are muscle mass dependent variations in the 
neural component contributing to sustained post-exercise vasodilation following small 
versus large muscle mass exercise.  
Activation of histamine receptors following exercise is the sine qua non of the 
local vascular mechanism of sustained post-exercise vasodilation. However, one 
important question remains - what is the ligand activating histamine H1 and H2 receptors 
during the recovery from exercise? The obvious choice is histamine, which has long been 
recognized for its potent vasodilator effects and long been supported as an intrinsic 
regulator of exercise hyperemia (178). 
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Over a century ago, Barger and Dale isolated beta-iminazolylethylamine (i.e. 
histamine) from ergot fungi (15). Dale and Laidlaw later found that histamine had several 
physiological effects such as smooth muscle contraction of the ileum and a shock-like 
syndrome when injected into animals (37, 38). It was not until 1927, when Best and 
colleagues discovered that histamine is formed endogenously within the liver and lung 
and that it had a potent vasodilatory effect (18). Needless to say, countless studies have 
since then built upon these seminal studies identifying histamine and its physiological 
role.  
Is histamine the ligand responsible for activating histamine H1 and H2 receptors 
during the recovery from exercise? Histamine meets all of the criteria outlined earlier 
with the exception of number three - the concentration in the interstitial fluid must be 
capable of causing and maintaining vasodilation, and there should be a close relationship 
between the interstitial fluid concentration and the blood flow. To our knowledge, 
interstitial histamine concentrations have never been measured in skeletal muscle during 
or following aerobic exercise. Thus, it still remains unclear if histamine is indeed the 
ligand activating histamine receptors following exercise.  
While interstitial concentrations have never been measured in skeletal muscle 
during or after exercise, several studies have measured histamine in circulation. Early 
studies by Anrep and colleagues reported that plasma histamine is elevated in the venous 
blood draining the active skeletal muscle using blood flow restricted and free flowing 
experimental models (3–5). More recent studies in healthy humans have provided further 
evidence that histamine is elevated in whole blood (25, 82) and serum (47), but is 
unchanged in arterial or venous plasma (82, 83, 132). Studies in our laboratory have 
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failed to document any rise in plasma or whole-blood histamine during the recovery from 
exercise (119, 125, 126). It is unclear why our studies vary from others but may be 
related to experimental methodologies or histamine assay techniques. Histamine 
quantitation is technically challenging due the numerous assays available and associated 
variability (66) and to a half-life of  just under two minutes (98). Moreover, it is possible 
that histamine is taken up by basophils when in circulation (149) or that histamine 
receptor sensitivity is increased during the recovery from exercise. Evidence recently 
collected in our laboratory points towards another explanation for the lack of elevated 
circulating histamine. Barrett-O'Keefe et al. documented that blood flow was elevated in 
the vascular bed perfusing the previously active quadriceps muscles in the exercised leg, 
whereas the blood flow in the contralateral, unexercised, leg was unchanged following 
dynamic knee extension exercise (16), which suggests that histamine is released locally 
within the skeletal muscle without spillover into the circulation.  
Histamine formation in skeletal muscle could be augmented during the recovery 
from exercise through two mechanisms, mast cell degranulation or de novo synthesis via 
histidine decarboxylase (74). Mast cells originate from hematopoietic progenitor cells in 
red bone marrow and circulate in an immature form until deposition in various tissues 
(129). Once in the tissue, mast cells will develop functional and structural characteristics 
under the influence of various factors within local environment. Several exercise-related 
factors such as oxidative stress (183), cytokine release, (129) and elevated temperatures 
(67) have been shown in other contexts to induce mast cell degranulation in an antigen-
independent manner. Alternatively, histidine decarboxylase could augment histamine 
synthesis in skeletal muscle through decarboxylation of the amino acid histidine (149, 
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192). Endo and colleagues have provided clear evidence that exercise augments both the 
gene expression and activity of histidine decarboxylase in mice (10, 55). Oxidative stress 
(90) and the transcription factor, hypoxia-inducible factor-1α (101) are associated with 
upregulated transcription of histidine decarboxylase. Histidine decarboxylase also 
appears to function optimally at elevated temperatures and an acidic pH, both conditions 
are associated with exercise (177). Lastly, a study by DeForrest et al. suggests that shear 
stress may increase de novo histamine synthesis within blood vessels through a shear 
stress dependent mechanism (41). Taken together, there are several lines of evidence 
suggesting that exercise-related factors could increase histamine formation through mast 
cell activation and/or de novo synthesis via histidine decarboxylase.  
Figure 2.2 illustrates the local vascular component of sustained post-exercise 
vasodilation, as recently reviewed by our laboratory (74). The activation of histamine 
receptors during the recovery from exercise is the key mechanism of sustained post-
exercise vasodilation. However, the ligand activating histamine receptors remains 
unclear, but the most likely candidate is histamine which may be formed locally within 
skeletal muscle through various mechanisms. Further, the factors known to stimulate 
histamine formation through the aforementioned mechanisms and that are also associated 
with exercise are yet to be examined.    
PHYSIOLOGICAL ADAPTATIONS AND SUSTAINED POST-EXERCISE 
VASODILATION 
  Why are histamine receptors activated during the recovery from exercise? The 
answer to this question is the last piece of the physiological puzzle that our laboratory has 
been recently investigating. It is well understood that chronic exercise training induces a 
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number of systemic cardio-metabolic adaptations in humans. By convention, 
physiologists assume that the exercise bout per se, is the main factor mediating these 
exercise adaptations. What happens after exercise? Could the exercise bout be the 
stimulus that “primes” the system and the recovery period serve as the conduit for the 
true phenotypic adaptations to occur? We are just now beginning to unravel the answer to 
this and many other questions regarding the adaptations associated with histamine 
receptor activation and sustained post-exercise vasodilation.  
 
 
 
 
Figure 2.2 Local Vascular Component of Sustained Post-exercise Vasodilation 
Histamine receptor activation is highlighted as the primary vascular mechanism of 
sustained post-exercise vasodilation. The unanswered questions regarding intramuscular 
histamine formation are also highlighted. From (74).  
 
 
 
Angiogenesis 
 We have recently speculated that histamine receptor mediated sustained post-
exercise vasodilation is linked to exercise-induced angiogenesis (74). Sustained post-
exercise vasodilation is not related to whole-body oxygen consumption (198). However, 
we have shown recently that H1/H2 histamine receptor antagonism reduces leg oxygen 
uptake following cycling exercise (54), suggesting that post-exercise histamine receptor 
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activation and subsequent vasodilation may be related to some unknown metabolically 
active process.  
 Exercise promotes growth and remodeling of the capillary network (angiogenesis) 
within skeletal muscle (70, 161, 196). Skeletal muscle angiogenesis is beneficial as it 
augments nutritive blood flow due to a decrease in red blood cell transit time, decreased 
diffusional path length, and an increased capillary surface area for diffusion (70). This 
expansion of muscle capillarity and nutritive blood flow should increase oxygen 
extraction and muscle performance. The mechanisms promoting angiogenesis in skeletal 
muscle remain unclear, but are thought to involve mechanical mechanisms such as shear 
stress and muscle overload/stretch, but may also be related to other metabolic factors and 
hypoxia (50, 51). Irrespective of the exercise related stimulus, angiogenesis depends 
critically on the balance of pro- and anti-angiogenic growth factors that are released in 
response to acute and chronic exercise (150).  
Expansion of the skeletal muscle capillary network is dependent on a set of highly 
coordinated cellular events that respond to pro- and anti-angiogenic growth factors. The 
physical process of capillary remodeling can occur due to sprouting or intussusceptive 
(splitting) angiogenesis. In general, sprouting angiogenesis involves five key steps: 1) 
increased capillary permeability; 2) endothelial cell proliferation; 3) degradation of 
basement membrane & interstitial matrix; 4) migration and extension of endothelial cells; 
and, 5) vessel stabilization and perfusion (1, 70). Angiogenesis via splitting angiogenesis 
is far less understood owing to its relatively recent discovery in human skeletal muscle. 
The current understanding is that pillar-like structures migrate intralumnially within the 
blood vessel where they connect with one another, thus creating two separate blood 
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vessels in parallel. Importantly, both forms of angiogenesis have been shown to occur in 
response to elevated blood flow and muscle overload, which are models used to dissect 
the exercise-related mechanisms that induce capillary growth and remodeling (49). 
Mechanical, metabolic, and hypoxic stimuli contribute to sprouting and 
intussusceptive angiogenesis in response to exercise through the release of pro- and anti-
angiogenic growth factors. The most highly studied growth factor is vascular endothelial 
growth factor (VEGF). However, many other factors are thought to contribute to 
exercise-induced angiogenesis. Matrix metalloproteinases, nitric oxide synthase, and 
monocyte chemotactic protein are just a few of the known pro-angiogenic growth factors 
that respond to acute exercise. It is important to note that the capillary remodeling in 
skeletal muscle is dependent on the angiogenic balance, which is the equilibrium state of 
pro- vs anti-angiogenic growth factors. If the balance is in favor of the pro-angiogenic 
growth factors then the muscle capillary network will remodel and expand, whereas 
capillary regression will occur if the balance favors the anti-angiogenic factors (150). 
Potent anti-angiogenic growth factors include thrombospondin 1 and endostatin, but 
many others have been identified. Importantly, acute aerobic exercise upregulates both 
pro- and anti-angiogenic factors within the previously active skeletal muscle. For 
example, acute aerobic exercise upregulates VEGF mRNA in animal models (19, 81) and 
humans (69, 170) which translates into long-term elevations in skeletal muscle VEGF 
content (68). Conversely, thrombospondin 1 mRNA is also upregulated following acute 
exercise (151), which is likely “applying the physiological brake” in response to the 
robust expression of pro-angiogenic factors.     
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 In addition to its potent vasodilator effects, histamine also induces angiogenesis in 
pathological and physiological settings. Histamine was first implicated as a potent 
angiogenic stimulus in the late 1960’s (202) and has since been studied in the angiogenic 
settings of wound healing, cancer development, and pregnancy (59, 100, 143). The 
angiogenic effect of histamine is due the induction of pro-angiogenic growth factors such 
as VEGF (64, 65) or matrix metalloproteinase 2 (44), and can be inhibited via histamine 
receptor antagonism, blockade of histamine formation, or both (142, 149). Additionally, 
recent evidence suggests that histamine may directly induce angiogenesis irrespective of 
growth factor stimulation (162). Thus, there is ample evidence that histamine can directly 
or indirectly promote angiogenesis. Does the activation of histamine receptors during the 
recovery from exercise contribute capillary remodeling through the upregulation of 
angiogenic growth factors? Curiously, the temporal expression VEGF mRNA following 
acute exercise tracks closely with temporal pattern of sustained post-exercise 
vasodilation. While this observation is not causative by any means, it does provide “food 
for thought.”   
 Taken together, exercise-induced angiogenesis within the skeletal muscle 
capillary network is a highly complex process. Exercise related factors such as elevated 
shear stress induce the release of pro- and anti-angiogenic factors that can then influence 
the angiogenic cascade. There is ample evidence that suggests that histamine receptor 
activation during the recovery from exercise may contribute to exercise-induced 
angiogenesis. This notion remains untested. 
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CHAPTER III 
METHODS 
SUBJECT CHARECTERIZATION 
 Studies conducted in this dissertation were approved by the Institutional Review 
Board at the University of Oregon (Protocol #02172011.029). Studies were conducted in 
accordance with guidelines set forth by the Office for Protection of Human Subjects at 
the University of Oregon. Written informed consent was obtained from all subjects 
subsequent to a verbal and written briefing of all experimental procedures for a given 
study.  
Sixty-four (38 men, 26 women) healthy subjects participated in studies detailed in 
this dissertation (age 22 ± 3 yrs, height 174 ± 8 cm, weight 72 ± 10 kg, body mass index 
23.5 2.4 kg m2, mean ± SD). Subjects were deemed healthy following a standard health 
screening. All subjects were required to abstain from caffeine, alcohol, and exercise for at 
least 24h prior to all studies. Subjects reported to the laboratory after an overnight fast for 
the study described in chapter IV and following a 2h fast for studies described in chapters 
V and VI. No subjects were using any over-the-counter or prescription medications at the 
time of the study, with the exception of oral contraceptives. For the studies detailed in 
chapters IV and V, female participants were studied during the early follicular phase of 
their menstrual cycle or during the placebo phase of their oral contraceptive. For the 
study detailed in chapter VI, women were studied irrespective of menstrual cycle phase. 
All female subjects had a negative pregnancy test prior to all studies. 
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GENERAL EXPERIMENTAL APPROACH 
The studies detailed in chapters IV and V were conducted on the University of 
Oregon Campus in Esslinger Hall. The study detailed in chapter VI was conducted in the 
Center for Medical Education and Research at Sacred Heart Medical Center.   
The study detailed in chapter IV was conducted in two parts. In study 1, subjects 
were studied under three conditions: control, ascorbate alone, and ascorbate plus H1 and 
H2 histamine receptor blockade. In the follow-up study, n-acetylcysteine was infused in 
lieu of ascorbate and subjects did not receive antihistamines. Central and peripheral 
hemodynamics were measured before and after 1 hr unilateral dynamic knee extension 
exercise within respective drug conditions.  
In the study described in chapter V, subjects were studied under resting conditions 
or having performed 1 hr unilateral dynamic knee extension exercise. Skeletal muscle 
microdialysis probes were implanted in the subjects right vastus lateralis and used to 
deliver drugs of interest and to collect the microdialysis effluent (dialysate). Central and 
peripheral hemodynamics were measured before and after 1hr seated rest or knee 
extension exercise. 
In the study detailed in chapter VI, skeletal muscle biopsies were obtained from 
the vastus lateralis in control subjects and those who received H1and H2 histamine 
receptor blockade. A pre-exercise biopsy was obtained from the non-exercised leg and 
two biopsies were obtained from the previously exercised leg. Central and peripheral 
hemodynamics were measured before and after 1 hr unilateral dynamic knee extension 
exercise.  
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UNILATERAL DYNAMIC KNEE-EXTENSION EXERCISE 
Studies described in this dissertation made use of a unilateral dynamic knee 
extension ergometer. Unilateral knee extension ergometry was originally developed at the 
Copenhagen Muscle Research Centre in Copenhagen, Denmark. Unilateral dynamic knee 
extension exercise was first used in a seminal publication by Per Andersen and the late 
Bengt Saltin (2). Since then, countless studies examining the physiology of exercise have 
utilized this exercise model. Unilateral dynamic knee extension exercise is unique in that 
it isolates muscle activation to the quadriceps femoris and allows for passive knee 
flexion, thus allowing for targeted investigation of a single muscle group.  
Historically our laboratory has utilized whole-body aerobic exercise such as 
cycling to investigate sustained post-exercise vasodilation. Moderate intensity cycling 
exercise of 1 hr in duration elicits a robust vasodilatory response during the recovery 
from exercise that is reduced by ~80% via H1 and H2 histamine receptor blockade (119, 
125, 126). In contrast, unilateral dynamic knee-extension exercise of 1 hr in duration 
elicits a vasodilatory response during the recovery from exercise that is abolished via H1 
and H2 histamine receptor blockade (119, 125, 126). The differential effects of histamine 
receptor blockade between exercise modalities appear to be due to the absence of 
baroreflex resetting and reduced sympathoinhibition following dynamic knee-extension 
exercise (unpublished observation). Thus, sustained post-exercise vasodilation following 
unilateral dynamic knee-extension exercise is entirely histamine receptor dependent and 
therefore provides optimal conditions to investigate the local vascular contribution.  
Unilateral dynamic knee-extension exercise was performed using custom-built 
knee extension ergometer based on a computer-controlled step-motor that provided 
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resistance against the subject’s lower leg. Based on real-time measures of angular 
velocity and torque, power was calculated and a feedback loop maintained measured 
power at the assigned level. Subjects were seated with their back at 60° upright and knee-
extension exercise was performed with the right leg over a 45° range of motion, starting 
with the leg hanging at ~90° of flexion. Subjects were asked to maintain a cadence of 45 
kicks min-1 while being provided with visual feedback of both kicking cadence and range 
of motion.  
Peak power was determined during maximal dynamic knee extension exercise 
test. Following a five minute warm-up at a workload of 5 watts, workload was ramped 
incrementally at a rate of 3 watts min-1. Subjects were required to maintain power within 
1 watt of the target workload and also maintain cadence within 5 kicks min-1. Subjects 
performed the exercise until volitional fatigue. 
Moderate intensity unilateral dynamic knee extension exercise was utilized in 
each study detailed within this dissertation. Power was ramped at the onset of exercise to 
60% peak power over the first 15 min for studies described in chapters IV and V. Power 
was ramped at the onset of exercise to 60% peak power over the first 5 min for the study 
described in chapter VI. Subjects were required to maintain power within 1 watt of the 
target workload and also maintain cadence within 5 kicks min-1. 
HEMODYNAMIC MEASUREMENTS 
In the studies detailed in chapters IV, V, and VI, resting hemodynamic 
measurements were made with the subjects in the supine position and in a thermoneutral 
room (~23°C). Some hemodynamic measurements were made with the subjects seated at 
60° upright and while performing the knee extension exercise or resting. 
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Heart Rate 
Heart rate was monitored using a three lead electrocardiograph (Datex-Ohmeda 
Cardiocap/5, GE Healthcare, Tewksbury, MA, USA) for study 1 in chapter IV. Due to 
technical difficulties, a different three lead electrocardiograph was used for the follow-up 
study in chapter IV and for all other studies (Tango+, SunTech Medical, Raleigh, N.C., 
USA).   
Arterial Blood Pressure  
Arterial blood pressure was measured in the right arm using an automated 
sphygmomanometer (Tango+, SunTech Medical, Raleigh, N.C., USA). Mean arterial 
pressure was calculated as: 
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Equation 3.1. Mean Arterial Pressure 
Femoral Blood Flow 
Although there are a number of techniques that can be used to assess regional 
blood flow, our laboratory uses Doppler ultrasound technology. Prior to the widespread 
adoption of Doppler ultrasound, most physiologists relied on other techniques such as 
plethysmography or indicator methods to measure regional blood flow in humans.  
Plethysmography is non-invasive, relatively inexpensive, and provides reasonable 
estimates of regional blood flow. Blood flow is based on the rate of limb distension 
following the occlusion of venous outflow. The major disadvantages to this technique is 
that it cannot differentiate blood flowing to various tissues (skin vs. muscle) and is also 
subject to inaccurate measurements due to unintentional occlusion of arterial inflow at 
pressures thought to occlude only venous outflow (24).  
     
 33
Indicator methods are classic techniques utilized in human integrative physiology 
research. This approach is based on the infusion of an indicator in a known concentration 
or temperature and subsequent measurement of the indicator following the infusion and 
thorough mixing within the blood. Various indicators have been utilized in humans such 
as indocyanine green dye, Evans blue dye, and ice-cold saline. Regarding dye indicators, 
blood flow is measured by the dilution of the dye within the blood.  Thus, regional blood 
flow is assumed to be proportional to the dye concentration in the blood relative to the 
known concentration prior to infusion (167). Thermodilution is based on the same 
principle but depends on the temperature change within a vessel during the constant 
infusion of ice-cold saline. Regional blood flow is assumed to be proportional to the 
temperature deflection within the blood (167). The indicator methods have been used to 
measure regional blood flow in humans with high accuracy at rest and during exercise (2, 
62, 105). These methods are fairly easy to perform but require invasive catheterization 
and steady-state conditions. Moreover, the cost associated with indicators dyes such as 
indocyanine green can be high.  
Doppler ultrasound derived blood flow velocities correlate highly with the 
thermodilution technique (166).  Unlike indicator methods, Doppler ultrasound provides 
high temporal resolution and continuous sampling as it does not require steady state 
conditions and is completely non-invasive (167). However, the equipment can be 
expensive and a highly skilled technician is needed to obtain accurate and reproducible 
measurements. Similar to venous occlusion plethysmography, Doppler ultrasound cannot 
differentiate between the blood perfusing various tissues within the region of interest. 
This limitation can be overcome by simultaneously measuring regional blood flow via 
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Doppler ultrasound and tissue specific blood flow. Given the aspects outlined for the 
various techniques available to measure regional blood flow in humans, Doppler 
ultrasound is the ideal technique for use in our studies.  
Femoral artery blood flow velocity was measured via duplex ultrasonography. A 
linear-array vascular ultrasound probe (10 MHz, GE Vingmed System 5, Horton, 
Norway) was used for studies in chapters IV and V while a different linear array vascular 
ultrasound probe was used for chapter VI (9 MHz, Phillips iE33, Andover, MA., USA). 
An insonation angle of 60° was used always to measure blood flow in the common 
femoral artery, approximately 2-3 cm proximal to the bifurcation. The Doppler 
ultrasound machines were interfaced with a computer running custom audio recording 
software. Velocity measurements were determined using an intensity-weighted algorithm 
(custom software), subsequent to demodulation of forward and reverse Doppler 
frequencies. Femoral diameter was measured in triplicate during diastole following 
velocity measurements. Femoral blood flow was expressed in ml per min and calculated 
using the following: 
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Equation 3.2. Femoral Blood Flow 
Femoral vascular conductance was used to account for arterial blood pressures influence 
on femoral blood flow. Vascular conductance was expressed as ml per min per mmHg 
and calculated using the following: 
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Equation 3.3. Femoral Vascular Conductance 
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Cutaneous Blood Flow 
Laser-Doppler flowmetry was used to determine red blood cell flux, an index of 
skin blood flow for the studies described in chapter IV. Laser-Doppler flowmetry was 
used in conjunction with Doppler ultrasound to simultaneously measure skin and femoral 
blood flow. In doing so, we can ensure that any alteration in post-exercise femoral 
vascular conductance due to the intervention was not mediated by changes in the 
cutaneous vasculature.  
Laser-Doppler flowmetry uses Doppler technology that is based on laser light 
emission into the skin at depth of ~1mm. The light is scattered by tissue and moving red 
blood cells and collected by the probe and transmitted to photo detector where it is 
processed electronically to derive the laser Doppler flux signal. Given the depth and non-
specific laser emission, laser-Doppler flowmetry assesses blood flow normally in the 
microvasculature (i.e. arterioles, capillaries, and venules).   
Laser-Doppler probes (DRT4, Moor Instruments LTD, Devon, UK) were placed 
anteriorly, on the midline, and halfway between the inguinal ligament and patella on both 
the active and inactive leg. Cutaneous vascular conductance was calculated by dividing 
laser Doppler flux by mean arterial pressure and normalized to maximal flux values 
measured during local heating to 43°C to account for the variability between laser 
Doppler sites (109, 197).  
INTRAVENOUS CATHETERIZATION 
Intravenous catheterization was utilized in the studies described in chapter IV. A 
22G intravenous catheter (ProtectIV Safety I.V. Catheter, Smiths-Medical, Dublin OH, 
USA) was inserted into a peripheral vein within the antecubital space of the subjects left 
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arm.  The intravenous catheter was kept patent through the use of a continuous saline drip 
(60 ml hr⁻1). Venous blood was collected immediately after placement, prior to any drug 
infusion, and immediately following exercise. 
SKELETAL MUSCLE MICRODIALYSIS 
 Skeletal muscle microdialysis is a powerful, yet complex technique that is used to 
obtain biological samples from the extracellular fluid compartment in vivo. The origin of 
microdialysis technique is attributable to the “push pull” cannula, which was used to 
study cerebral tissue chemistry (61). The technique was later refined with the advent of 
the “dialytrode” which was introduced by Delgado and colleagues in 1971 (42). 
Ungerstedt and Pycock developed what is thought to be the modern microdialysis probe 
consisting of a hollow semi-permeable membrane which they implanted in the brain of 
conscious, freely moving rats (189).  
 The modern skeletal muscle microdialysis technique allows for the continuous 
monitoring of substances that are associated with metabolism, blood flow regulation, and 
other physiological events using the principle of diffusion (120). A unique quality of 
microdialysis is the localization of fluid sampling and drug delivery to the interstitial 
space. In general, fluid sampling and drug delivery will occur within 1 cm3 of the 
microdialysis probe (86).  
Microdialysis probes are constructed using two different designs; non-linear 
(Figure 3.1.) and linear. While the nomenclature of the probes lacks creativity the design 
of the probes does not. The semi-permeable membrane is made from a variety of 
materials such as polyarylethersulphone and regenerated cellulose. Membranes are 
designated by their molecular weight cutoff which identifies the “pore” size in which 
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substances in the interstitial space can traverse. Molecular weight cutoff can vary from 3 
kilodaltons to 100 kilodaltons. The membrane is usually attached to inlet/outlet tubing 
that is made of a soft malleable plastic such as polyurethane. 
 
  
Figure 3.1. Non-linear Skeletal Muscle Microdialysis Probe Schematic 
Filled circles denote substances perfused into the interstitial space. Small open circles 
denote substances capable of traversing the semi-permeable membrane. Large open 
circles denote substances that are too large to traverse the semi-permeable membrane. 
This schematic was adapted from artwork developed originally by Chris Minson and 
colleagues.   
 
The recovery of substances from the interstitial space is dependent on 1) perfusion 
rate, 2) probe length, 3) probe membrane characteristics, and 4) the rate of diffusion in 
the interstitial space (108, 122, 139). The first three factors are usually fixed within an 
experiment and therefore do not affect recovery across a study, but can vary greatly 
between studies and need to be taken into account when determining recovery. The rate 
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of diffusion is influenced by a number of factors and can vary greatly both between and 
within studies. The diffusion of substances is dependent on: tortuosity, volume fraction, 
blood flow, and perfusate flow rate (86, 108, 122, 139). Experiments with dynamic 
conditions such as exercise or pharmacological interventions can greatly alter the factors 
that influence diffusion. Thus, an in vivo calibration should be performed in such 
conditions in order to account for changes in probe recovery. 
Given the complex technical factors associated with microdialysis we used the 
best available approach for the studies described in chapter V.  We chose to use the non-
linear skeletal muscle microdialysis probe as it is better tolerated by human subjects 
when performing exercise and the membrane is better able to withstand the force exerted 
onto the probe during vigorous muscle contractions. All probes were implanted using 
sterile technique. The skin and underlying fascia were anesthetized using 1% lidocaine 
HCL (Hospira Worldwide, Lake Forest, IL, USA) buffered with sodium bicarbonate 
(Hospira Worldwide, Lake Forest, IL, USA). Care was taken to ensure that the lidocaine 
was not injected into the skeletal muscle. Probes were implanted in the vastus lateralis in 
a direction parallel with muscle fiber orientation (~19°, relative to long-axis of muscle)  
using a splitable introducer. After implantation, probes were held in place by covering the 
entry site with a sterile transparent medical dressing.   
A probe with a 30 mm polyarylethersulphone membrane and a 20 kilodalton 
molecular weight cutoff (63 MD Catheter, MDialysis, Stockholm, Sweden) was used to 
measure interstitial histamine and to assess interstitial fluid flux. The probe was perfused 
with 0.9% saline at rate of 5µl min-1 using a microinfusion pump (CMA 400 
Microdialysis pump, CMA, North Chelmsford, MA, USA). Because perfusion rates 
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above 0.3 µl min-1 do not allow for complete equilibration with the interstitial fluid, the 
internal reference technique (179) was used to for in vivo calibration of recovery by 
adding 0.40 µCi per ml of tritiated histamine [3H] to the perfusate. Additionally, ethanol 
(5 mM) was added to the perfusate in order to assess interstitial fluid flux via the ethanol 
washout technique. A detailed description of the internal reference and ethanol washout 
techniques and associated analyses are provided in subsequent sections. As detailed in a 
subsequent section, specific drugs were also added to the perfusate in some of the 
implanted probes. Interstitial tryptase was measured using a probe with a 30 mm 
polyarylethersulphone membrane and a 100 kilodalton molecular weight cutoff (71 High 
Cut-off Brain MD Catheter, MDialysis, Stockholm, Sweden). The probe was perfused 
with 0.9% saline at rate of 5µl min-1 using a microinfusion pump (CMA 400 
Microdialysis pump, CMA, North Chelmsford, MA, USA). Tritiated water (3H2O) was 
added to the perfusate to help assess probe stability during exercise but was not used to 
calibrate for probe recovery.  
Dialysate was collected into microtubes every 30 min throughout the studies. 
Microtubes were covered with non-porous tape during each sampling period in order to 
prevent ethanol evaporation. Microtube weight was documented before and after 
dialysate collection in order to assess fluid loss and estimate perfusion rate of the probe. 
A small volume (10 µL) of the dialysate was pipetted immediately after collection for 
scintillation counting. The remaining volume of dialysate was stored at -20°C for the 
remainder of the study. Thereafter, the samples were stored at -80°C until analysis.    
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SKELETAL MUSCLE BIOPSY 
 All skeletal muscle biopsies were performed by Dr. Hans C. Dreyer, an expert 
muscle physiologist. All biopsies were performed in the vastus lateralis under sterile 
technique. The first biopsy was taken just prior to unilateral dynamic knee extension 
exercise from the left, non-exercising leg. The second biopsy was taken immediately 
following exercise. The final biopsy was taken from the same incision as the previous, 
but at a site directly opposite to that of the prior biopsy. The post-exercise biopsies were 
taken immediately after and three hours following the completion of exercise. The skin 
and underlying fascia were anesthetized using 1% lidocaine HCL (Hospira Worldwide, 
Lake Forest, IL, USA). A 5 mm Bergström biopsy needle was inserted through a small 
incision made in the skin and muscle fascia. A 140 cc syringe and tubing were attached to 
an aspiration port on the biopsy needle in order apply negative pressure in the biopsy 
needle and increase the sample recovered. A single suture is placed after the biopsy is 
complete. The suture is also covered with bacitracin and a sterile transparent dressing to 
help prevent infection during the healing process. Harvested skeletal muscle tissue was 
blotted and removed of any adipose tissue and snap frozen in liquid nitrogen. When 
applicable, a small portion of the muscle sample was removed for future histological 
analysis. These tissue samples were snap frozen in isopentane cooled with liquid nitrogen 
and stored at -80°C until analysis.       
PHARMACOLOGICAL INTERVENTIONS 
Oral Drugs 
Oral antihistamine drugs were used in study 1 of chapter IV and the study detailed 
in chapter VI. Histamine H1 and H2 receptors were blocked using 540 mg fexofenadine 
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and 300 mg ranitidine. This combination of fexofenadine and ranitidine inhibits sustained 
post-exercise vasodilation following unilateral dynamic knee extension exercise (16). 
This dosage of oral fexofenadine has been shown to selectively block H1 receptors (time 
to peak concentration 1.15 h and half-life 12 h), while the dose of oral ranitidine has been 
shown to selectively block H2 receptors (time to peak plasma concentration 2.2 h and 2.6 
h half-life) (63, 173). Responses are 90% inhibited within 1 h and remain inhibited 6 h 
after administration (22, 63). Fexofenadine and ranitidine do not appear to cross into the 
central nervous system or possess sedative actions (22). Furthermore, these drugs do not 
have any direct cardiovascular effects in the absence of histamine receptor stimulation 
(i.e., when given under normal resting conditions, these drugs do not elicit any changes in 
heart rate, blood pressure, or smooth muscle tone) (126). Subjects ingested the histamine 
receptor antagonists with water 1 hr prior to exercise in all studies.  
Intravenous Drugs 
Systemic intravenous drugs were used in the studies detailed in chapter IV. 
Ascorbate (Bioniche Pharma, Morgantown, WV, USA) used in study 1 in chapter IV was 
diluted in saline and infused intravenously for 20 min prior to exercise (primer dose, 0.5 
g kg⁻1 body weight) and during 60 min of dynamic knee extension exercise (maintenance 
dose, 0.017 g kg⁻1 body weight). The primer dose of ascorbate was diluted with saline to 
a final volume of 60 ml and infused at a rate of 3.0 ml min-1 while the loading dose was 
diluted with saline to a final volume of 30 ml and infused at a rate of 0.5 ml min-1. Both 
doses of ascorbate were infused along with a continuous saline drip (60 ml hr⁻1). This 
pharmacological approach has been used in humans to significantly increase plasma 
ascorbate concentrations (17, 56, 99). Furthermore, ascorbate has been used successfully 
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to reduce both direct and indirect markers of oxidative stress following exhaustive 
aerobic exercise in humans (9). Ascorbate does not appear to have any direct 
cardiovascular effects under resting conditions in healthy young adults (17, 56, 99). 
Ascorbate is a water-soluble scavenger of reactive species such as superoxide and 
peroxynitrite (73) and has a half-life of 30 min when administered intravenously (46, 
153). 
N-acetylcysteine was infused in the follow-up study detailed in chapter IV. N-
acetylcysteine (Acetadote ®, Cumberland Pharmaceuticals Inc., Nashville, TN, USA) was 
diluted in saline and infused intravenously for 15 min prior to exercise (primer dose, 125 
mg kg⁻1 hr⁻1) and during 60 min of dynamic knee extension exercise (maintenance dose, 
25 mg kg⁻1 hr⁻1). The primer dose of n-acetylcysteine was diluted with saline to a final 
volume of 45 ml and infused at a rate of 3.0 ml min-1 while the maintenance dose was 
diluted with saline to a final volume of 60 ml and infused at a rate of 1.0 ml min-1. Both 
doses of n-acetylcysteine were infused along with a continuous saline drip (60 ml hr⁻1). 
This pharmacological approach has been used in humans to significantly increase plasma 
n-acetylcysteine concentrations prior to and during exercise (20, 127, 128). Furthermore, 
n-acetylcysteine has been used successfully to alter blood redox status in both short-term 
high intensity and prolonged cycle exercise in humans (127, 128). N-acetylcysteine does 
not appear to have any direct cardiovascular effects under resting conditions in healthy 
young adults (144). N-acetylcysteine is potent water-soluble pharmacological antioxidant 
with a half-life of ~5 hrs. It can directly scavenge reactive species such as hydrogen 
peroxide and hydroxyl radical and can also indirectly reduce reactive species by 
augmenting glutathione production via intracellular cysteine formation (35, 73, 176). 
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Microdialysis Drugs  
Drugs delivered via muscle microdialysis were used in studies described in 
chapter V. Pyrilamine maleate (1mM) was used to block H1 histamine receptors and 
cimetidine (3mM) was used to block H2 histamine receptors (Sigma-Aldrich, St. Louis, 
MO, USA). These doses have been used previously in our lab to reduce successfully 
sustained post-exercise vasodilation (155). α-fluoromethylhistidine dihydrochloride 
(200µM) was infused to irreversibly inhibit histidine decarboxylase activity (193). This 
dose was extrapolated from studies using α-fluoromethylhistidine dihydrochloride to 
inhibit histidine decarboxylase in cell culture (181, 200). 10 mM of the mast cell 
degranulater, compound 48/80 (Sigma-Aldrich, St. Louis, MO, USA), was infused in a 
total of four subjects to verify the diffusive ability of tryptase through the 100 kilodalton 
membrane. This dose has been used successfully in our lab to activate mast cells and 
produce localized vasodilation within the skeletal muscle.  
ASSAYS AND ANALYSIS 
Oxidative Stress Analysis 
Plasma F2 Isoprostanes Assay. Plasma F2-isoprostanes were used as an in vivo 
biomarker of exercise-induced oxidative stress for study 1 in chapter IV. Countless 
indirect biomarkers of oxidative stress exist but most are considered inaccurate and/or 
obsolete (e.g. thiobarbituric acid reactive substances assay) (73). Oxidative stress via free 
radicals can damage biomolecules such as DNA, lipids, and proteins (73, 131).  Indirect 
biomarkers of oxidative stress are typically byproducts of free radical mediated damage. 
F2-isoprostanes are prostaglandin-like substances that result from lipid peroxidation, 
specifically free radical mediated peroxidation of arachidonic acid (131). It is important 
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to note that this is mediated independent of cyclooxygenase enzyme activity. F2-
isoprostanes are considered the ideal biomarker of oxidative stress and have been assayed 
within the context exercise (141).       
Venous blood collected into a vacutainer® and immediately centrifuged at 1,300 
RCF for 10 minutes. Blood plasma (500 µl) was then aliquoted into cryogenic vials, 
immediately snap frozen in liquid nitrogen, and stored at -80°C. Butylated 
hydroxytoluene (0.005%) was added to each 500µl plasma sample prior to snap freezing 
to prevent ex vivo oxidation. Total plasma F2-isoprostanes were assayed using gas 
chromatography/negative ion chemical ionization mass spectrometry (GC/NICI-MS) 
using stable isotope dilution with [2H4]-15-F2t-Isoprostane as the internal standard 
(Vanderbilt University Eicosanoid Core Laboratory). Gas chromatography/negative ion 
chemical ionization mass spectrometry is considered the gold standard assay for F2-
isoprostanes (172). 
Dialysate Analysis 
Microdialysis Probe Recovery. The internal reference method (179) was used to 
continuously monitor probe recovery when determining interstitial histamine 
concentration. This technique requires the use of a radioisotope added to the 
microdialysis perfusate. The internal reference method assumes that the loss of 
radioisotope from the perfusate is equal to the recovery of the target analyte from the 
interstitial space. Thus, we can account for any change in analyte concentration that is not 
caused by a change in true interstitial concentration. 
 Tritiated histamine [3H] (0.40 µCi ml) was added to the perfusate. 10 µl of 
perfusate and dialysate were pipetted into 5 ml polypropylene scintillation vials 
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containing 3 ml of scintillation cocktail (Ultima Gold, Shelton CT, USA). The 
scintillation vials were then capped and vortexed for 20 sec. Radioactivity was then 
measured (counts min-1) in duplicate using a liquid scintillation counter (Beckman LS 
6000SC, Brea, CA, USA). Probe recovery was then calculated using the following 
equation: 
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Equation 3.4. Probe Recovery via the Internal Reference Technique 
Assessing prove recovery when analyzing for tryptase was performed using a 
different method due to a number of issues. First, radiolabelled tryptase is unavailable, 
thus using the internal reference technique to account for probe recovery was of limited 
use. Second, granular storage of tryptase in mast cells occurs at a pH of ~5.5 and is also 
thought to be dependent on mast cell heparin (72). Thus, tryptase may be converted from 
its tetrameric structure into active monomers when released into the interstitial space at a 
neutral pH and with low heparin concentrations. Third, the ELISA used to quantitate 
tryptase utilized the majority of the dialysate sample leaving ~10 - 20 µl remaining. 
Therefore, we decided to measure the total protein in a given sample to account for 
changes in probe recovery during and following exercise. This method has not been 
validated but was the only method available given the limited volume of dialysate 
remaining after measuring tryptase. 
Total protein was assayed using a 96-well based kit (Quant-iT™, Invitrogen, 
Eugene OR, USA). 200 ul of a working solution containing 100 ul of Quant-iT™ protein 
reagent and 20 ml Quant-iT™ protein buffer was added to a black 96-well microplate. 5 
ul of dialysate was then added to each well. The fluorescent signal of each well was then 
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measured using an excitation of 485 nm and an emission of 590 nm (Synergy HT, Biotek, 
Winooski, VT, USA) and plotted against the fluorescent signal of a set of known protein 
standards using a 5-paramter logistic regression. 
Interstitial Fluid Flux via Ethanol Washout. Interstitial fluid flux was assessed via the 
ethanol washout technique. Introduced by Hickner and colleagues, the ethanol washout 
technique was originally developed to measure relative changes in blood flow in close 
vicinity of the implanted microdialysis probe (86, 88, 89). To do this, ethanol is added to 
the perfusate where it can diffuse freely into the interstitial space, cells, and 
microcirculation (86). Thus, the rate in which ethanol had cleared once diffused into the 
area around the probe is thought to relate directly to local blood flow. Calculating the 
ratio of ethanol remaining in the dialysate to that in the perfusate is thought to represent 
an inverse surrogate of microvascular blood flow. In other words, the lower the ethanol 
outflow-inflow ratio, the higher the microvascular blood flow. 
 The ethanol washout technique was originally validated in human and non-human 
models using a number of techniques to manipulate skeletal muscle blood flow (85–87, 
89). However, Rådegran et al. reported that the ethanol washout technique may reflect 
changes in probe recovery rather than microvascular blood flow, as the femoral artery 
infusion of the adenosine failed to reduce the ethanol outflow-inflow ratio at rest and 
during knee extension exercise (164). Given the complex nature and multiple 
mechanisms governing the interstitial environment, ethanol washout most likely reflects a 
number of factors within interstitial space such as blood flow, vascular permeability, and 
volume fraction. Thus, we believe that ethanol washout technique in general measures 
interstitial fluid flux, but can still be used as a surrogate marker of local perfusion. 
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Importantly, local blockade of H1/H2 histamine receptors via microdialysis attenuates the 
reduction in the ethanol outflow-inflow ratio during the recovery from exercise (155). 
This suggests that the mutability of interstitial fluid (and thus local perfusion) is 
inherently dependent on histamine receptor activation during the recovery from exercise. 
Thus, the ethanol washout technique should be useful in pharmaco-dissecting the possible 
mechanisms increasing local histamine formation and mediating sustained post-exercise 
vasodilation. 
 The washout of ethanol from the microdialysis probe was measured using a 
modified alcohol dehydrogenase enzymatic assay (89, 157). The assay uses alcohol 
dehydrogenase to catalyze the oxidation of ethanol using nicotinamide adenine 
dinucleotide (NAD+) as the electron acceptor. The enzymatic reaction yields 
acetaldehyde, the oxidized form of ethanol. 150 ul of a glycine-hydrazine buffer (pH 8.9) 
containing .5 µM NAD+ was added to a standard black 96-well microplate. Ethanol was 
measured in the perfusate, where 5mM ethanol (Sigma-Aldrich, St. Louis, MO, USA) 
was added, and in all dialysate samples. 2ul dialysate or perfusate and 10 ul alcohol 
dehydrogenase were then added to each well and the plate was incubated in the dark, at 
room temperature (~23°C) for 1 hr. The fluorescent signal of each well was then 
measured using an excitation of 360 nm and an emission of 460 nm (Synergy HT, Biotek, 
Winooski, VT, USA) and plotted against the fluorescent signal of a set of known ethanol 
standards using a 5-paramter logistic regression. The resulting ethanol concentrations 
were used to calculate the ethanol outflow-inflow ratio using the following equation: 
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Equation 3.5. Ethanol Outflow-inflow Ratio 
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Tryptase Assay. Interstitial tryptase was measured using a standard “sandwich” enzyme-
linked immunosorbent assay and performed in accordance to the manufactures 
instructions with slight modification (Kamiya Biomedical, Seattle, WA, USA). 50 ul 
dialysate was added to a 96-well microplate pre-coated with an antibody raised against 
human tryptase. 100 ul of a detection reagent containing a biotin-conjugated antibody 
specific to tryptase was then added to each well. The plate was incubated for 1 hr at 37°C 
and then washed using a standard wash buffer. 100 ul of a secondary detection reagent 
containing avidin conjugated to horseradish peroxidase was then added to each well. The 
plate was again incubated for 1 hr at 37°C and then washed using a standard wash buffer. 
Finally, a tetramethylbenzidine substrate solution was added to each well and incubated 
for ~3 min at 37°C. The enzyme-substrate reaction was then terminated by adding 50 ul 
of a stop solution containing sulfuric acid. The absorbance was then measured at a 
wavelength of 450 (Synergy HT, Biotek, Winooski, VT, USA) for each sample and 
plotted against the absorbance of a set of known tryptase standards using a 5-paramter 
logistic regression.  
Histamine Assay. Interstitial histamine was measured using a standard “competitive” 
enzyme-linked immunosorbent assay (Rocky Mountain Diagnostics, Colorado Springs, 
CO, USA) and performed in accordance to the manufactures instructions. The assay was 
performed in two phases - the acylation phase and the enzyme-linked immunosorbent 
assay phase. All samples and standards were acylated by combining them with 25 µl 
acylation buffer and 25µl acylation reagent and incubating on a plate shaker (600 rpm) 
for 45 min at room temperature. 200 µl distilled water was then added to all wells and the 
microplate was incubated on a plate shaker (600 rpm) for 15 min at room temperature.  
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 25 µl of the acylated samples and standards were transferred to a 96-well 
microplate pre-coated with an antibody raised against human histamine. 100 ul of a 
histamine goat anti-serum was added to all wells. The microplate was then incubated on a 
plate shaker (600 rpm) for 3 hrs at room temperature. The plate was then washed four 
times and 100 µl of an enzyme conjugate containing an anti-goat IgG conjugated with 
peroxidase was added to all wells and incubated on a plate shaker (600 rpm) for 30 mins 
at room temperature. The plate was again washed four times and 100 µl of a 
tetramethylbenzidine substrate solution was added to all wells and incubated on a plate 
shaker (600 rpm) for 25 min at room temperature. Finally, 100 ul of a stop solution 
containing sulfuric acid was added to all wells. The absorbance was then measured at a 
wavelength of 450 (Synergy HT, Biotek, Winooski, VT, USA) for each sample and 
plotted against the absorbance of a set of known histamine standards using a 5-paramter 
logistic regression.  
Gene Expression Analysis 
mRNA expression was evaluated for the study detailed in chapter VI. We utilized 
next-generation RNA sequencing to probe gene expression on a transcriptome-wide 
level. RNA sequencing provides a comprehensive index of all of the genes expressed in 
the transcriptome at the time when the host tissue and cells were obtained (191). Thus, 
RNA sequencing technology allows us to exhaustively and precisely examine transcripts 
related to acute exercise, angiogenesis, and histamine receptor activation. Additionally, 
RNA sequencing will allows us to interrogate additional genes and pathways unrelated to 
angiogenesis but that may respond to acute exercise and histamine receptor activation so 
that we can generate novel hypothesis driven research questions.  
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Gene expression analysis via RNA sequencing was performed at the University of 
Oregon Genomics Core Facility following RNA isolation by the Muscle Physiology 
Laboratory. The following sections were written in consultation with the Muscle 
Physiology Laboratory and the Genomics Core Facility. 
RNA Isolation. Approximately 15 mg of skeletal muscle tissue was homogenized in 
Eppendorph RNase-free tubes containing 1 ml TRI reagent. The sample was then 
separated using 0.2 ml chloroform and precipitated with 0.5 ml isopropanol. The 
resulting RNA pellet was washed twice in 75% alcohol, dried, and subsequently 
dissolved in 1.5 µl 0.1 mM EDTA for each 1 mg of starting skeletal muscle tissue. 
RNA Sequencing. Following RNA isolation, sequencing was carried using the following 
standardized workflow within the Genomics Core Facility: 1) RNA preparation 2) cDNA 
library preparation 3) sequencing and 4) bioinformatics analysis. Because mRNA is only 
1 - 5% of total RNA, an isolation procedure is necessary to ensure that the sample is not 
contaminated with non-polyadenylated mRNA (e.g. ribosomal). Pure mRNA was isolated 
from the total RNA preparation using a commercially available kit (Dynabeads® mRNA 
Purification Kit, Life Technologies, Eugene, OR, USA). Input RNA yield and integrity 
was analyzed prior to library construction via automated capillary electrophoresis 
(Fragment Analyzer, Advanced Analytical Technologies, Inc., Ames, IA, USA) coupled 
with a High Sensitivity RNA Analysis Kit (DNF-491, Advanced Analytical 
Technologies, Inc., Ames, IA, USA).  
The cDNA library preparations was performed using a KAPA Stranded RNA-Seq 
Library Preparation Kit (Kapa Biosystems, Boston, MA, USA), which is designed 
specifically for Illumina Sequencers. Briefly, isolated mRNA was first fragmented by 
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heating each sample to 94°C in the presence of magnesium. Double-stranded cDNA was 
then synthesized from the fragmented RNA using a two-step process which includes 1st 
strand cDNA synthesis via random priming and 2nd strand cDNA synthesis which 
converts the cDNA:RNA hybrid to double-stranded cDNA. Adapters were then ligated to 
the ends of the cDNA preceding library amplification using high-fidelity, low-bias 
polymerase chain reaction. Constructed libraries were validated using the High 
Sensitivity NGS Fragment Analysis Kit (DNF-486, Advanced Analytical Technologies, 
Inc., Ames, IA, USA) and quantitated using a Qubit 2.0 fluorometer coupled with a High 
Sensitivity DNA assay kit (Life Technologies, Eugene, OR, USA).  
Subsequent to cDNA library preparation, flowcells were loaded with samples and 
clusters were formed and replicated for each oligo. Flowcells were then placed in the 
sequencer (Illumina HiSeq 2000, Illumina, San Diego CA, USA) and fluorescently 
tagged nucleotides were competitively attached to complimentary bases within each 
cluster. Single-end sequencing was performed at a length of 100 nucleotides.  
 Following the read process, adapters were removed and sequences were tiled and 
aligned to the reference human genome. RNA sequencing is in the final stages of 
analysis. Thus, the bioinformatics component of data analysis is yet to be completed.  
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CHAPTER IV 
SUSTAINED POST-EXERCISE VASODILATION, OXIDATIVE STRESS, AND 
HISTAMINE RECEPTOR ACTIVATION 
INTRODUCTION 
Blood flow to the previously active skeletal muscle remains elevated for several 
hours following an acute bout of aerobic exercise (74, 77, 114). This sustained post-
exercise vasodilation occurs following both whole-body exercise (78, 79, 154) and 
isolated small muscle-mass exercise (16). In humans, following large muscle-mass 
exercise, sustained post-exercise vasodilation results from a combination of histamine H1 
and H2 receptor activation (119, 125, 126) alterations in the central neural control of 
sympathetic outflow (78), and a reduced ability to transduce sympathetic nerve activation 
into vasoconstriction (75). In contrast, H1 and H2 receptor blockade abolishes sustained 
post-exercise vasodilation following small-muscle mass exercise, suggesting that this 
phenomenon is primarily histaminergic in origin and may occur independent of the neural 
mechanisms (16). The upstream signaling that drives sustained post-exercise 
histaminergic vasodilation remains undetermined, but presumably relies on the release or 
formation of histamine within the skeletal muscle vascular bed. Histamine may be 
released by mast cells via degranulation. Alternatively, local histamine formation may be 
increased post-exercise through de novo synthesis in non-mast cells by the inducible 
enzyme histidine decarboxylase. Exercise-related factors such as increased intramuscular 
temperature and oxidative stress have been proposed to stimulate local histamine release 
or formation within the previously active skeletal muscle (74), but these theories are 
untested. Notably, oxidative stress has been linked to mast cell degranulation using both 
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in vitro and in vivo experimental models (146–148), and has also been linked to induction 
of histidine decarboxylase in vitro (90). 
By common definition, oxidative stress is a condition in which pro-oxidants 
overwhelm antioxidant defense mechanisms resulting in macromolecular damage and 
altered redox signaling and control (104, 182). In humans, Dillard and colleagues showed 
that acute whole-body aerobic exercise increases oxidative stress (43). This was first 
demonstrated indirectly by increased lipid peroxidation, and subsequently confirmed in 
rats (40) and later in humans (8) using electron paramagnetic spectroscopy. Involvement 
of whole body exercise is not a prerequisite for oxidative stress, as unilateral dynamic 
knee extension exercise similarly induces oxidative stress within the exercising muscle 
group (11, 12).  
Thus, we propose that there may be a distinct mechanistic link between exercise-
induced oxidative stress and sustained post-exercise histaminergic vasodilation. 
Therefore, the purpose of this study was to determine if acute exercise-induced oxidative 
stress is an important part of the upstream signaling that leads to sustained post-exercise 
vasodilation via activation of histamine receptors. In study 1, we tested the hypothesis 
that the infusion of ascorbate, a potent antioxidant, would inhibit sustained post-exercise 
vasodilation, and that this inhibition would be similar in magnitude to that observed with 
histamine receptor antagonism in prior studies. Further, we hypothesized that H1 and H2 
blockade in combination with ascorbate would not further reduce the vasodilation beyond 
the effect of ascorbate alone. Given the potential for ascorbate to interact directly with 
histamine we conducted a follow-up study using an alternative antioxidant, n-
acetylcysteine. The purpose of the follow-up study was to determine if the findings from 
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study 1 were due to the blunting of exercise-induced oxidative stress and thus 
inactivation of a histaminergic signaling pathway or due to the direct degradative action 
of ascorbate on histamine. We tested the hypothesis that the infusion of the potent 
antioxidant, n-acetylcysteine would, similar to ascorbate, inhibit sustained post-exercise 
vasodilation. 
METHODS 
Subjects  
Nineteen young healthy subjects were invited to participate in this study. Seven 
men and 4 women participated in study 1 whereas 5 men and 3 women participated in the 
follow-up study. Written informed consent was obtained from all subjects subsequent to a 
verbal and written briefing of all experimental procedures. Subjects were deemed healthy 
following a standard health history questionnaire. All subjects were required to abstain 
from caffeine, alcohol, and exercise for 24h prior to the study. Additionally, subjects 
reported to the laboratory after an overnight fast. No subjects were using any over-the-
counter or prescription medications at the time of the study, with the exception of oral 
contraceptives. Female participants were studied during the early follicular phase of their 
menstrual cycle or during the placebo phase of their oral contraceptive. This study was 
approved by the Institutional Review Board at the University of Oregon and was 
performed in accordance to the principles outlined by the Declaration of Helsinki. 
 
Screening Visit 
The screening visit was used to determine peak power output during a unilateral 
dynamic knee extension exercise test performed to volitional fatigue. Dynamic knee-
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extension exercise during all visits was performed using a custom-built knee extension 
ergometer based on a computer-controlled step-motor that provided resistance against the 
subject’s lower leg. Based on real-time measures of angular velocity and torque, power 
was calculated and a feedback loop maintained measured power at the assigned level. 
Subjects were seated with their back at 60° upright and knee-extension exercise was 
performed with the right leg over a 45° range of motion, starting with the leg hanging at 
~90° of flexion. Subjects were asked to maintain a cadence of 45 kicks min-1 while being 
provided with visual feedback of both kicking cadence and range of motion. Workload 
was ramped incrementally at a rate of 3 watts min-1. During the dynamic knee extension 
exercise test subjects reached peak power in 9.9 ± 0.7 min (range 7 - 13 min).  
Experimental Approach  
Study 1. Following the screening visit, subjects were required to visit the laboratory on 
three separate occasions and were studied within three different conditions: 1) control 2) 
ascorbate infusion and 3) ascorbate infusion plus H1/H2 receptor blockade. Conditions 
were randomized, counterbalanced, and were separated by at least 7 days. Leg 
hemodynamics were assessed during each visit before and after 60 min of unilateral 
dynamic knee extension exercise performed at 60% of peak power and a cadence of 45 
kicks min-1. Power was ramped at the onset of exercise to 60% peak power over the first 
15 min. Power output was recorded continuously throughout 60 min dynamic knee 
extension exercise.  
Ascorbate (Bioniche Pharma, Morgantown, WV, USA) was diluted in saline and 
infused intravenously for 20 min prior to exercise (primer dose, 0.5 g kg⁻1 body weight) 
and during 60 min of dynamic knee extension exercise (maintenance dose, 0.017 g kg⁻1 
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body weight). The primer dose of ascorbate was diluted with saline to a final volume of 
60 ml and infused at a rate of 3.0 ml min-1 while the maintanence dose was diluted with 
saline to a final volume of 30 ml and infused at a rate of 0.5 ml min-1. Both doses of 
ascorbate were infused along with a continuous saline drip (60 ml hr⁻1). This 
pharmacological approach has been used in humans to significantly increase plasma 
ascorbate concentrations (17, 56, 99). Furthermore, ascorbate has been used successfully 
to reduce both direct and indirect markers of oxidative stress following exhaustive 
aerobic exercise in humans (9). Ascorbate does not appear to have any direct 
cardiovascular effects under resting conditions in healthy young adults (17, 56, 99). 
Ascorbate is a water-soluble scavenger of reactive species such as superoxide and 
peroxynitrite (73), and has a half-life of 30 min when administered intravenously (46, 
153).  
For study 1, histamine H1 and H2 receptors were blocked using 540 mg 
fexofenadine and 300 mg ranitidine. This combination of fexofenadine and ranitidine 
reduces sustained post-exercise vasodilation by ~86% following unilateral dynamic knee 
extension exercise (16). This dosage of oral fexofenadine has been shown to selectively 
block H1 receptors (time to peak concentration 1.15 h and half-life 12 h), while the dose 
of oral ranitidine has been shown to selectively block H2 receptors (time to peak plasma 
concentration 2.2 h and 2.6 h half-life) (63, 173). Responses are 90% inhibited within 1 h 
and remain inhibited 6 h after administration (22, 63). Fexofenadine and ranitidine do not 
appear to cross into the central nervous system or possess sedative actions (22). 
Furthermore, these drugs do not have any direct cardiovascular effects in the absence of 
histamine receptor stimulation (i.e., when given under normal resting conditions, these 
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drugs do not elicit any changes in heart rate, blood pressure, or smooth muscle tone) 
(126). Subjects ingested the histamine receptor antagonists with water 1 hr prior to 
exercise. On the control day, saline was infused in lieu of ascorbate and subjects did not 
receive fexofenadine or ranitidine. 
Follow-up Study. Following the screening visit, subjects were required to visit the 
laboratory on two separate occasions and were studied within two different conditions: 1) 
control 2) n-acetylcysteine infusion. We chose to not add a third condition combining n-
acetylcysteine and H1/H2 receptor blockade as the follow-up study was conducted in 
order to determine if the findings from study 1 were related to the antioxidant effect of 
ascorbate or were due to a direct interaction with histamine. Conditions were randomized, 
counterbalanced, and were separated by at least 7 days. Leg hemodynamics were 
assessed during each visit before and after 60 min of unilateral dynamic knee extension 
exercise performed at 60% of peak power and a cadence of 45 kicks min-1. Power output 
was ramped at the onset of exercise to 60% peak power over the first 15 min. Power 
output was recorded continuously throughout 60 min dynamic knee extension exercise. 
N-acetylcysteine (Acetadote ®, Cumberland Pharmaceuticals Inc., Nashville, TN, USA) 
was diluted in saline and infused intravenously for 15 min prior to exercise (primer dose, 
125 mg kg⁻1 hr⁻1) and during 60 min of dynamic knee extension exercise (maintenance 
dose, 25 mg kg⁻1 hr⁻1). The primer dose of n-acetylcysteine was diluted with saline to a 
final volume of 45 ml and infused at a rate of 3.0 ml min-1 while the maintenance dose 
was diluted with saline to a final volume of 60 ml and infused at a rate of 1.0 ml min-1. 
Both doses of n-acetylcysteine were infused along with a continuous saline drip (60 ml 
hr⁻1). This pharmacological approach has been used in humans to significantly increase 
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plasma n-acetylcysteine concentrations prior to and during exercise (20, 127, 128). 
Furthermore, n-acetylcysteine has been used successfully to alter blood redox status in 
both short-term high intensity and prolonged cycle exercise in humans (127, 128). N-
acetylcysteine does not appear to have any direct cardiovascular effects under resting 
conditions in healthy young adults (144). N-acetylcysteine is potent water-soluble 
pharmacological antioxidant with a half-life of ~5 hrs. It can directly scavenge reactive 
species such as hydrogen peroxide and hydroxyl radical and can also indirectly reduce 
reactive species by augmenting glutathione production via intracellular cysteine 
formation (35, 73, 176). Histamine receptor blockade was not used in this study.  
Measurements 
All resting measurements were made pre- and post-exercise with the subjects in 
the supine position. Subjects were asked to remain quiet and relaxed during all 
hemodynamic measurements. Room temperature remained thermoneutral (~23°C) 
throughout the study. All measurements were identical between study 1 and the follow-
up study with the exception of venous blood sampling. 
Heart Rate and Blood Pressure. Arterial blood pressure was measured in the right arm 
using an automated sphygmomanometer (Tango+, SunTech Medical, Raleigh, NC, 
USA). Heart rate was monitored continuously using a three lead electrocardiograph 
(Datex-Ohmeda Cardiocap/5, GE Healthcare, Tewksbury, MA, USA) for study 1 and 
was monitored using a three lead electrocardiograph in the follow-up study (Tango+, 
SunTech Medical, Raleigh, NC, USA). Heart rate and blood pressure were also measured 
during 60 min dynamic knee extension exercise. 
Femoral Blood Flow. A pressure cuff (Hokanson E20 Rapid Cuff Inflator, D. E. 
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Hokanson, Inc., Bellevue, WA. USA) was placed on both legs, immediately distal to the 
patella and inflated to 250 mmHg to ensure that blood flow measured in the femoral 
artery was indicative of blood flow to the thigh region. Femoral artery blood flow 
velocity was measured via duplex ultrasonography. A linear-array vascular ultrasound 
probe (10 MHz, GE Vingmed System 5, Horton, Norway) and an insonation angle of 60° 
was used to measure blood flow in the common femoral artery, approximately 2-3 cm 
proximal to the bifurcation. The Doppler ultrasound machine was interfaced with a 
computer running custom audio recording software. Velocity measurements were 
determined using an intensity-weighted algorithm (custom software), subsequent to 
demodulation of forward and reverse Doppler frequencies. For study 1, velocity 
measurements were made at an average depth of 1.63 ± 0.01 cm and were thin-beam 
corrected, based on a known beam-width of 2.21 mm which resulted in an average 
correction factor of 0.766 ± 0.001, as outlined by Buck et al. (23). For the follow-up 
study, velocity measurements were made at an average depth of 1.72 ± 0.01 cm and were 
thin-beam corrected which resulted in an average correction factor of 0.765 ± 0.0001.  
Femoral diameter was measured in triplicate during diastole following velocity 
measurements. The average femoral artery diameter was 8.89 ± 0.03 mm for study 1 and 
9.09 ± 0.04 mm for the follow-up study. Leg blood flow was calculated as cross-sectional 
area multiplied by femoral mean blood velocity and reported in ml per min. Femoral 
vascular conductance was calculated by dividing femoral blood flow by mean arterial 
pressures and expressed as ml per min per mmHg.  
Skin Blood Flow. Laser-Doppler flowmetry (DRT4, Moor Instruments LTD, Devon, 
UK) was used to determine red blood cell flux, an index of skin blood flow. Laser-
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Doppler probes were placed anteriorly, on the midline, and halfway between the inguinal 
ligament and patella on both the active and inactive leg. Cutaneous vascular conductance 
was calculated by dividing laser Doppler flux by mean arterial pressure and normalized 
to maximal flux values measured during local heating to 43°C to account for the 
variability between laser Doppler sites (109, 197).  
Blood Sampling and Analysis. A 22 gauge intravenous catheter was placed in the 
subjects left arm and was used for infusions and blood sampling. Venous blood was 
collected and analyzed for only study 1. Venous blood was sampled before exercise 
preceding all infusions and immediately post-exercise. Venous blood was collected into a 
vacutainer® and centrifuged at 1,300 RCF within five minutes. Blood plasma (500 µl) 
was then aliquoted into cryogenic vials, immediately snap frozen in liquid nitrogen, and 
stored at -80°C. Butylated hydroxytoluene (0.005%) was added to each 500µl plasma 
sample prior to snap freezing to prevent ex vivo oxidation. Total plasma F2-isoprostanes 
were assayed using gas chromatography/negative ion chemical ionization mass 
spectrometry (GC/NICI-MS) using stable isotope dilution with [2H4]-15-F2t-Isoprostane 
as the internal standard (Vanderbilt University Eicosanoid Core Laboratory). Plasma F2-
isoprostanes were used as an indirect biomarker of exercise-induced oxidative stress.  
Electromyography. Surface electromyography (Z03 EMG preamplifiers, Motion Lab 
Systems, Baton Rouge, La., USA) was used to ensure the subjects right quadriceps and 
posterior thigh muscles were not activated during knee flexion and to ensure that the 
muscles in the non-exercised leg remained inactive during exercise. Electromyography 
probes were placed on the anterolateral aspect of the thigh 8 - 10 cm above the patella 
and posteriorly one-third of the distance between the popliteal fossa and ischial tuberosity 
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on both the active legs and inactive legs. Electromyography probes were placed in 
parallel with the pennation angle of the skeletal muscle fibers. The electromyography 
probes were integrated with custom built software in order to provide visual feedback to 
investigators during performance of knee extension exercise.  
Statistical Analyses 
 Preliminary statistical analysis indicated that our primary outcome variables did 
not vary by sex for study 1. As such, all subsequent analyses for study 1 were performed 
after grouping data for both men and women. Given the limited number of female 
subjects in the follow-up study, the primary outcome variables were not assessed by sex. 
All analyses for the follow-up study were performed after grouping data for both men and 
women.  
The statistical analysis was identical for both studies. Baseline differences 
between conditions were analyzed using a one-way mixed model analysis of variance 
with repeated measures. Exercise responses were also analyzed using a one-way mixed 
model analysis of variance with repeated measures. Our primary outcome variables 
during the recovery from exercise were analyzed using a stepwise regression and carried 
out with SAS Proc GLMSELECT (SAS version 9.2; SAS Institute Inc. Cary, NC, USA). 
As opposed to the traditional approach which would use ANOVA to test for differences 
between conditions at discrete time points during the recovery from exercise, our 
stepwise approach allows the examination of both linear and quadratic relationships 
across time and tests whether or not these relationships differ between conditions. 
Independent variables remained in the model if a minimum P-value threshold was met (P 
     
 62
< 0.15). Significance was set at P < 0.05. Data are reported as mean ± SEM unless stated 
otherwise (e.g., SD is used in Table 1 to indicate the variability in the subject pool). 
RESULTS 
Subject Characteristics 
 Subject physical characteristics and data obtained during the screening visit are 
shown in Table 4.1. Subject characteristics are similar to those obtained previously in our 
laboratory in young healthy subjects and consistent with recreationally active individuals.  
Table 4.1. Subject Characteristics 
 Study 1 Follow-up Study 
n 11 8 
Age (yrs) 22.2 ± 1.9 20.6 ± 2.3 
Height (cm) 173 ± 9 178 ± 8 
Weight (kg) 72.8 ± 11.4 75.0 ± 14.0 
Body mass index (kg m⁻2) 24.0 ± 2.8 23.5 ± 3.4 
Baecke sport index (arbitrary units) 3.0 ± 0.7 3.3 ± 0.7 
Physical activity index (MET hr⁻1 week⁻1) 88 ± 54 39 ± 17 
Peak power output (W) 35.2 ± 6.4 34.8 ± 6.9 
Values are mean ± SD. MET, metabolic equivalents.  
Study 1 
Pre-exercise Hemodynamics. Pre-exercise heart rate and mean arterial blood pressure 
are shown in Table 4.2. Both heart rate (P = 0.3) and mean arterial pressure (P = 0.9) did 
not differ across the three conditions of control, ascorbate, and ascorbate plus H1/H2 
blockade. As shown in Table 4.3, cutaneous vascular conductance within both the active 
leg and inactive leg did not differ across the three conditions (P = 0.9). Pre-exercise 
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femoral blood flow and femoral vascular conductance are shown in Figure 4.1. Within 
the active leg, femoral blood flow did not differ (P = 0.6) across the three conditions. 
Likewise, within the inactive leg, femoral blood flow did not differ across the three 
conditions (P = 0.6). Within the active leg, femoral vascular conductance did not differ 
across the three conditions (P = 0.6). Likewise, within the inactive leg, femoral vascular 
conductance did not differ across the three conditions (P = 0.6).  
Exercise Responses. Power output during steady state dynamic knee extension exercise 
was similar for the three conditions of control (20.8 ± 1.3 W), ascorbate (20.0 ± 1.1 W), 
and ascorbate plus H1/H2 blockade (19.9 ± 1.4 W) (P = 0.1). Power output for each 
condition was within 2 W of the estimated 60% workload (21 W). Compared with the 
control condition (96.8 ± 1.0 mmHg), mean arterial blood pressure was higher for the 
ascorbate condition (100.0 ± 1.3 mmHg, P < 0.05), but was similar with the ascorbate 
plus H1/H2 blockade condition (98.2 ± 1.3 mmHg, P = 0.3). Mean arterial pressure did 
not differ for ascorbate and ascorbate plus H1/H2 blockade conditions (P = 0.2). Heart 
rate was similar for the three conditions of control (90.6 ± 3.3 beats min-1), ascorbate 
(95.5 ± 4.2 beats min-1), and ascorbate plus H1/H2 blockade (90.9 ± 3.8 beats min
-1) (P = 
0.1).  
Oxidative Stress. Pre-exercise F2-isoprostane concentration did not differ across the 
three conditions (control 87.1 ± 8.7 pg ml-1; ascorbate 88.7 ± 8.2 pg ml-1; ascorbate plus 
H1/H2 blockade 84.7 ± 7.2 pg ml
-1; P = 0.4). Compared with pre-exercise, F2-isoprostane 
concentration was not elevated immediately following dynamic knee extension exercise 
for all three conditions (P = 0.4). Likewise, post-exercise F2-isoprostane concentrations 
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did not differ across the three conditions (control 84.0 ± 7.7 pg ml-1; ascorbate 94.3 ± 
11.0 pg ml-1; ascorbate plus H1/H2 blockade 88.7 ± 10.1 pg ml
-1; P = 0.4). 
Post-exercise Hemodynamics. Table 4.2 shows heart rate and mean arterial blood 
pressure during recovery from exercise. Compared with the control condition, mean 
arterial blood pressure was similar for the ascorbate condition (P = 0.7) and the ascorbate 
plus H1/H2 blockade condition (P = 0.8). Mean arterial pressure was not different 
between ascorbate and ascorbate plus H1/H2 blockade conditions (P = 0.6). Compared 
with the control condition, heart rate was similar for the ascorbate condition (P = 0.4) and 
the ascorbate plus H1/H2 blockade condition (P = 0.8). Heart rate was not different 
between ascorbate and ascorbate plus H1/H2 blockade conditions (P = 0.5).  
As shown in Table 4.3, cutaneous vascular conductance in the active leg was 
similar across all three conditions during the recovery from exercise (P > 0.15). However, 
in the inactive leg, cutaneous vascular conductance was lower with ascorbate plus H1/H2 
blockade than either the control or the ascorbate conditions (P < 0.05).  
Figure 4.1 shows femoral blood flow and femoral vascular conductance during the 
recovery from exercise. In the active leg, the increase from pre-exercise in femoral blood 
flow at 1 h post-exercise was reduced for both the ascorbate (13 ± 7 %, P < 0.05) and 
ascorbate plus H1/H2 blockade (15 ± 7%, P < 0.05) conditions compared with the control 
condition (37 ± 7 %). The change in femoral blood flow did not differ between ascorbate 
and ascorbate plus H1/H2 blockade conditions (P = 0.8). Likewise, the increase from pre-
exercise in femoral vascular conductance at 1 h post-exercise was reduced for the both 
the ascorbate (14 ± 8 %, P < 0.05) and ascorbate plus H1/H2 blockade (18 ± 7%, P < 
0.05) conditions compared with the control condition (43 ± 9 %).
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Table 4.2. Central Hemodynamics 
 
Heart Rate (beats min⁻1)  Mean Arterial Pressure (mmHg) 
Time Point Control Ascorbate 
Ascorbate + 
H1/H2 
Blockade 
 Control Ascorbate 
Ascorbate + 
H1/H2 
Blockade 
Pre-exercise 57.1 ± 0.5 60.1 ± 0.7 56.7 ± 0.7  83.0 ± 0.6 82.9 ± 0.8 82.6 ± 0.6 
Time post-
exercise 
20 min 60.8 ± 1.0* 61.6 ± 1.4 61.6 ± 1.2*  81.4 ± 0.7 83.1 ± 1.2 81.6 ± 0.7 
40 min 57.8 ± 0.9 59.5 ± 1.2 58.6 ± 1.0*  80.8 ± 0.7* 81.7 ± 1.2 81.7 ± 0.7 
60 min 56.6 ± 0.8 58.4 ± 1.1 57.7 ± 1.2  82.3 ± 1.1 84.3 ± 1.3 81.1 ± 0.7 
80 min 56.7 ± 1.0 57.3 ± 1.1* 56.8 ± 1.2  83.2 ± 0.9 83.7 ± 1.2 83.4 ± 0.6 
100 min 56.2 ± 0.8 57.4 ± 0.8* 57.2 ± 1.0  85.3 ± 0.8* 84.0 ± 1.1 83.9 ± 0.7 
120 min 56.4 ± 0.9 57.4 ± 0.8* 56.5 ± 0.9  85.3 ± 0.9* 85.3 ± 1.1 85.0 ± 0.7* 
Values are mean ± SEM, *P < 0.05 vs. pre-exercise. 
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 Table 4.3 Cutaneous Vascular Conductance
 Inactive Leg  Active Leg 
Time Point Control Ascorbate 
Ascorbate + 
H1/H2 
Blockade  Control Ascorbate 
Ascorbate + 
H1/H2 
Blockade 
Pre-exercise 8.3 ± 1.6 10.8 ± 2.5 7.8 ± 1.1  10.0 ± 2.4 14.6 ± 4.5 9.9 ± 1.9 
Time post-
exercise 
20 min 10.7 ± 2.2 10.0 ± 1.1 8.0 ± 1.4*  20.3 ± 3.3 25.1 ± 4.6 21.3 ± 4.2 
40 min 10.0 ± 2.4 8.5 ± 1.0 7.2 ± 1.2*  18.6 ± 3.9 20.3 ± 3.4 17.4 ± 3.2 
60 min 8.4 ± 1.4 7.8 ± 1.0 7.2 ± 1.1*  15.9 ± 3.5 16.2 ± 2.7 15.7 ± 3.2 
80 min 8.5 ± 1.4 7.8 ± 1.1 6.6 ± 1.0*  14.0 ± 3.1 14.1 ± 2.2 13.9 ± 2.8 
100 min 7.5 ± 1.1 7.7 ± 1.2 6.6 ± 0.9*  11.7 ± 2.6 13.0 ± 2.4 13.1 ± 2.9 
120 min 7.8 ± 1.4 7.1 ± 0.9 6.9 ± 0.9*  10.8 ± 2.5 12.4 ± 2.2 12.3 ± 2.7 
Data are presented as percentage of maximal cutaneous vascular conductance. Values are mean ± SEM. *P < 0.05 
vs. control and ascorbate conditions. 
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The change in femoral vascular conductance did not differ between ascorbate and 
ascorbate plus H1/H2 blockade conditions (P = 0.7).  
In the inactive leg, the femoral blood flow change from pre-exercise to 1h post-
exercise did not differ between the ascorbate (-1 ± 5 %, P = 0.3) and control (6 ± 2 %)  
conditions, and also between the ascorbate plus H1/H2 blockade (4 ± 5 %, P = 0.8) and 
control conditions. The change in femoral blood flow did not differ between ascorbate 
and ascorbate plus H1/H2 blockade conditions (P = 0.4). Likewise, the femoral vascular 
conductance change from pre-exercise to 1h post-exercise did not differ between the 
ascorbate (-1 ± 5 %, P = 0.2) and control (7 ± 4 %) conditions, and also between the 
ascorbate plus H1/H2 blockade (8 ± 6 %, P = 0.9) and control conditions. The change in 
femoral vascular conductance did not differ between ascorbate and ascorbate plus H1/H2 
blockade conditions (P = 0.2) 
 
Follow-up Study 
Pre-exercise Hemodynamics. Pre-exercise heart rate and mean arterial blood pressure 
are shown in Table 4.4. Compared with the control condition heart rate was greater for 
the n-acetylcysteine condition (P < 0.05). Mean arterial pressure did not differ between 
the two conditions (P = 0.9). As shown in Table 4.5, cutaneous vascular conductance 
within both the active leg and inactive leg did not differ between the two conditions (P = 
0.9). Pre-exercise femoral blood flow and femoral vascular conductance are shown in 
Figure 4.2. Within the active leg, femoral blood flow did not differ (P = 0.9) between the 
two conditions. Likewise, within the inactive leg, femoral blood flow did not differ 
between the two conditions (P = 0.9). Within the active leg, femoral vascular 
conductance did not differ between the two conditions (P = 0.9). Likewise, within the 
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inactive leg, femoral vascular conductance did not differ between the two conditions (P = 
0.9).  
Exercise Responses. Power output during steady state dynamic knee extension exercise 
was similar for the control (21.2 ± 0.6 W) and n-acetylcysteine conditions (21.1 ± 0.6 W, 
P = 0.3). Power output for each condition matched the estimated 60% workload (21 W). 
Mean arterial blood pressure was similar between control (100.8 ± 1.6 mmHg) and n-
acetylcysteine conditions (101.0 ± 1.9 mmHg, P = 0.8). Compared with the control 
condition (92.5 ± 1.6 beats min-1), heart rate was higher for n-acetylcysteine condition 
(101.5 ± 1.6 beats min-1, P < 0.05). 
 
   Table 4.4. Central Hemodynamics 
 
Heart Rate (beats min⁻1)  Mean Arterial Pressure (mmHg) 
Time Point Control n-acetylcysteine 
 
Control n-acetylcysteine 
Pre-exercise 59.7 ± 0.9 63.8 ± 1.0†  86.0 ± 0.7 86.9 ± 1.2 
Time post-
exercise 
20 min 61.5 ± 1.3 70.4 ± 1.9*†  87.1 ± 1.0 88.6 ± 0.9 
40 min 59.3 ± 1.3 66.6 ± 1.5†  86.8 ± 0.9 88.6 ± 1.0 
60 min 56.9 ± 1.2 64.5 ± 1.4†  87.8 ± 0.7 89.0 ± 1.1 
80 min 56.0 ± 1.4* 63.8 ± 1.4†  88.8 ± 0.8 91.0 ± 0.9* 
100 min 57.1 ± 1.4 64.4 ± 1.4†  89.2 ± 0.7* 91.3 ± 1.1* 
120 min 57.2 ± 1.6 63.7 ± 1.4†  90.2 ± 0.9* 92.1 ± 1.0* 
Values are mean ± SEM. *P < 0.05 vs. pre-exercise; †P < 0.05 vs. control 
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Post-exercise Hemodynamics. Table 4.4 shows heart rate and mean arterial blood 
pressure during recovery from exercise. Mean arterial blood pressure did not differ 
between control and n-acetylcysteine conditions (P = 0.8). Compared with the control 
condition, heart rate was higher for the n-acetylcysteine condition throughout the 
recovery from exercise (P < 0.05). 
 
 
  Table 4.5. Cutaneous Vascular Conductance 
 
Inactive Leg 
 
Active Leg 
Time Point Control n-acetylcysteine 
 
Control n-acetylcysteine 
Pre-exercise 7.5 ± 0.4 7.1 ± 0.5  8.2 ± 0.7 8.8 ± 0.7 
Time post-
exercise 
20 min 7.1 ± 0.6 7.3 ± 0.5  11.7 ± 1.6 19.7 ± 1.9*† 
40 min 6.5 ± 0.5 7.0 ± 0.6  10.0 ± 1.3 16.3 ± 1.1*† 
60 min 5.9 ± 0.5 6.8 ± 0.6  9.5 ± 1.2 15.2 ± 1.2*† 
80 min 5.7 ± 0.5 6.2 ± 0.7  9.4 ± 1.4 13.1 ± 0.9* 
100 min 5.6 ± 0.5 6.7 ± 0.6  9.0 ± 1.3 11.9 ± 1.2 
120 min 5.7 ± 0.5 6.9 ± 0.7  8.8 ± 1.4 12.6 ± 1.3 
Data are presented as percentage of maximal cutaneous vascular conductance. 
Values are mean ± SEM. *P < 0.05 vs. pre-exercise; †P < 0.05 vs. control  
 
Cutaneous vascular conductance during the recovery from exercise is shown in 
Table 4.5. Compared with the control condition, cutaneous vascular conductance in the 
active leg was higher for the n-acetylcysteine condition through the first 60 min of 
exercise recovery (P < 0.05). In the inactive leg, cutaneous vascular conductance did not 
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differ between control and n-acetylcysteine conditions throughout the recovery from 
exercise (P = 0.6).  
 
 
 
 
 
Figure 4.1. Femoral Blood Flow & Femoral Vascular Conductance 
Femoral blood flow and femoral vascular conductance are shown for study 1 in both the 
inactive (left panels) and active (right panels) leg prior to exercise and throughout two 
hours of recovery. Open circles, control condition; Gray circles, ascorbate condition; 
Closed circles, ascorbate plus H1/H2 blockade. Parallel regression lines for femoral blood 
flow and femoral vascular conductance (right panels) indicate a significant drug effect (P 
< 0.05) for ascorbate and ascorbate plus H1/H2 blockade conditions versus control 
condition during the recovery from exercise. Solitary regression lines (left panels) 
indicate the absence of main effects or interactions for the control, ascorbate, and 
ascorbate plus H1/H2 blockade conditions during the recovery from exercise. 
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Figure 4.2. Femoral Blood Flow & Femoral Vascular Conductance 
Femoral blood flow and femoral vascular conductance are shown for the follow-up study 
in both the inactive (left panels and active (right panels) leg prior to exercise and 
throughout two hours of recovery. Open circles, control condition. Closed circles, n-
acetylcysteine condition. Parallel regression lines for femoral vascular conductance 
(bottom, left panel) indicate a significant drug effect (P < 0.05) for n-acetylcysteine 
condition versus control condition during the recovery from exercise. Solitary regression 
line for femoral blood flow (upper, left panel) indicates the absence of main effects or 
interactions for the control and n-acetylcysteine conditions during the recovery from 
exercise. Solitary regression lines (right panels) indicate the absence of main effects or 
interactions for the control and n-acetylcysteine conditions during the recovery from 
exercise. 
 
Figure 4.2 shows femoral blood flow and femoral vascular conductance during the 
recovery from exercise. In the active leg, the increase from pre-exercise in femoral blood 
flow at 1 h post-exercise did not differ between control (22 ± 4 %) and n-acetylcysteine 
(18 ± 7%, P = 0.4) conditions. Likewise, the increase from pre-exercise in femoral 
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vascular conductance at 1 h post-exercise did not differ between control (22 ± 4 %) and 
n-acetylcysteine (16 ± 8 %, P = 0.4) conditions.  
In the inactive leg, the femoral blood flow change from pre-exercise to 1h post-
exercise did not differ between control (1 ± 4 %) and n-acetylcysteine (-6 ± 4 %, P = 0.1) 
conditions. Likewise, the femoral vascular conductance change from pre-exercise to 1h 
post-exercise did not differ between control (-0.4 ± 5 %) and n-acetylcysteine (-10 ± 4 %, 
P = 0.1) conditions.  
DISCUSSION 
 The purpose of this study was to determine if exercise-induced oxidative stress 
contributes to sustained post-exercise vasodilation. In agreement with our hypothesis for 
study 1, we observed that the infusion of the potent antioxidant, ascorbate, inhibited 
sustained post-exercise vasodilation. The degree of inhibition we observed with ascorbate 
was similar to what we have found in our previous work utilizing H1/H2 receptor 
blockade. Furthermore, the inhibition produced by ascorbate was not augmented with the 
addition of H1/H2 receptor blockade. In disagreement with our hypothesis for the follow-
up study, we observed that sustained post-exercise vasodilation was unaffected by the 
infusion of the potent antioxidant, n-acetylcysteine. Taken together, these results suggest 
that the inhibition of sustained post-exercise vasodilation by ascorbate was due to a direct 
degradative effect on histamine and not to the blunting of exercise-induced oxidative 
stress as n-acetylcysteine, an antioxidant with no known histaminergic interaction, had no 
effect on sustained post-exercise vasodilation.    
Sustained Post-exercise Vasodilation and Exercise-Induced Oxidative Stress  
Our laboratory has demonstrated in several studies that sustained post-exercise 
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vasodilation is largely inhibited by H1/H2 receptor blockade following either large muscle 
mass exercise such as cycling (119, 125, 126), or more recently following unilateral 
dynamic knee-extension (16). There are several advantages to the use of the single-leg 
model, including the availability of a “control” non-exercising limb. We therefore chose 
to utilize the dynamic knee-extension exercise model in order to isolate the histaminergic 
component of sustained post-exercise vasodilation and to directly assess the role of 
exercise-induced oxidative stress.  
It is well understood that acute aerobic exercise increases oxidative stress that 
results predominantly from reactive oxygen and nitrogen species formation within 
contracting skeletal muscle (159). Because the local formation of oxidative stress is 
augmented within active skeletal muscle during dynamic knee extension exercise (11, 12) 
and given the relationship between oxidative stress and histamine formation in other 
settings (90, 183), we proposed that exercise-induced oxidative stress may contribute to 
sustained post-exercise vasodilation.  
Given independently or in combination, ascorbate and H1/H2 receptor blockade 
each inhibit sustained post-exercise vasodilation to a similar extent, suggesting that under 
normal exercise conditions oxidative stress could activate a histaminergic signaling 
mechanism located upstream of histamine receptors. However, this interpretation is 
complicated due to a degradative interaction between ascorbate and histamine. Several 
early studies provided evidence of the histamine degradative potential of ascorbate (28, 
29, 96, 97, 136, 186). Uchida and colleagues later demonstrated that ascorbate degrades 
histamine through a selective and direct interaction at the imidazole ring (188). Ascorbate 
may also reduce histamine through inhibition of histidine decarboxylase, the enzyme that 
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catalyzes the formation of histamine from the amino acid L-histidine (48, 145). Several 
investigations have also provided evidence of the histamine-reducing effect of ascorbate 
in humans. Clemetson was the first to demonstrate that three days of oral administration 
of 1g ascorbate reduced blood histamine concentrations (33). Similar results were found 
later using chronic ascorbate administration (102, 103). Importantly, a recent study 
demonstrated that the acute intravenous administration of high dose ascorbate, an 
approach similar to that used in our study, reduced serum histamine concentrations in 
patients with allergic and infectious diseases (71). These studies provide evidence that 
ascorbate may reduce histamine concentrations in vivo. It is important to note that the 
combination of ascorbate and H1/H2 receptor blockade does not further reduce sustained 
post-exercise vasodilation which supports our interpretation these that interventions block 
a single common pathway for vasodilation with ascorbate inhibiting the upstream 
formation of histamine and H1/H2 receptor blockade preventing activation of histamine 
receptors. 
We conducted the follow-up study to determine if the inhibition of sustained post-
exercise vasodilation observed in study 1 was the result of blunted exercise-induced 
oxidative stress or the result of histamine degradation by ascorbate. We designed the 
study to pharmaco-dissect the parallel pathways affected by ascorbate. We isolated the 
oxidative stress pathway by intravenously infusing n-acetylcysteine, a potent antioxidant 
with no known histaminergic interactions. In contrast to the findings in study one using 
ascorbate, blood flow to the previously active skeletal muscle remained elevated 
throughout recovery and was nearly identical to that observed in the control condition. 
These findings support the view that ascorbate inhibits sustained post-exercise 
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vasodilation through histamine degradation and not through oxidative stress related 
signaling mechanisms. 
Emerging Mechanisms of Sustained Post-exercise Vasodilation 
 Significant progress has been made recently in identifying the mechanisms that 
mediate sustained post-exercise vasodilation. While both neural and local vascular 
mechanisms contribute to sustained post-exercise vasodilation following whole-body 
exercise, the local vascular mechanism (i.e. histamine receptor activation) predominates 
following small muscle mass exercise. By using the dynamic knee extension exercise 
model to isolate the histaminergic component of sustained post-exercise vasodilation, we 
are now able to better dissect the signaling mechanisms that drive local histamine 
formation and to eventually identify the source of histamine. New and colleagues 
recently reported that lipid hydroperoxides, an indirect marker of oxidative stress, and 
systemic vascular conductance were elevated in parallel throughout 120 min of exercise 
recovery. The authors proposed that sustained post-exercise vasodilation and associated 
hypotension may be linked to exercise-induced oxidative stress. Our findings indicate 
that exercise-induced oxidative stress has no affect and that another upstream exercise-
related factor is driving this response.   
Histamine is notoriously difficult to measure when released or produced locally 
because it is metabolized quickly by histamine-N-methyltransferase and/or diamine 
oxidase or taken up by basophils in the bloodstream. Several studies in our lab have 
reported that histamine measured in both plasma and whole-blood is unchanged during 
the recovery from exercise despite a clear histamine receptor-mediated vasodilation (119, 
125, 126). While the results from this study failed to provide a mechanistic link between 
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oxidative stress and sustained post-exercise vasodilation, they do provide evidence that 
histamine is indeed the ligand activating histamine receptors during the recovery from 
exercise. One can test a proposed physiological mechanism by inhibiting or augmenting 
one or more of critical components that mediate the response. Blockade of histamine at 
the receptor level inhibits sustained post-exercise vasodilation following dynamic knee 
extension exercise (16). By inhibiting local histamine formation with ascorbate sustained 
post-exercise vasodilation was inhibited to a similar degree to that observed with H1/H2 
blockade, thus providing additional evidence that this physiological response is indeed 
histamine dependent.  
Cutaneous Circulation  
 Sustained post-exercise histaminergic vasodilation is not related to changes in 
cutaneous vascular conductance following large-muscle mass exercise (119, 125, 126, 
197). However, we measured cutaneous vascular conductance to ensure that any 
alteration in post-exercise femoral vascular conductance due to ascorbate, H1/H2 
blockade, or n-acetylcysteine administration was not mediated by changes in the 
cutaneous vasculature. Importantly, the administration of ascorbate, H1/H2 blockade, or 
n-acetylcysteine had no effect on cutaneous vasculature in the active leg. However, 
within the inactive leg, cutaneous vascular conductance was reduced slightly in the 
ascorbate plus H1/H2 blockade condition. This is interesting given that systemic H1 and/or 
H2 receptor blockade has no effect on thigh cutaneous vascular conductance following 
whole-body exercise (119, 125, 126). It is not completely clear why cutaneous vascular 
conductance in the inactive leg is reduced with ascorbate plus H1/H2 receptor blockade in 
the present study. It is possible that histamine receptor activation in the cutaneous 
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circulation varies between the type of exercise (whole-body vs. small-muscle mass 
exercise) and the location measured (active vs. inactive leg). Regardless, the small 
reduction in cutaneous vascular conductance observed in the ascorbate plus H1/H2 
blockade condition did not influence regional blood flow as femoral vascular 
conductance was similar to control and ascorbate conditions during recovery from 
exercise.  
Considerations 
 Several experimental considerations warrant discussion. First, we chose to 
intravenously infuse ascorbate and n-acetylcysteine to reduce exercise-induced oxidative 
stress. These experimental approaches have been used successfully in humans to 
pharmaco-dissect the interactions between oxidative stress and physiological regulatory 
mechanisms (17, 20, 56, 99, 127, 128, 156). It is always prudent to consider whether such 
interventions might alter central or local vascular regulatory mechanisms, thus 
confounding the interpretation of an experiment. Along these lines, it is unlikely that 
ascorbate administration affected central control of the vasculature as ascorbate is unable 
to freely traverse the blood-brain barrier. This is further supported by Bell et al. who 
documented that muscle sympathetic nerve activity, an index of central sympathetic 
outflow, is unchanged following high dose ascorbate administration (17). Furthermore, 
baseline blood flow and femoral vascular conductance did not differ across our three 
conditions indicating both the central and local vascular regulatory mechanisms were 
unaffected with ascorbate administration. The infusion of n-acetylcysteine is used less 
often in human studies investigating the influence of oxidative stress on cardiovascular 
regulatory mechanisms. However, a recent study using an infusion protocol similar to 
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ours reported that both arterial blood pressure and femoral vascular conductance are 
unaffected with high dose intravenous n-acetylcysteine (144). We reported similar 
findings, thus suggesting n-acetylcysteine does not have a direct effect on cardiovascular 
regulatory mechanisms. Second, the effect of H1/H2 receptor blockade alone on sustained 
post-exercise vasodilation was not examined in this current investigation. We felt there 
was no added benefit to include this condition as we have previously established the 
efficacy of H1/H2 receptor blockade to inhibit sustained post-exercise vasodilation 
following unilateral dynamic knee extension exercise (16). Third, plasma F2-isoprostanes 
were measured in only study 1 and were not increased with exercise and were also 
unaffected by ascorbate administration. We do not believe that this reflects a lack of 
exercise-induced oxidative stress and the inability of ascorbate to scavenge reactive 
species. Our results more likely reflect the use of remote venous blood sampling to assess 
oxidative stress induced by moderate intensity small muscle-mass exercise. While these 
considerations are valid points of discussion, our experimental approaches represent the 
best methods available to test our hypothesis in humans and we remain confident that 
these considerations do not limit or undermine our interpretation.  
Perspectives 
Pharmaco-dissecting the control systems and pathways that regulate the human 
cardiovascular system is inherently complex. Mechanistic studies provide an added level 
of complexity. We are often limited by the invasiveness of the experimental protocol or 
the limited availability of pharmacological agents that are available for use in humans. 
Most importantly, the pharmacological agents used in human investigations may affect 
physiological systems other than that targeted for investigation. Thus, conclusions drawn 
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from these studies may be inadvertently incorrect or misleading. Thus, understanding the 
pharmacology and potential the “side effects” of the chosen drug is critical. The number 
of human studies investigating the link between oxidative stress and pathophysiological 
conditions has increased tremendously within the last decade. Additionally, recent studies 
have also provided unique insight between acute and chronic cardiovascular and 
metabolic changes that occur as a result of exercise-induced oxidative stress. These 
studies often use antioxidants of various forms to pharmaco-dissect these interactions. 
The mechanistic links drawn from the results of these studies may not necessarily reflect 
the true nature of the response as the antioxidants may have unintentional consequences. 
Thus, understanding the pharmacology of the antioxidants and the multiple systems and 
pathways they may affect is essential in human investigations. 
Summary & Bridge 
 Acute aerobic exercise promotes a sustained post-exercise histaminergic 
vasodilation within the vasculature perfusing the previously active skeletal muscle. This 
study contributes further to the understanding of the mechanisms that drive this response. 
The findings from this study demonstrate that exercise-induced oxidative stress does not 
contribute to sustained post-exercise vasodilation. While the systemic infusion of n-
acetylcysteine did not affect sustained post-exercise vasodilation, ascorbate, an 
antioxidant with the unique ability to catalyze the degradation of histamine, inhibited the 
vasodilation to a similar degree of that observed in our previous work utilizing H1/H2 
receptor blockade. This observation provides the first line of evidence that histamine is 
likely released locally within the previously exercised muscle and where it can then 
activate H1/H2 receptors leading to sustained post-exercise vasodilation. Chapter V will 
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build upon this observation and attempt to directly measure interstitial histamine within 
skeletal muscle during and following exercise. Further, we will attempt to identify the 
specific source of local histamine formation.   
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CHAPTER V 
EXERCISE AND HISTAMINE FORMATION: IMPLICATIONS FOR SUSTAINED 
POST-EXERCISE VASODILATION 
INTRODUCTION 
Blood flow to previously active skeletal muscle remains elevated for several 
hours following an acute bout of aerobic exercise (74, 77, 114). This sustained post-
exercise vasodilation occurs following both whole-body exercise (78, 79, 154) and 
isolated small muscle-mass exercise (16). In humans, both central neural mechanisms and 
local vascular mechanisms contribute to sustained post-exercise vasodilation following 
large muscle mass exercise. Conversely, H1 and H2 histamine receptor blockade abolishes 
sustained post-exercise vasodilation following unilateral dynamic knee extension 
exercise, suggesting that this phenomenon is primarily histaminergic in origin and may 
occur independent of the neural mechanisms following isolated small muscle mass 
exercise (16).  
The reduction in blood flow observed with H1/H2 histamine receptor blockade 
illustrates that histamine receptor activation is a critical step in the signaling process of 
sustained post-exercise vasodilation. Presumably, histamine is the ligand activating H1/H2 
histamine receptors during the recovery from exercise. However, studies in our 
laboratory and others have failed to document any rise in arterial and venous plasma or 
whole-blood histamine during the recovery from exercise (82, 83, 119, 125, 126, 132). 
Conversely, several investigations have reported that histamine is elevated in whole 
blood (25, 82) and serum (47). It is unclear why there are such conflicting reports, but the 
varied findings may be related to experimental methodologies or assay techniques used to 
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measure histamine concentrations. Histamine quantitation is technically challenging 
owing to a half-life of just under two minutes (98). Moreover, there is clear variability 
and bias between the numerous assays available (66). Nevertheless, evidence collected 
recently in our laboratory points towards another explanation for the lack of elevated 
circulating histamine following exercise. Barrett-O'Keefe et al. documented that blood 
flow was elevated in the vascular bed perfusing the previously active quadriceps muscles 
following unilateral dynamic knee extension exercise, whereas blood flow in the 
unexercised leg was unchanged (16), suggesting that histamine is released locally within 
the skeletal muscle without spillover into the circulation. To date, histamine has not been 
measured locally in skeletal muscle during or following acute aerobic exercise.  
Histamine could be elevated in skeletal muscle in response to exercise through 
two histaminergic mechanisms. First, in skeletal muscle, mast cells are located adjacent 
to blood vessels and nerves and also within connective tissue (129, 201). Degranulation 
of these mast cells could augment histamine release within the skeletal muscle during or 
following exercise. Alternatively, histamine can be synthesized de novo in non-mast cells 
by the inducible rate-limiting enzyme, histidine decarboxylase, which catalyzes the 
formation of histamine via decarboxylation of the amino acid L-histidine (135, 192). 
Augmented gene expression and/or activity of histidine decarboxylase in response to 
acute aerobic exercise could increase histamine formation within previously active 
skeletal muscle. Both mast cell degranulation and histidine decarboxylase induction are 
thought to increase intramuscular histamine in mice during prolonged exercise (10, 55, 
140, 201). However, these studies have never measured blood flow in their studies, nor 
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have they quantitated skeletal muscle histamine or tryptase, a marker of mast cell 
degranulation, during or after exercise. 
The purpose of this project was twofold. First, we wanted to quantitate interstitial 
histamine concentrations in skeletal muscle during and after exercise. Second, we wanted 
to delineate the histaminergic mechanism responsible for local histamine formation 
within previously active skeletal muscle. This purpose was addressed in two separate 
studies. In study 1, we tested the hypothesis that interstitial histamine is elevated in 
skeletal muscle during and following 1h unilateral dynamic knee extension exercise and 
that blockade of histidine decarboxylase, via the irreversible inhibitor α-
fluoromethylhistidine, would inhibit this rise. Additionally, we tested the hypothesis that 
that blockade of histidine decarboxylase would blunt the histamine receptor dependent 
flux of interstitial fluid, a surrogate marker of local blood flow, during the recovery from 
exercise and that this effect would be similar in magnitude to that observed with local 
H1/H2 histamine receptor blockade. In study 2, we tested the hypothesis that mast cells 
are not activated during or following 1h unilateral dynamic knee extension exercise.  
METHODS   
Subjects 
Twenty-nine subjects were invited to participate in this study. Five men and five 
women participated in study 1, whereas eleven men and eight women participated in 
study 2. Written informed consent was obtained from all subjects subsequent to a verbal 
and written briefing of all experimental procedures. Subjects were deemed healthy 
following a standard health history questionnaire. All subjects were required to abstain 
from caffeine, alcohol, and exercise for 24h prior to the study. Additionally, subjects 
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reported to the laboratory 2h post-prandial. No subjects were using any over-the-counter 
or prescription medications at the time of the study, with the exception of oral 
contraceptives. Female participants were studied during the early follicular phase of their 
menstrual cycle or during the placebo phase of their oral contraceptive. This study was 
approved by the Institutional Review Board at the University of Oregon and was 
performed in accordance to the principles outlined by the Declaration of Helsinki. 
Screening Visit 
The screening visit was used to determine peak power output during a unilateral 
dynamic knee extension exercise test performed to volitional fatigue. Dynamic knee-
extension exercise during all visits was performed using a custom-built knee extension 
ergometer based on a computer-controlled step-motor that provided resistance against the 
subject’s lower leg. Based on real-time measures of angular velocity and torque, power 
was calculated and a feedback loop maintained measured power at the assigned level. 
Subjects were seated with their back at 60° upright and knee-extension exercise was 
performed with the right leg over a 45° range of motion, starting with the leg hanging at 
~90° of flexion. Subjects were asked to maintain a cadence of 45 kicks min-1 while being 
provided with visual feedback of both kicking cadence and range of motion. Workload 
was ramped incrementally at a rate of 3 watts min-1.  
Experimental Approach  
Following the screening visit, subjects were randomly assigned to sham or 
exercise conditions for both studies. Subjects in the exercise condition performed 60 min 
of unilateral dynamic knee extension exercise at 60% of peak power and a cadence of 45 
kicks min-1. Power was ramped at the onset of exercise to 60% peak power over the first 
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15 min. Power output was recorded continuously throughout 60 min dynamic knee 
extension exercise. Subjects in the sham group sat upright for 60 min. Skeletal muscle 
microdialysis probes were implanted 2.5h prior to exercise or upright rest and used to 
sample interstitial fluid from the vastus lateralis. Microdialysis effluent (dialysate) was 
collected every 30 min prior to, during, and following exercise or upright rest. 
Hemodynamic measurements were made prior to exercise and every 30 min throughout 
the 90 min exercise recovery period.    
Probe Implantation. All probes were implanted using sterile technique. The skin and 
underlying fascia were anesthetized using 1% lidocaine HCL (Hospira Worldwide, Lake 
Forest, IL, USA) buffered with sodium bicarbonate (Hospira Worldwide, Lake Forest, IL, 
USA). Care was taken to ensure that the lidocaine was not injected into the skeletal 
muscle. Probes were implanted in the vastus lateralis in a direction parallel with muscle 
fiber orientation (~19°, relative to long-axis of muscle) using a splitable introducer. After 
implantation, probes were held in place by covering the entry site with a sterile 
transparent medical dressing. 
Probe Specifications. In study 1, all probes had a 20 kilodalton molecular weight cutoff 
with a 30 mm polyarylethersulphone membrane (63 MD Catheter, MDialysis, 
Stockholm, Sweden) and were used to measure interstitial histamine and interstitial fluid 
flux. In study 2, probes had a 100 kilodalton molecular weight cutoff with a 30 mm 
polyarylethersulphone membrane (71 High Cut-off Brain MD Catheter, MDialysis, 
Stockholm, Sweden) and was used to measure interstitial tryptase, which is a gold 
standard marker of mast cell activation (91).  
Perfusate & Dialysate. Subsequent to implantation, microdialysis probes were attached 
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to microinfusion pump (CMA 400 Microdialysis pump, CMA, North Chelmsford, MA, 
USA and set to perfuse at a rate of 5µl min-1. All probes study 1 were perfused with 0.9% 
saline that also contained 0.40 µCi ml-1 of tritiated histamine [3H] and 5 mM ethanol. 
Tritiated histamine was used for the in vivo calibration of probe recovery (179) and 
ethanol was used to assess interstitial fluid flux via the ethanol washout technique (88). 
The microdialysis probe targeting tryptase in study 2 was perfused with 0.9% saline.  
Several drugs were added to the perfusate in study 1. Pyrilamine maleate (1mM) 
was used to block H1 histamine receptors and cimetidine (3mM) was used to block H2 
histamine receptors (Sigma-Aldrich, St. Louis, MO, USA). These doses have been used 
previously in our lab to locally block H1/H2 receptors and reduce successfully sustained 
post-exercise vasodilation (155). α-fluoromethylhistidine dihydrochloride (α-FMH, 200 
µM) (Santa Cruz Biotechnology, Dallas TX, USA) was used to irreversibly inhibit 
histidine decarboxylase activity (193). This dose was extrapolated from studies using α-
fluoromethylhistidine dihydrochloride to inhibit histidine decarboxylase in cell culture 
(181, 200).  
Microtubes were covered with non-porous tape during each sampling period in 
order to prevent dialysate and ethanol evaporation. Microtube weight was documented 
before and after dialysate collection in order to assess fluid loss and estimate perfusion 
rate of the probe. Dialysate was stored at -20°C for the duration of the study. Thereafter, 
the samples were stored at -80°C until analysis.     
Dialysate Analysis 
Interstitial histamine was measured using a “competitive” enzyme-linked 
immunosorbent assay (Rocky Mountain Diagnostics, Colorado Springs, CO, USA) and 
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performed in accordance to the manufactures instructions. Interstitial tryptase was 
measured using a standard “sandwich” enzyme-linked immunosorbent assay and 
performed in accordance to the manufactures instructions with slight modification 
(Kamiya Biomedical, Seattle, WA, USA).  
In probes measuring interstitial histamine, 10 µl of perfusate and dialysate were 
pipetted into 5 ml polypropylene scintillation vials containing 3 ml of scintillation 
cocktail (Ultima Gold, Shelton CT, USA) immediately after the sampling period. 
Radioactivity was then measured (counts min-1) in duplicate using a liquid scintillation 
counter (Beckman LS 6000SC, Brea, CA, USA) and used to determine probe recovery 
using Equation 3.4. Assessing probe recovery when analyzing for tryptase was 
performed using a commercially available fluorescence assay (Quant-iT™, Invitrogen, 
Eugene OR, USA) and performed according to manufacturer’s instructions.  
Interstitial fluid flux was assessed by measuring ethanol washout from the 
interstitial space. Ethanol in the perfusate and dialysate was measured using a modified 
alcohol dehydrogenase enzymatic assay (89, 157) as previously performed in our 
laboratory (155). The assay uses alcohol dehydrogenase to catalyze the oxidation of 
ethanol using nicotinamide adenine dinucleotide as the electron acceptor.  
Hemodynamic Measurements 
All resting measurements were made pre- and post-exercise with the subjects in 
the supine position. Subjects were asked to remain quiet and relaxed during all 
hemodynamic measurements. Room temperature remained thermoneutral (~23°C) 
throughout the study.  
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Heart Rate and Blood Pressure. Arterial blood pressure was measured in the right arm 
using an automated sphygmomanometer (Tango+, SunTech Medical, Raleigh, NC, 
USA). Heart rate monitored using a three lead electrocardiograph (Tango+, SunTech 
Medical, Raleigh, NC, USA). Heart rate and blood pressure were also measured during 
60 min dynamic knee extension exercise. 
Femoral Blood Flow. Femoral artery blood flow velocity was measured via duplex 
ultrasonography. A linear-array vascular ultrasound probe (10 MHz, GE Vingmed 
System 5, Horton, Norway) and an insonation angle of 60° was used to measure blood 
flow in the common femoral artery, approximately 2-3 cm proximal to the bifurcation. 
The Doppler ultrasound machine was interfaced with a computer running custom audio 
recording software. Velocity measurements were determined using an intensity-weighted 
algorithm (custom software), subsequent to demodulation of forward and reverse Doppler 
frequencies. Velocity measurements were made at an average depth of 1.56 ± 0.04 cm for 
study 1 and a depth of 1.68 ± 0.02 cm for study 2. Velocities were thin-beam corrected, 
based on a known beam-width of 2.21 mm which resulted in an average correction factor 
of 0.766 ± 0.0002 for study 1 and 0.766 ± 0.0002 for study 2, as outlined by Buck et al. 
(23). Leg blood flow was calculated as cross-sectional area multiplied by femoral mean 
blood velocity and reported in ml per min. The average femoral artery diameter was 8.69 
± 0.08 mm for study 1, and 8.78 ± 0.07 mm for study 2. Femoral vascular conductance 
was calculated by dividing femoral blood flow by mean arterial pressures and expressed 
as ml per min per mmHg. 
     
 89
Statistical Analysis 
The statistical analysis was identical for study 1 and study 2. Preliminary 
statistical analysis indicated that our primary outcome variables did not vary by sex. As 
such, all subsequent analyses were performed after grouping data for both men and 
women. Our primary outcome variables during the recovery from exercise were analyzed 
using a two-way mixed model analysis of variance with repeated measures (JMP Pro 10; 
SAS Institute Inc. Cary, NC, USA). We used a priori contrasts to examine specific 
condition-time interactions. General interactions were examined using Tukey’s post hoc 
procedure. Significance was set at P < 0.05. Data are reported as mean ± SEM unless 
stated otherwise (e.g., SD is used in Table 1 to indicate the variability in the subject 
pool). 
RESULTS 
Subject Characteristics 
 Subject physical characteristics and data obtained during the screening visit are 
shown in Table 5.1. Subject characteristics are similar to those obtained previously in our 
laboratory in young healthy subjects and are consistent with recreationally active 
individuals 
Study 1 
Pre-exercise Hemodynamics. Absolute systemic hemodynamics prior to exercise are 
shown in Table 5.2. Both heart rate (P = 0.9) and mean arterial pressure (P = 1.0) did not 
differ between sham and exercise conditions. Femoral blood flow did not differ between 
sham and exercise conditions (P = 0.9). Likewise, femoral vascular conductance did not 
differ between sham and exercise conditions (P = 0.9).  
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Table 5.1. Subject Characteristics 
 
Exercise & Sham Responses. Power output during steady state dynamic knee extension 
exercise for the exercise condition was (15.5 ± 0.7 W). Power output was within 2 W of 
the estimated average 60% workload (17.2 W). Compared with the sham condition (74.2 
± 2.0 beats min-1), heart rate was higher for the exercise condition (98.9 ± 4.4 beats min-1) 
(P < 0.05). Compared with the sham condition (86.0 ± 5.2 mmHg), mean arterial blood 
pressure did not differ with the exercise condition (96.3 ± 5.2 mmHg, P = 0.2).  
Post-exercise Hemodynamics. Absolute systemic hemodynamics for sham and exercise 
conditions are shown in Table 5.2. The change from pre-exercise in heart rate at 1h post-
exercise did not differ between the sham (2 ± 1%) and exercise conditions (4 ± 3%, P = 
0.5). Likewise, the change from pre-exercise in mean arterial pressure at 1h post-exercise 
 Study 1 Study 2 
Sham Exercise Sham Exercise 
n 4 6 9 10 
Age (yrs) 22.0 ± 1.6 20.1 ± 2.2 23.4 ± 5.2 21.4 ± 1.8 
Height (cm) 170 ±8 174 ± 4 179 ± 9 173 ± 6 
Weight (kg) 67.3 ± 13.4 68.3 ± 6.5 76.4 ± 13.3 68.6 ± 6.8 
Body mass index 
(kg m⁻2) 
23.1 ± 2.9 22.4 ± 2.8 23.6 ± 2.4 22.6 ± 1.2 
Baecke sport index 
(arbitrary units) 
3.1 ± 0.6 3.6 ± 0.6 3.1 ± 0.7 2.9 ± 0.8 
Physical activity index 
(MET hr⁻1 week⁻1) 
29.8 ± 7 60 ± 27.9 32.6 ± 10 39.7 ± 21 
Peak power output (W) 35.7 ± 15.6 29.9 ± 4.1 24.6 ± 6.0 17.3 ± 2.7 
Values are mean ± SD. MET, metabolic equivalents.   
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did not differ between the sham (-3 ± 1%) and exercise conditions (0 ± 2%, P = 0.2). The 
change from pre-exercise in femoral blood flow at 1h post-exercise was negligible for the 
sham condition (-2 ± 12 %) compared with the exercise condition (36 ± 4%, P < 0.05). 
Likewise, the change from pre-exercise in femoral vascular conductance at 1h post-
exercise was negligible for the sham condition (-1 ± 10 %) compared with the exercise 
condition (36 ± 4%, P < 0.05). 
Interstitial Histamine Concentrations. Histamine concentrations for control and H1/H2 
blockade probes were grouped together and referred to collectively as “control.”   
Raw histamine concentrations for sham and exercise conditions are shown in the 
left panels of Figure 5.1. In the sham condition, histamine did not differ between control 
and α-FMH probes prior to upright rest (P = 0.9). Likewise, histamine did not differ 
between control and α-FMH probes during (P = 0.9) and following (P = 0.9) upright rest. 
In the exercise condition, histamine did not differ between control (3.0 ± 0.6 ng ml-1) and 
α-FMH (2.9 ± 0.6 ng ml-1) probes prior to exercise (P = 0.8). Compared with pre-
exercise, histamine was elevated during exercise in the control (7.2 ± 0.6 ng ml-1, P < 
0.05) and α-FMH probes (5.4 ± 0.6 ng ml-1, P < 0.05). 
Compared with the control probes, histamine was lower during exercise in the α-
FMH probes (P < 0.05).   Compared with pre-exercise, histamine was elevated during the 
recovery from exercise in the control probes (4.1 ± 0.5 ng ml-1, P < 0.05), but not in the 
α-FMH probes (2.9 ± 0.6 ng ml-1, P = 0.9). Compared with the control probes, histamine 
was lower in α-FMH probe during the recovery from exercise (P < 0.05). 
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         Table 5.2. Study 1 Hemodynamics 
 
Time (min) 
Variable Pre 30 60 90 
Heart rate (beats min-1)  
Sham 61.0 ± 1.7 60.7 ± 1.8 62.5 ± 1.4 62.0 ± 1.7 
Exercise 58.0 ± 3.0 63.5 ± 2.4* 62.1 ± 2.5 60.6 ± 2.5 
Mean arterial pressure (mmHg)  
Sham 84.9 ± 2.8 79.9 ± 3.1 81.9 ± 3.0 85.0 ± 3.1 
Exercise 86.5 ± 1.6 83.0 ± 2.6 86.2 ± 1.8 85.7 ± 3.0 
Femoral blood flow (ml min-1)  
Sham 194.8 ± 21.2 172.3 ± 17.0 207.6 ± 37.8 232.3 ± 26.9 
Exercise 214.7 ± 11.4 318.7 ± 16.9*† 337.6 ± 13.3* 366.5 ± 14.7* 
Femoral Vascular Conductance (ml min-1 mmHg)  
Sham 2.2 ± 0.1 2.1 ± 0.1 2.4 ± 0.3 2.6 ± 0.2 
Exercise 2.4 ± 0.1  3.8 ± 0.1*† 3.9 ± 0.1*† 4.2 ± 0.1*† 
Values are mean ± SEM. *P < 0.05 vs. pre-exercise. †P < 0.05 vs. sham within time period 
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Corrected histamine concentrations for sham and exercise conditions are shown in 
the right panels of Figure 5.1. In the sham condition, histamine did not differ between 
control and α-FMH probes prior to upright rest (P = 0.9). Likewise, histamine did not 
differ between control and α-FMH probes during (P = 0.8) and following (P = 0.3) 
upright rest.  
In the exercise condition, histamine did not differ between control (13.4 ± 1.5 ng 
ml-1) and α-FMH (11.9 ± 1.8 ng ml-1) probes prior to exercise (P = 0.3). Compared with 
pre-exercise, histamine did not differ during exercise in the control probes (15.0 ± 1.5 ng 
ml-1, P = 0.3) and in the α-FMH probes (10.1 ± 1.8 ng ml-1, P = 0.3). Compared with the 
control probes, histamine during exercise was lower in α-FMH probes (P < 0.05). 
Compared with pre-exercise, histamine did not differ following exercise in the control 
probes (13.6 ± 1.4 ng ml-1, P = 0.8), but was reduced in the α-FMH probes (8.3 ± 1.6 ng 
ml-1, P = 0.05). Compared with the control probes, histamine was lower in the α-FMH 
probes (P < 0.05) during the recovery from exercise. 
Interstitial Fluid Flux. Figure 5.2 shows the percent change of interstitial fluid flux 
from pre-exercise to during and following exercise for control, H1/H2 blockade, and α-
FMH probes in both sham and exercise conditions. The greater the percent reduction is 
equivalent to a greater flux of interstitial fluid and is an inverse surrogate marker of local 
perfusion. 
 In the sham condition, compared with control probes, the percent change of 
interstitial fluid flux from pre-rest to upright rest did not differ from H1/H2 blockade (P = 
0.9) and α-FMH probes (P = 0.9). Likewise, the percent change of interstitial fluid flux 
from pre-rest to upright rest did not differ between H1/H2 blockade and α-FMH probes (P 
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= 0.3). Compared with control probes, the percent change of interstitial fluid from pre-
rest to the recovery period did not differ from H1/H2 blockade (P = 0.3) and α-FMH 
probes (P = 0.6). Likewise, the percent change of interstitial fluid flux from pre-rest to 
the recovery period did not differ between H1/H2 blockade probes and α-FMH probes (P 
= 0.8).  
In the exercise condition, compared with the control probes (-115 ± 23 %), the 
percent change of interstitial fluid flux from pre-exercise to exercise tended to be lower 
for H1/H2 blockade (-50 ± 30 %, P = 0.1) and α-FMH probes (-65 ± 26 %, P = 0.1). The 
percent change of interstitial fluid flux from pre-exercise to exercise did not differ 
between H1/H2 blockade and α-FMH probes (P = 0.6). Compared with control probes (-
44 ± 13 %), the percent change of interstitial fluid flux from pre-exercise to the recovery 
period was lower for H1/H2 blockade (-7 ± 14 %, P < 0.05) and α-FMH probes (-5 ± 13 
%, P < 0.05). The percent change of interstitial fluid flux from pre-exercise to the 
recovery period did not differ between H1/H2 blockade probes and α-FMH probes (P = 
0.9). 
Study 2 
Pre-exercise Hemodynamics. Absolute systemic hemodynamics prior to exercise are 
shown in Table 5.3. Both heart rate (P = 0.3) and mean arterial pressure (P = 0.4) did not 
differ between sham and exercise conditions. Femoral blood flow did not differ between 
sham and exercise conditions (P = 1.0). Likewise, femoral vascular conductance did not 
differ between sham and exercise conditions (P = 1.0).  
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Figure 5.1. Interstitial Histamine Concentrations 
Raw histamine is shown in the left panels and corrected histamine concentrations in the right panels. Top panels, sham condition; 
Lower panels, exercise condition. Open bars, control; Gray bars, α-FMH. *P < 0.05 vs. pre-exercise; † P < 0.05 vs. α-FMH
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Figure 5.2. Interstitial Fluid Flux 
Interstitial fluid flux is shown as the percent change from pre-rest (top panel) or pre-
exercise (bottom panel). Open bars, control probe; Closed bars, H1/H2 Blockade; Gray 
bars, α-FMH. *P < 0.05 vs. control probe 
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Exercise & Sham Responses. Power output during steady state dynamic knee extension 
exercise was (16.7 ± 0.7 W). Power output was within 1 W of the average 60% workload 
(17.2 W). Compared with the sham condition (65 ± 1.0 beats min-1), heart rate was higher 
for the exercise condition (107.2 ± 4.2 beats min-1) (P < 0.05). Compared with the sham 
condition (93.0 ± 3.2 mmHg), mean arterial blood pressure did not differ with the 
exercise condition (97.4 ± 1.8 mmHg, P = 0.2).  
Post-exercise Hemodynamics. Absolute systemic hemodynamics for sham and exercise 
conditions are shown in Table 5.3. The change from pre-exercise in heart rate at 1 h post-
exercise did not differ between the sham (4 ± 1%) and exercise conditions (4 ± 1%, P = 
0.9). Likewise, the change from pre-exercise in mean arterial pressure at 1 h post-exercise 
did not differ between the sham (-2 ± 2%) and exercise conditions (0 ± 2%, P = 0.4). The 
increase from pre-exercise in femoral blood flow at 1 h post-exercise was negligible for 
the sham condition (-2 ± 5 %) compared with the exercise condition (37 ± 4%, P < 0.05). 
Likewise, the increase from pre-exercise in femoral vascular conductance at 1 h post-
exercise was negligible for the sham condition (-1 ± 5 %) compared with the exercise 
condition (37 ± 5%, P < 0.05). 
Interstitial Tryptase Concentrations. Raw tryptase concentrations for sham (upright 
rest) and exercise conditions are shown in the top panel of Figure 5.3. Baseline tryptase 
did not differ between sham (2.7 ± 0.7 ng ml-1) and exercise (2.8 ± 0.7 ng ml-1, P = 0.9) 
conditions. Compared with pre-exercise, tryptase was elevated during exercise (8.1 ± 0.6 
ng ml-1, P < 0.05), but not upright rest (3.6 ± 0.6 ng ml-1, P = 0.1). Compared with 
upright rest, tryptase was greater during exercise (P < 0.05).
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 Table 5.3. Study 2 Hemodynamics 
 
 
 
 
 
 
 
 
Time (min) 
Variable Pre 30 60 90 
Heart rate (beats min-1)  
Sham 55.1 ± 2.2 57.6 ± 2.3 57.5 ± 2.1 56.2 ± 2.1 
Exercise 63.8 ± 1.5 69.8 ± 1.8* 67.0 ± 1.5 66.2 ± 1.6 
Mean arterial pressure (mmHg)  
Sham 92.8 ± 1.3 87.0 ± 1.5* 91.3 ± 1.8 91.1 ± 1.8 
Exercise 86.6 ± 1.4 85.9 ± 1.7 87.0 ± 1.7 86.3 ± 1.2 
Femoral blood flow (ml min-1)  
Sham 237.6 ± 10.9 232.6 ± 15.2 237.6 ± 14.3 240.2 ± 11.9 
Exercise 228.9 ± 16.1 353.1 ± 27.2* 379.8 ± 31.0*† 425.2 ± 27.9*† 
Femoral Vascular Conductance (ml min-1 mmHg)  
Sham 2.5 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 2.6 ± 0.1 
Exercise 2.6 ± 0.1  4.0 ± 0.2* 4.3 ± 0.3*† 4.9 ± 0.3*† 
Values are mean ± SEM. *P < 0.05 vs. pre-exercise. †P < 0.05 vs. sham within time period 
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Compared with pre-exercise, tryptase was elevated during the recovery from exercise 
(5.5 ± 0.6 ng ml-1, P < 0.05), but not during the recovery from upright rest (3.3 ± 0.6 ng 
ml-1, P = 0.2). Compared with the recovery from upright rest, tryptase was greater during 
the recovery from exercise (P < 0.05). 
Corrected tryptase is expressed as the ratio of tryptase to total protein in the sample and is 
shown in Figure 5.3 for sham and exercise conditions. Baseline tryptase did not differ 
between sham (1.2x10-4 ± 1.6x10-6) and exercise (1.3x10-4 ± 1.9x10-5, P = 0.7) 
conditions. Compared with pre-exercise, tryptase tended to be lower during exercise 
(1.0x10-4 ± 1.2x10-5, P = 0.06), but not upright rest (1.1x10-4 ± 9.6x10-6, P = 0.6). 
Compared with upright rest, tryptase did not differ during exercise (P = 0.5). Compared 
with pre-exercise, tryptase did not differ during the recovery from exercise (1.1x10-4 ± 
1.1x10-5, P = 0.2) and during the recovery from upright rest (1.4x10-4 ± 1.1x10-5, P = 
0.1). Compared with the recovery from upright rest, tryptase did not differ during the 
recovery from exercise (P = 0.9). 
DISCUSSION 
 The purpose of this project was twofold. First, we wanted to quantitate interstitial 
histamine concentrations in skeletal muscle during and after exercise. Second, we wanted 
to delineate the histaminergic mechanism responsible for local histamine formation 
within previously active skeletal muscle. In agreement with our hypothesis for study 1, 
we documented that interstitial histamine is elevated during and following 1 hr unilateral 
dynamic knee extension exercise. Moreover, blockade of histidine decarboxylase, via the 
irreversible inhibitor α-FMH, reduced the rise in interstitial histamine formation.
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Figure 5.3. Interstitial Tryptase 
The top panel shows raw interstitial tryptase concentrations throughout sham or exercise 
conditions. The bottom panel shows the ratio of tryptase to total protein throughout sham 
or exercise conditions. Open bars, sham condition; Closed bars, exercise condition. *P < 
0.05 vs. pre-exercise. †P < 0.05 vs. sham within time period 
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In agreement with the secondary hypothesis for study 1, blockade of histidine 
decarboxylase tended to reduce the flux of interstitial fluid during exercise and 
completely inhibited it after exercise. This effect was similar in magnitude to that 
observed with local H1/H2 histamine receptor blockade. In opposition to our hypothesis in 
study 2, it appears that mast cells are activated during and following 1 hr unilateral 
dynamic knee extension exercise, as tryptase was elevated during and after exercise. 
Collectively, these studies demonstrate that histamine is the ligand activating H1/H2 
receptors during the recovery from exercise. Induction of histidine decarboxylase is the 
primary histaminergic mechanisms augmenting local histamine formation in skeletal 
muscle along with a possible contribution from mast cell activation. 
Histaminergic Mechanisms of Sustained Post-exercise Vasodilation 
This study provides unique insight into the histaminergic mechanisms regulating 
sustained post-exercise vasodilation. Using skeletal muscle microdialysis, we attempted 
to pharmaco-dissect parallel histaminergic pathways that may respond to exercise. We 
documented that interstitial histamine concentrations are elevated during and after 
exercise, but can be reduced by infusing an irreversible inhibitor of histidine 
decarboxylase, the enzyme responsible for de novo histamine synthesis. This observation 
points towards the induction of histidine decarboxylase as a primary mechanism 
augmenting histamine locally in active skeletal muscle during exercise. It should be noted 
that irreversibly inhibiting histidine decarboxylase during exercise appears to partially 
reduce the rise in interstitial histamine. This inability to fully blunt the rise in histamine 
suggests that the drug may not fully inhibit histidine decarboxylase in vivo, or that 
another mechanism accounts for the histidine decarboxylase independent portion of 
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histamine formation. We infused α-FMH at a concentration of 200 µM, a dose 
extrapolated from studies using the drug to inhibit histidine decarboxylase in cell culture 
(181, 200). It is possible that this dose is lower than necessary to fully inhibit the large 
induction of histidine decarboxylase during exercise. Alternatively, the results in study 2 
point toward mast cells as the secondary source of local histamine formation. Tryptase, a 
marker of mast cell degranulation, was elevated with exercise indicating that mast cells 
may degranulate in response to exercise. Histamine is released in addition to tryptase 
upon activation of mast cells and may therefore be responsible for the unaccounted for 
rise in histamine during exercise. 
Interestingly, α-FMH fully inhibited the rise in histamine during the first 30 min 
of exercise recovery, an effect that tended to remain throughout the recovery from 
exercise. Likewise, the percent reduction in interstitial fluid flux was similar between 
H1/H2 blockade and α-FMH probes at the same time points. Together these observations 
suggest that the contribution of the parallel histaminergic pathways differs during and 
following exercise. Perhaps, both the induction of histidine decarboxylase and mast cell 
activation contribute to the rise in histamine during exercise, but de novo synthesis 
predominates following exercise. 
 Taken together, histidine decarboxylase induction is the primary mechanism 
augmenting interstitial histamine during and after exercise. However, mast cells may also 
contribute to the rise in interstitial histamine. If so, it is possible that these parallel 
histaminergic pathways cooperatively mediate sustained post-exercise vasodilation. 
Evidence in support of this has been provided by the work of Endo and colleagues (10, 
55, 140, 201). Their elegant work over the last decade has led them to propose that the 
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induction of histidine decarboxylase replenishes the pool of mast cell histamine lost with 
degranulation during exercise. Our study provides evidence that a similar mechanism 
may occur in humans, but future research is needed to clarify if mast cells are activated 
with exercise and if they function synergistically with histidine decarboxylase.  
Microdialysis Probe Recovery: To Correct or Not? If So, How? 
Skeletal muscle microdialysis is a powerful yet complex technique that allows for 
the measurement of various target analyates in a fluid compartment not readily 
accessible. The recovery of substances from the interstitial space is dependent on: 1) 
perfusion rate; 2) probe length; 3) probe membrane characteristics; and, 4) the rate of 
diffusion in the interstitial space (108, 122, 139). The first three factors are fixed within 
an experiment and therefore do not affect recovery. However, the rate of diffusion is 
influenced by a number of factors and can vary greatly within a study thus influencing 
the recovery of a target analyte. The diffusion of substances from the interstitial space is 
dependent on: tortuosity, volume fraction, blood flow, and perfusate flow rate (86, 108, 
122, 139).  Experiments with dynamic conditions such as exercise can greatly alter the 
factors that influence diffusion. Thus, an in vivo calibration should be performed in such 
conditions in order to account for changes in probe recovery.  
In study 1, we used the internal standard technique (179) to correct for probe 
recovery. The histamine concentrations when adjusting for probe recovery appear to 
follow the same trends during and after exercise when not correcting for probe recovery, 
but a clear picture does not emerge as the “waters have been muddied.” The internal 
standard technique is easily performed but may have inherent limitations due to its 
simplistic approach. It assumes diffusion from the probe down a concentration gradient to 
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zero at an infinite distance from the probe. However, changes in perfusion (and washout 
of the analyte) or metabolism of the analyte impact the nature of the diffusion gradient 
such that this method may falsely correct the data. Perhaps, an endogenous “tracer” such 
as urea can be used to better account for changes in probe recovery, thus providing a 
more clear view and ultimately improving our ability to interpret the data.  
Even though the correcting for probe recovery adds some inconsistency to the 
data, we believe our interpretation to be true. Multiple lines of evidence support our view 
that interstitial histamine is increased during and after exercise and is dependent on de 
novo synthesis via histidine decarboxylase. First, histamine concentrations were 
unaffected prior to exercise but were reduced during and after exercise, suggesting that 
the normal increase, irrespective of recovery, was inhibited by α-FMH. Moreover, this 
inhibition occurred at a time when we would expect the induction of histidine 
decarboxylase to increase. Second, given that the flux of interstitial fluid tended to be 
reduced during exercise and was inhibited during the recovery period with the infusion of 
α-FMH demonstrates a clear relationship between the histidine decarboxylase dependent 
synthesis of histamine and regulation of local microvasculature blood flow in the area of 
the probe.  
 In study 2, we  attempted to correct for probe recovery by measuring the total 
protein in the sample. This approach has never been used in microdialysis studies nor has 
it been validated as an acceptable measure of probe recovery. However, we attempted to 
use this approach as we were limited by the volume of dialysate remaining after 
analyzing tryptase via ELISA. Therefore, it is very probable that the correction of probe 
recovery in this manner does not reflect the physiology in vivo.  
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 These microdialysis studies have provided evidence regarding the histaminergic 
mechanisms regulating local histamine formation in skeletal muscle and sustained post-
exercise vasodilation. However, we believe that additional evidence is needed to support 
our initial findings. Using imaging techniques such as immunohistochemistry, we plan to 
visualize mast cells and their activation in the skeletal muscle tissues collected from the 
study detailed in chapter VI. Likewise, we can visualize the localization (e.g. endothelial 
cells) of histidine decarboxylase and examine its gene expression in response to acute 
exercise. Data from these future analysis coupled with that of the current study should 
collectively provide a clear picture of histaminergic mechanisms mediating sustained 
post-exercise vasodilation. 
Summary & Bridge 
 As highlighted in chapter in II and originally presented by John T. Shepard, a 
proposed mediator of hyperemia must meet the following criteria: 1) the substance(s) or 
its precursor(s) should be present in skeletal muscle; 2) the substance(s) should have 
access to the muscle resistance vessels; 3) the concentration in the interstitial fluid must 
be capable of causing and maintaining vasodilation, and there should be a close 
relationship between the interstitial fluid concentration and the blood flow; and, 4) the 
substance(s) should be capable of producing dilatation of arterioles on topical application. 
Our laboratory’s prior findings coupled with those in this current investigation reveal that 
histamine satisfies each of the above criteria. Thus, histamine is indeed the ligand 
activating histamine receptors during the recovery from exercise thus mediating sustained 
post-exercise vasodilation. Moreover, histidine decarboxylase induction is the primary 
mechanism augmenting local histamine formation within the skeletal muscle. Mast cells 
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may also contribute, but future work is needed to determine their exact role in the 
formation of histamine in skeletal muscle 
 Chapters IV and V of this dissertation have focused on the upstream mechanisms 
mediating sustained post-exercise vasodilation. The final chapter focuses on some of the 
downstream adaptations associated with the activation of histamine receptor during the 
recovery from exercise, specifically exercise-induced angiogenesis.        
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CHAPTER VI 
EFFECT OF HISTAMINE RECEPTOR BLOCKADE ON THE EXPRESSION OF 
PRO-ANGIOGENIC GROWTH FACTORS DURING THE RECOVERY FROM 
AEROBIC EXERCISE 
INTRODUCTION 
Acute aerobic exercise induces a prolonged vasodilation within the previously 
active skeletal muscle vasculature. This sustained post-exercise vasodilation lasts 
upwards of several hours and occurs following both whole-body exercise (78, 79, 154) 
and isolated small muscle-mass exercise (16). Histamine H1 and H2 receptor activation 
(119, 125, 126) and alterations in the sympathetic control of the peripheral vascular 
system (75, 78) mediate sustained post-exercise vasodilation in humans following large 
muscle mass exercise. In contrast, H1 and H2 receptor blockade abolishes sustained post-
exercise vasodilation following small-muscle mass exercise (16).  
The recovery from aerobic exercise is not simply a return to pre-exercise 
homeostasis, but is a critical period in which multiple physiological systems are primed 
for functional and structural adaptations. Much of these adaptations are due to 
transcriptional and translational changes that ultimately alter signaling pathways within 
skeletal muscle. Chronic activation of these cellular pathways leads to the well-known 
phenotypic changes that occur with aerobic exercise training. 
  The skeletal muscle vascular system adapts exquisitely to chronic aerobic 
exercise training via functional and structural changes (114). Functional changes 
encompass adaptations that improve vasomotor function/sensitivity. Structural 
adaptations include vascular remodeling of larger conduit blood vessels which is referred 
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to as arteriogenesis and angiogenesis which is the expansion of the capillary network.  In 
general, the functional adaptations and arteriogenesis improve regional or “bulk” blood 
flow. On the other hand, angiogenesis is beneficial as it augments microvascular blood 
flow which is thought to occur from decreased red blood cell transit time, decreased 
diffusional path length, and increased capillary surface area for diffusion (70). Greater 
microvascular blood flow improves the delivery of nutrients and the removal of 
metabolic byproducts.  
Angiogenesis in skeletal muscle has long been known to occur with chronic 
exercise training (27, 161) and is thought to result from the induction of pro- and anti-
angiogenic growth factors via mechanical, metabolic, and hypoxic stimuli (50, 70). A 
number of pro- and anti-angiogenic growth factors respond to acute exercise (50, 70, 
150); however the specific regulatory mechanism(s) that govern their release in humans 
remain uncertain.  
What physiological purpose is subserved by sustained post-exercise histaminergic 
vasodilation? Recently our laboratory postulated that sustained post-exercise vasodilation 
may contribute to exercise-induced angiogenesis through upregulation of pro-angiogenic 
growth factors. In addition to its potent vasodilator effect, histamine has been implicated 
in angiogenesis since the late 1960’s (202). Recent observations implicating histamine 
and its receptors (subtypes H1 and/or H2) as potent angiogenic stimuli in pathological and 
physiological angiogenesis (59, 64, 65, 100, 142, 184) have generated renewed interest in 
this biological amine.  
Thus, we propose that there may be a distinct mechanistic link between sustained 
post-exercise vasodilation, histamine receptor activation, and the expression of pro- and 
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anti-angiogenic growth factors. Therefore, the purpose of this study was to determine if 
activation of histamine H1 and H2 receptors contributes to the expression of pro- and anti-
angiogenic factors during the recovery from acute aerobic exercise. We tested the 
hypothesis that histamine H1 and H2 receptor blockade would blunt the expression of 
several pro-and anti-angiogenic growth factors during the recovery from 1 hr unilateral 
dynamic knee extension exercise.  
METHODS 
Subjects 
Sixteen subjects (10 men and 6 women) were invited to participate in this study. 
Written informed consent was obtained from all subjects subsequent to a verbal and 
written briefing of all experimental procedures. Subjects were deemed healthy following 
a standard health history questionnaire. All subjects were required to abstain from 
caffeine, alcohol, and exercise for 24h prior to the study. Additionally, subjects reported 
to the laboratory 2h post-prandial. No subjects were using any over-the-counter or 
prescription medications at the time of the study, with the exception of oral 
contraceptives. Female participants were studied irrespective of their menstrual cycle 
phase. This study was approved by the Institutional Review Board at the University of 
Oregon and was performed in accordance to the principles outlined by the Declaration of 
Helsinki.  
Screening Visit 
The screening visit was used to determine peak power output during a unilateral 
dynamic knee extension exercise test performed to volitional fatigue. Dynamic knee-
extension exercise during all visits was performed using a custom-built knee extension 
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ergometer based on a computer-controlled step-motor that provided resistance against the 
subject’s lower leg. Based on real-time measures of angular velocity and torque, power 
was calculated and a feedback loop maintained measured power at the assigned level. 
Subjects were seated with their back at 60° upright and knee-extension exercise was 
performed with the right leg over a 45° range of motion, starting with the leg hanging at 
~90° of flexion. Subjects were asked to maintain a cadence of 45 kicks min-1 while being 
provided with visual feedback of both kicking cadence and range of motion. Workload 
was ramped incrementally at a rate of 3 watts min-1.  
Experimental Approach 
Following the screening visit, subjects were randomly assigned to control or 
histamine receptor blockade conditions. All subjects performed 60 min of unilateral 
dynamic knee extension exercise at 60% of peak power and a cadence of 45 kicks min-1. 
Power was ramped at the onset of exercise to 60% peak power over the first 5 min. Power 
output was recorded continuously throughout 60 min dynamic knee extension exercise. 
Skeletal muscle tissue was obtained via biopsy of the vastus lateralis before, immediately 
after, and 3 hours following dynamic knee extension exercise. All pre-exercise biopsies 
were performed in the non-exercised leg, whereas both of the post-exercise biopsies were 
performed in the previously exercise leg. Hemodynamic measurements were made prior 
to exercise and every 30 min throughout the 3 h recovery period. 
Histamine Receptor Blockade. Histamine H1 and H2 receptors were blocked using 540 
mg fexofenadine and 300 mg ranitidine. This combination of fexofenadine and ranitidine 
reduces sustained post-exercise vasodilation by ~86% following unilateral dynamic knee 
extension exercise (14). This dosage of oral fexofenadine has been shown to selectively 
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block H1 receptors (time to peak concentration 1.15 h and half-life 12 h), while the dose 
of oral ranitidine has been shown to selectively block H2 receptors (time to peak plasma 
concentration 2.2 h and 2.6 h half-life) (56, 156). Responses are 90% inhibited within 1 h 
and remain inhibited 6 h after administration (20, 56). Fexofenadine and ranitidine do not 
appear to cross into the central nervous system or possess sedative actions (20). 
Furthermore, these drugs do not have any direct cardiovascular effects in the absence of 
histamine receptor stimulation (i.e., when given under normal resting conditions, these 
drugs do not elicit any changes in heart rate, blood pressure, or smooth muscle tone) 
(114). Subjects ingested the histamine receptor antagonists with water at least 1 hr prior 
to exercise in all studies. 
Skeletal Muscle Biopsy. All skeletal muscle biopsies were performed under sterile 
technique. The skin and underlying fascia were anesthetized using 1% lidocaine HCL 
(Hospira Worldwide, Lake Forest, IL, USA). Skeletal muscle was obtained using a 5 mm 
Bergström biopsy needle inserted through a small incision made in the skin and muscle 
fascia. Harvested skeletal muscle tissue was blotted, removed of any adipose tissue, and 
snap frozen in liquid nitrogen. When applicable, a small portion of the muscle sample 
was removed for future histological analysis. These tissue samples were snap frozen in 
isopentane cooled with liquid nitrogen and stored at -80°C until analysis.       
Gene Expression 
We utilized next-generation RNA sequencing to probe gene expression on a 
transcriptome-wide level. RNA sequencing provides a comprehensive index of all of the 
genes expressed in the transcriptome at the time when the host tissue and cells were 
obtained (191). Thus, RNA sequencing technology allows us to exhaustively and 
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precisely examine transcripts related to acute exercise, angiogenesis, and histamine 
receptor activation. Additionally, RNA sequencing will allows us to interrogate 
additional genes and pathways unrelated to angiogenesis but that may respond to acute 
exercise and histamine receptor activation so that we can generate novel hypothesis 
driven research questions. Gene expression analysis via RNA sequencing was performed 
at the University of Oregon Genomics Core Facility. 
RNA Isolation. Approximately 15 mg of skeletal muscle tissue was homogenized in 
Eppendorph RNase-free tubes containing 1 ml TRI reagent. The sample was then 
separated using 0.2 ml chloroform and precipitated with 0.5 ml isopropanol. The 
resulting RNA pellet was washed twice in 75% alcohol, dried, and subsequently 
dissolved in 1.5 µl 0.1 mM EDTA for each 1 mg of starting skeletal muscle tissue. 
RNA Sequencing. Following RNA isolation, sequencing was carried using the following 
standardized workflow within the Genomics Core Facility: 1) RNA preparation; 2) 
cDNA library preparation; 3) sequencing; and, 4) bioinformatics analysis. Because 
mRNA is only 1 - 5% of total RNA, an isolation procedure is necessary to ensure that the 
sample is not contaminated with non-polyadenylated mRNA (e.g. ribosomal). Pure 
mRNA was isolated from the total RNA preparation using a commercially available kit 
(Dynabeads® mRNA Purification Kit, Life Technologies, Eugene, OR, USA). Input RNA 
yield and integrity was analyzed prior to library construction via automated capillary 
electrophoresis (Fragment Analyzer, Advanced Analytical Technologies, Inc., Ames, IA, 
USA) coupled with a High Sensitivity RNA Analysis Kit (DNF-491, Advanced 
Analytical Technologies, Inc., Ames, IA, USA).  
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The cDNA library preparation was performed using a KAPA Stranded RNA-Seq 
Library Preparation Kit (Kapa Biosystems, Boston, MA, USA), which is designed 
specifically for Illumina sequencers. Briefly, isolated mRNA was first fragmented by 
heating each sample to 94°C in the presence of magnesium. Double-stranded cDNA was 
then synthesized from the fragmented RNA using a two-step process which includes 1st 
strand cDNA synthesis via random priming and 2nd strand cDNA synthesis which 
converts the cDNA:RNA hybrid to double-stranded cDNA. Adapters were then ligated to 
the ends of the cDNA preceding library amplification using high-fidelity, low-bias 
polymerase chain reaction. Constructed libraries were validated using the High 
Sensitivity NGS Fragment Analysis Kit (DNF-486, Advanced Analytical Technologies, 
Inc., Ames, IA, USA) and quantitated using a Qubit 2.0 fluorometer coupled with a High 
Sensitivity DNA assay kit (Life Technologies, Eugene, OR, USA).  
Subsequent to cDNA library preparation, flowcells were loaded with samples and 
clusters were formed and replicated for each oligo. Flowcells were then placed in the 
sequencer (Illumina HiSeq 2000, Illumina, San Diego CA, USA) and fluorescently 
tagged nucleotides were competitively attached to complimentary bases within each 
cluster. Single-end sequencing was performed at a length of 100 nucleotides.  
 Following the read process, adapters were removed and sequences were tiled and 
aligned to the reference human genome. At the time of this writing (9/17/2014) RNA 
sequencing is in the final stages of preparation and analysis. Thus, the bioinformatics 
component of data analysis is yet to be completed. The preliminary data presented herein 
were analyzed using standard real-time polymerase chain reaction (see appendix). Select 
genes of interest that are associated with histamine receptor activation, exercise, and 
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angiogenesis were identified a priori and are shown in Table 6.1. This hypothesis driven 
approach is in addition transcriptome wide approach that allows us to “cast a wide net” 
and investigate relationships not defined in our hypothesis. 
Table 6.1. Select Genes of Interest 
EntrezID Symbol Name 
7422 VEGFA Vascular endothelial growth factor A 
3791 KDR Kinase insert domain receptor 
4846 NOS3 Nitric oxide synthase 3 (endothelial cell) 
4313 MMP2 Matrix metallopeptidase 2 
6347 CCL2 CCL22 chemokine (c-c motif) ligand 2 
2247 FGF2 Fibroblast growth factor 2 (basic) 
3164 NR4A1 Nuclear receptor subfamily 4, group a, member 1 
7057 THBS1 Thrombospondin 1 
10891 PPARGC1A Peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha 
3091 HIF1A Hypoxia inducible factor 1, alpha subunit 
 
Hemodynamic Measurements  
All resting measurements were made pre- and post-exercise with the subjects in 
the supine position. Subjects were asked to remain quiet and relaxed during all 
hemodynamic measurements. Room temperature remained thermoneutral (~23°C) 
throughout the study.  
Heart Rate and Blood Pressure. Arterial blood pressure was measured in the right arm 
using an automated sphygmomanometer (Tango+, SunTech Medical, Raleigh, NC, 
USA). Heart rate was monitored using a three lead electrocardiograph (Tango+, SunTech 
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Medical, Raleigh, NC, USA). Heart rate and blood pressure were also measured during 
60 min dynamic knee extension exercise. 
Femoral Blood Flow. Femoral artery blood flow velocity was measured via duplex 
ultrasonography. A linear-array vascular ultrasound probe (9 MHz, Phillips iE33, 
Andover, MA., USA) and an insonation angle of 60° was used to measure blood flow in 
the common femoral artery, approximately 2-3 cm proximal to the bifurcation. The 
Doppler ultrasound machine was interfaced with a computer running custom audio 
recording software. Velocity measurements were determined using an intensity-weighted 
algorithm (custom software), subsequent to demodulation of forward and reverse Doppler 
frequencies. Velocity measurements were made at an average depth of 1.77 ± 0.01 cm. 
Leg blood flow was calculated as cross-sectional area multiplied by femoral mean blood 
velocity and reported in ml per min. The average femoral artery diameter was 8.80 ± 0.07 
mm. Femoral vascular conductance was calculated by dividing femoral blood flow by 
mean arterial pressures and expressed as ml per min per mmHg. 
Statistics. Preliminary statistical analysis indicated that our primary hemodynamic 
outcome variables did not vary by sex. As such, all subsequent analyses were performed 
after grouping data for both men and women. Our primary hemodynamic outcome 
variables were analyzed using a two-way mixed model analysis of variance with repeated 
measures (JMP Pro 10; SAS Institute Inc. Cary, NC, USA). We used a priori contrasts to 
examine specific condition-time interactions. General interactions were examined using 
Tukey’s post hoc procedure. Significance was set at P < 0.05. Data are reported as mean 
± SEM unless stated otherwise (e.g., SD is used in Table 2 to indicate the variability in 
the subject pool). 
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RESULTS 
Subject Characteristics 
Subject physical characteristics and data obtained during the screening visit are 
shown in Table 6.2. Subject characteristics are similar to those obtained previously in our 
laboratory in young healthy subjects and are consistent with recreationally active 
individuals.  
 
Table 6.2. Subject Characteristics 
 Control H1/H2 blockade 
n 8 8 
Age (yrs) 23.0 ± 4.4 24.5 ± 5.4 
Height (cm) 169 ± 9 175 ± 4 
Weight (kg) 68.1 ± 10.1 75.9 ± 6.3 
Body mass index (kg m⁻2) 23.7 ± 2.0 24.7 ± 1.9 
Baecke sport index (arbitrary units) 3.4 ± 0.8 2.8 ± 0.9 
Physical activity index (MET hr⁻1 week⁻1) 49 ± 22 38 ± 25 
Peak power output (W) 29.4 ± 7.1 38.4 ± 10.8 
Values are mean ± SD. MET, metabolic equivalents.   
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Hemodynamics 
Pre-exercise Hemodynamics. Pre-exercise heart rate and mean arterial blood pressure 
are shown in Table 6.2. Both heart rate (P = 1.0) and mean arterial pressure (P = 0.6) did 
not differ between control and H1/H2 blockade conditions. Pre-exercise femoral blood 
flow and femoral vascular conductance are shown in Table 6.3. Femoral blood flow did 
not differ (P = 0.5) between control and H1/H2 blockade conditions. Likewise, femoral 
vascular conductance did not differ between control and H1/H2 blockade conditions (P = 
0.7). 
Exercise Responses. Power output during steady state dynamic knee extension exercise 
was similar between control (17.1 ± 1.4 W) and H1/H2 blockade conditions (21.6 ± 2.9 
W) (P = 0.1). Power output for each condition was within 1 W of the estimated 60% 
workload for the control condition (17.7 W) and the H1/H2 blockade condition (22.2 W). 
Mean arterial blood pressure did not differ between control (106.0 ± 2.9 mmHg) and 
H1/H2 blockade conditions (110.0 ± 3.8 mmHg) (P = 0.4). Heart rate did not differ 
between control (100.9 ± 3.5 beats min-1) and H1/H2 blockade conditions (95.7 ± 3.5 
beats min-1) (P = 0.3).  
Post-exercise Hemodynamics. Table 6.3 shows heart rate and mean arterial blood 
pressure during recovery from exercise. Heart rate was not different between control and 
H1/H2 blockade conditions (P = 0.06). Likewise, mean arterial pressure did not differ 
between control and H1/H2 blockade conditions (P = 0.1). Figure 6.1 shows percent 
change from pre-exercise throughout the recovery from exercise for femoral blood flow 
and femoral vascular conductance. Absolute values for femoral blood flow and femoral 
vascular conductance are shown in Table 6.4.  
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   Table 6.3. Central Hemodynamics 
 
Heart Rate (beats min⁻1)  Mean Arterial Pressure (mmHg) 
Time Point Control H1/H2 Blockade 
 
Control H1/H2 Blockade 
Pre-exercise 63.6 ± 1.2 63.5 ± 1.7  82.5 ± 1.6 89.6 ± 1.2 
Time post-
exercise 
30 min 65.5 ± 1.2 59.0 ± 0.8  81.1 ± 1.5 88.1 ± 1.2 
60 min 62.6 ± 2.0 60.8 ± 1.5  80.9 ± 1.7 89.0 ± 1.9 
90 min 63.8 ± 1.8 60.6 ± 1.7  81.2 ± 2.3 89.1 ± 1.9 
120 min 63.3 ± 1.6 60.3 ± 1.8  82.8 ± 1.5 86.6 ± 1.5 
150 min 63.8 ± 1.5 64.0 ± 2.4  79.0 ± 1.8 89.4 ± 1.8 
180 min 64.7 ± 1.5 64.0 ± 3.0  82.4 ± 1.2 88.2 ± 1.9 
Values are mean ± SEM 
 
 
   Table 6.4. Absolute Femoral Blood Flow and Femoral Vascular Conductance 
 
Femoral Blood Flow              
(ml min⁻1) 
 
Femoral Vascular Conductance 
(ml min⁻1 mmHg) 
Time Point Control H1/H2 Blockade 
 
Control H1/H2 Blockade 
Pre-exercise 350 ± 21 394 ± 16  4.31 ± 0.3 4.39 ± 0.1 
Time post-
exercise 
30 min 467 ± 36* 403 ± 27  5.84 ± 0.5* 4.60 ± 0.3 
60 min 428 ± 34* 379 ± 21  5.34 ± 0.4* 4.26 ± 0.2 
90 min 465 ± 38* 403 ± 31  5.89 ± 0.5* 4.49 ± 0.2 
120 min 461 ± 41* 422 ± 33  5.60 ± 0.5* 4.86 ± 0.3 
150 min 480 ± 31* 409 ± 35  6.08 ± 0.3* 4.58 ± 0.3 
180 min 450 ± 26* 426 ± 35  5.50 ± 0.3* 4.77 ± 0.3 
Values are mean ± SEM. *P < 0.05 vs. pre-exercise 
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Figure 6.1. Femoral Blood Flow & Femoral Vascular Conductance 
Top panel shows the percent change from pre-exercise of femoral blood flow throughout 
180 min of exercise recovery. Bottom panel shows the percent change from pre-exercise 
of femoral vascular conductance. Open bars control group; Closed bars H1/H2 blockade 
group; * denotes P < 0.05 vs. blockade. 
     
 120
Differential Gene Expression 
RNA sequencing is currently underway in the University of Oregon Genomics 
Core. I have therefore included preliminary gene expression data as determined by real-
time polymerase chain reaction analysis for vascular endothelial growth factor A 
(VEGF), CCL2 chemokine (c-c motif) ligand 2 (CCL2), peroxisome proliferator-
activated receptor gamma, coactivator 1 alpha, and fibroblast growth factor 2 (basic) in 
order to provide a preview of the expected gene expression levels of specific pro-
angiogenic growth factors (Figure 6.2).  
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Figure 6.2. Pro-Angiogenic Growth Factor Gene Expression 
Figure show mRNA expression for select genes prior to, immediately after, and 3 hr after 
exercise. Panel A - vascular endothelial growth factor A. Panel B - CCL22 chemokine (c-
c motif) ligand 22. Panel C - peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha. Panel D - fibroblast growth factor 2 (basic); Open bars control group; 
Closed bars H1/H2 blockade group; *P < 0.05 vs. pre-exercise within condition. †P < 0.05 
vs. H1/H2 Blockade within time point 
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DISCUSSION 
 The purpose of this study was to determine if activation of histamine H1/H2 
receptors contributes to the expression of pro- and anti-angiogenic factors during the 
recovery from acute aerobic exercise. In agreement with our hypothesis, we documented 
that blockade of histamine H1/H2 receptors blunted the gene expression of VEGF and 
CCL2 3 hours into recovery from 1hr unilateral dynamic knee extension exercise. These 
preliminary results indicate that there is indeed a mechanistic link between sustained 
post-exercise vasodilation, histamine receptor activation, and the expression of pro-
angiogenic growth factors. Moreover, these data provide novel evidence that histamine, a 
biological amine normally associated with pathological or anaphylactic conditions, may 
contribute beneficially to the normal changes that occur within skeletal muscle during the 
recovery from exercise and perhaps be an important mechanism contributing the 
expansion of the capillary network that accompanies chronic exercise training. 
Histamine Receptor Activation and Angiogenesis  
Histamine has long been linked with angiogenesis (202). Recent observations 
have provided detailed information regarding the specific mechanisms in which 
histamine and its receptors mediate the angiogenic response in vivo. These investigations 
have highlighted this biological amine as key mechanism contributing to both 
pathological and physiological angiogenesis. Histamine is synthesized de novo through 
decarboxylation of L-histidine by histidine decarboxylase and can function thereafter in a 
paracrine or endocrine fashion or can be taken up by mast cells or basophils. Much of the 
research regarding histamine formation/release, histamine receptor activation, and 
angiogenesis has focused on wound healing and cancer/tumor progression (59, 143, 149). 
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The notion that histamine and its receptors may play an important role in exercise-
induced angiogenesis has only recently been investigated. To date, only one study has 
investigated the role of mast cell derived histamine in a model of compensatory muscle 
overload induced angiogenesis via synergist muscle ablation (45). In this study, Doyle 
and colleagues documented that muscle overload induced mast cell activation, but the 
chronic administration of the mast cell stabilizer, cromolyn, had no effect on the protein 
content of several pro-angiogeneic growth factors nor did it inhibit angiogenesis. These 
findings suggest that mast cell derived histamine is not a requisite for exercise-induced 
induced angiogenesis. However, it is unclear to what extent cromolyn stabilized mast 
cells during muscle overload as this was not reported. Additionally, the efficacy of 
cromolyn to stabilize mast cells has been questioned recently (194). Moreover, 
compensatory muscle overload via synergist muscle ablation does not replicate in vivo 
conditions encountered during aerobic exercise. While it is unclear to what extent the 
findings by Doyle and colleagues can be extended to humans, perhaps there is an 
alternative explanation. It remains possible that de novo histamine synthesis, and not mast 
cell activation, is the primary histaminergic mechanism contributing to exercise-induced 
angiogenesis. This is a reasonable explanation given the observation that both histidine 
decarboxylase activity and mRNA expression are elevated during acute aerobic exercise 
(10, 55, 140). This notion is further supported the findings documented in chapter V.  
Potential Mechanism of Histamine Receptor Mediated Expression of Angiogenic 
Growth Factors 
 VEGF is arguably the most potent angiogenic stimulus that is upregulated with 
exercise and is also required for the full expression of skeletal muscle capillarity and 
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ultimately aerobic performance/capacity (152). In skeletal muscle, VEGF activates the 
kinase insert domain receptor/fetal liver kinase 1 receptor which activates a myriad of 
signaling pathways that contribute to angiogenesis by augmenting endothelial cell 
proliferation, migration, and survival (26, 70). Skeletal muscle VEGF is found in 
myocytes, endothelial cells, and pericytes, but skeletal muscle myocytes are thought to be 
the primary source of VEGF secretion during exercise (92, 93). Myocytes store VEGF in 
vesicles that translocate to the plasma membrane where it is then released into the 
interstitial space during and following exercise (93). Hoier and colleagues have proposed 
that augmented VEGF mRNA expression that occurs in the hours following acute aerobic 
exercise subserves the replenishment of the VEGF containing vesicles within skeletal 
muscle myocytes (93). 
There are four known histamine receptors (H1 - H4), but it appears that subtypes 
H1/H2 mediate angiogenesis in vivo (65, 162, 184). Histamine H1 and H2 receptors are G-
coupled protein receptors that when activated stimulate inositol triphosphate and adenylyl 
cyclase dependent signaling mechanisms that ultimately augment VEGF mRNA 
expression through transcriptional activation (65, 162). Thus, histamine receptor 
activation may contribute to exercise-induced angiogenesis by augmenting VEGF 
transcription and ultimately replenishing vesicular stores. Additionally, H1/H2 histamine 
receptor activation may indirectly increase VEGF expression through nitric oxide/shear-
stress dependent mechanisms (50–52).  
CCL2 chemokine (c-c motif) ligand 22, also known as monocyte chemotactic 
protein-1, is a pro-angiogenic growth factor (7, 174) that is upregulated following aerobic 
exercise (50, 117, 138).  CCL2 induces angiogenesis by recruiting 
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monocyte/macrophages to the tissue where they can release growth factors such as 
fibroblast growth factor 2 (7). CCL2 can also stimulate directly endothelial cell 
chemotaxis (174). More recent evidence suggests that the angiogenic actions of CCL are 
mediated by activation of the novel transcription factor MCP-1 induced protein. It is 
unclear which mechanism/s are contribute to exercise-induced angiogenesis.  
Fujikara et al. were the first to provide clear evidence linking histamine H1 
receptor activation to upregulation of CCL2 mRNA expression (60). Activation of H1 
histamine receptors stimulates inositol triphosphate signaling mechanisms that appear to 
upregulate CCL2 mRNA transcription through transcription factors  nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-KB) and activator protein-1 (113). 
Moreover, Marumo et al. have shown that VEGF induces CCL2 mRNA expression in 
endothelial cells (123). Thus, H1/H1 receptor activation may indirectly increase CCL2 
mRNA expression by upregulating VEGF mRNA transcription. Taken together, multiple 
histaminergic pathways exist that may independently and/or cooperatively augment 
CCL2 mRNA expression during the recovery from exercise. 
Considerations 
The findings from this study indicate that histamine receptor activation increases 
the gene expression of pro-angiogenic growth factors during the recovery from aerobic 
exercise. It should be noted that our results provide evidence at only the transcriptional 
level that may not reflect true downstream changes at the protein level. For example, 
VEGF can undergo post-transcriptional and/or post-translation modification (6) thus 
preventing the formation of cellular VEGF. To our knowledge there have been no studies 
that have reported post-transcriptional and/or post-translation modifications of pro-
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angiogenic growth factors during the recovery from exercise. Moreover, VEGF protein is 
elevated in both plasma and skeletal muscle hours into the recovery from acute aerobic 
exercise suggesting that the changes in gene expression reported in our study may 
translate into downstream changes in protein content. Additional analyses are necessary 
to determine if the changes observed at the transcriptional level indeed translate into 
changes at the protein level.    
Perspectives 
This study provides novel evidence that the activation histamine receptors during 
the recovery from exercise contributes to the full expression of pro-angiogenic growth 
factors during the recovery from exercise. Moreover, these data reveal that histamine 
receptors may contribute beneficially to the normal regulation of the vascular system and 
perhaps be an important mechanism contributing the expansion of the capillary network 
that accompanies chronic exercise training. 
Can the chronic use of antihistamines blunt the angiogenic response that 
accompanies aerobic exercise training? Nearly one-half of Americans suffer from nasal 
allergy symptoms (e.g. rhinitis) that are attributable to seasonal allergies (137). Likewise, 
approximately 20% of Americans suffer from gastroesophageal reflux disease (53). 
Histamine H1/H2 receptor blockers (e.g. fexofenadine HCL and ranitidine HCL) are 
usually the first line of defense in the treatment of nasal symptoms associated with 
seasonal allergies and for acid reflux disease. Thus, it is possible that anyone taking 
Histamine H1/H2 receptor blockers for histamine mediated disorders may have a blunted 
angiogenic response if they participate an exercise training program.  
     
 126
Summary 
We documented that H1/H2 histamine receptor blockade blunted the gene 
expression of VEGF and CCL2 mRNA 3 hours into recovery from 1hr unilateral 
dynamic knee extension exercise. These preliminary results indicate that there is indeed a 
mechanistic link between sustained post-exercise vasodilation, histamine receptor 
activation, and the expression of pro-angiogenic growth factors. Once RNA sequencing is 
complete, we expect to confirm these preliminary findings and expand in depth upon 
these findings. Future research is necessary to determine if the reduction in gene 
expression of pro-angiogenic growth factors by H1/H2 histamine receptor blockade 
observed in this study may blunt the angiogenic response associated with long term 
exercise training.  
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CHAPTER VII 
CONCLUSIONS 
MAIN FINDINGS 
For over a decade our laboratory has studied cardiovascular regulation during the 
recovery from aerobic exercise. Our laboratory has focused its recent efforts on exploring 
the mechanisms and potential adaptations related to sustained post-exercise vasodilation. 
The studies detailed in this dissertation were designed to build upon these earlier studies 
regarding histaminergic mechanisms and adaptations of sustained post-exercise 
vasodilation. 
In the study detailed in chapter VI, we examined if oxidative stress is the 
exercise-related factor mediating sustained post-exercise vasodilation. We intravenously 
infused the potent antioxidant ascorbate prior to and throughout exercise and examined 
its influence on sustained post-exercise vasodilation. We demonstrated that ascorbate 
blunted sustained post-exercise vasodilation and that this reduction was similar in 
magnitude to that observed with H1\H2 blockade. However, in addition to its antioxidant 
effect, ascorbate can directly degrade histamine and may also blunt de novo synthesis via 
histidine decarboxylase. Therefore, we conducted a follow-up study to verify the findings 
in study 1. In this study we intravenous infused n-acetylcysteine, a potent antioxidant 
with no known histaminergic interactions. We demonstrated that n-acetylcysteine had no 
effect on sustained post-exercise vasodilation, indicating that exercise-induced oxidative 
stress is not the exercise-related factor mediating sustained post-exercise vasodilation and 
that the results in study 1 were due to ascorbates degradative effect on histamine.  
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In the study detailed in chapter V, we attempted to quantitate interstitial histamine 
in an effort to demonstrate that exercise induces the local formation of histamine in 
previously active skeletal muscle. Additionally, we wanted to determine if the source of 
histamine was from mast cell activation or de novo synthesis via histidine decarboxylase. 
Collectively, these studies would determine if histamine is the ligand activating histamine 
receptors during the recovery from exercise and determine its source. We found that 
histamine is increased in the interstitial fluid within skeletal muscle during and after 
exercise. Histidine decarboxylase appears to be the primary mechanism responsible for 
the local formation of histamine in active skeletal muscle, as irreversibly inhibiting this 
enzyme reduced the rise in histamine during and after exercise. Mast cells may also play 
an important role given the observation that inhibition of histidine decarboxylase did not 
fully blunt the rise in histamine during exercise and that tryptase was elevated during and 
after exercise. 
Finally, in chapter VI, we attempted to determine if histamine receptor activation 
contributes to the expression of pro- and anti-angiogenic growth factors during the 
recovery from exercise. Our preliminary findings indicate that activation of histamine 
receptors may play a role in the expression of pro-angiogenic growth factors during the 
recovery from acute aerobic exercise. RNA sequencing analysis will provided a more 
thorough account of the effect of post-exercise histamine receptor activation on the 
expression of pro- and anti-angiogenic growth factors. 
EXPANDING THE MODEL OF SUSTAINED POST-EXERCISE 
VASODILATION 
 Progress has been made recently in identifying the mechanisms that mediate 
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sustained post-exercise vasodilation. While both neural and local vascular mechanisms 
contribute to sustained post-exercise vasodilation following whole-body exercise, the 
local vascular mechanism (i.e. histamine receptor activation) predominates following 
small muscle mass exercise. By using the dynamic knee extension exercise model to 
isolate the histaminergic component of sustained post-exercise vasodilation, we are now 
able to better dissect the signaling mechanisms associated with the local control of 
sustained post-exercise vasodilation. 
 The studies detailed in this dissertation have provided clarity to our working 
model of the local vascular mechanisms of sustained post-exercise vasodilation. Figure 
7.1 reflects our current understanding of the mechanisms responsible and highlights some 
of the benefits associated sustained post-exercise histaminergic vasodilation. Our current 
understanding is as follows. An unknown exercise related factor increases local histamine 
formation through induction of histidine decarboxylase and possibly through the 
activation of mast cells. Subsequent formation of histamine locally within active skeletal 
muscle leads to activation of H1 and H2 histamine receptors which promotes vasodilation 
thus contributing to reductions in arterial blood pressure, increased glucose delivery, and 
to the expression of pro-angiogenic growth factors.  
FUTURE DIRECTIONS 
 We now have a more comprehensive understanding of the histaminergic 
mechanisms and adaptations associated with sustained post-exercise vasodilation. 
However, several key questions remain unanswered. Future investigations will need to 
identify the exercise-related factor contributing to histamine formation that occurs with 
acute exercise. 
     
 130
 
Figure 7.1. Updated Model of the Local Vascular Component of Sustained Post-
exercise Vasodilation 
Exercise-induced oxidative stress has been removed from the list and other candidates 
have been added as possible exercise related factors. The working model now reflects the 
possible role of mast cell activation and the induction histidine decarboxylase as the 
primary mediator of local histamine formation in active skeletal muscle. The model also 
reflects our current understanding of the benefits that are associated activation of H1 and 
H2 histamine receptors. Inhibitors of local histamine formation are also included. From 
(74).  
  
Likewise, additional studies will be needed to determine if the acute changes in the 
expression of pro-angiogenic growth factors translate into long term changes in the 
microvascular phenotype. Data from the RNA sequencing analysis may open a 
“Pandora’s Box” with respect to other beneficial adaptations associated with exercise and 
histamine receptor activation, but this is yet to be seen. Once we have developed a clear 
picture of all of the mechanisms and adaptations associated with sustained post-exercise 
histaminergic vasodilation, we can develop physiological and pharmacological 
interventions targeting these pathways in order to improve vascular health.  
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APPENDIX A 
A. INFORMED CONSENT DOCUMENTS 
Chapter IV: Study 1 
TITLE: Exercise, histamine, receptors, and vascular function (Experiment 2) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD: July 25, 2012 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? When humans exercise, there is an increase in 
blood flow to the skeletal muscle. This increase in blood flow lasts for several hours after 
exercise but we do not understand all the mechanisms that cause this increase in blood 
flow or why it happens. The purpose of this study is to provide more information on what 
causes blood flow increases to occur after exercise. This protocol will explore whether 
Vitamin C, an antioxidant, reduces muscle blood flow responses after exercise. This topic 
is both clinically and scientific important. As such, this study is currently funded by The 
American Heart Association. You have been asked to participate in this study because 
you are a young healthy individual, who is recreationally active and free from any know 
cardiovascular disease.  
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What will happen in the study? 
Initial Visit  
1. You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately one hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
laboratory, and to read this form. Your height and weight and resting blood pressure 
will be measured, and you will be asked questions about your health history. You will 
be given a physical activity questionnaire, which will allow investigators to determine 
your activity level. The questionnaire will take approximately 15 minutes to 
complete. You will need to wear a t-shirt and refrain from eating for two hours prior 
to arrival.  
2. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the initial visit (and again during the study visit). For this test, 
you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center. 
3. During the initial visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm.  
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4. You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose threshold or 
specific value that participants need to achieve; participants simply need to do their 
best. While you exercise you will be wearing a mouth piece and nose clip. The total 
time for either test (including initial height and weight measurements, completion of 
the survey, placement of electrodes on your skin, warm-up, exercise, and cool-down) 
is approximately one hour.  
5. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness.  
6. This session will serve to familiarize you with the procedures to be used on the study 
days. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study days. 
Study Visits  
1. You will then return to Dr. Halliwill’s laboratory to participate in the three study 
visits, one of which will be between 7 and 10 days after the initial visit and the other 
will be between 7 and 10 days after that. These three testing session will take 
approximately 4 hours each.  
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2. You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine (for example, 
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for 12 
hours prior to the study and abstain from alcohol or exercise for 24 hours prior to the 
study. If you use oral contraceptives, you should take this when you normally do so.  
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visits.  
4. During the study visits, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a blood pressure cuff around your 
arm. The electrical activity of the muscle in your legs will also be monitored by 
electromyogram electrodes on the skin of the back and front of your leg.  
5. You will have one small flexible needle (“intravenous catheter”) placed into a vein 
near your elbow before the exercise protocol. The skin will be sterilized before this 
procedure. This catheter will remain in your skin throughout the three hour study. 
After the study, we will remove the flexible needle in your vein and a bandage will be 
placed over that area of skin.  
6. Before you exercise, we will administer a sterile solution containing Vitamin C 
through the intravenous catheter in two stages. First we will infuse a large dose over 
20 minutes. Then, we will continue to infuse a smaller dose over 1 hour while you 
perform one-legged knee extension exercise at a moderate intensity. You will only 
receive Vitamin C on two of the study visits. On the other study visit, you will receive 
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a similar volume of sterile solution, but it will not contain Vitamin C. On each visit, 
we will obtain a small blood sample before and after the solutions are administered. 
The total amount of blood obtained for this experiment is less than three tablespoons 
per visit. 
7. On one of the study visits you will be given a 540 mg dose of fexofenadine 
hydrochloride (brand name Allegra) and a 300 mg dose of ranitidine hydrochloride 
(brand name Zantac) in combination with the Vitamin C administration. 
8. During each study visit, you will perform one-legged knee extension exercise while 
seated on an exercise machine that measures how hard you are working. During these 
exercise sessions you will be asked to maintain a selected kicking rate for 60 minutes.  
9. Before and after the exercise session, a small probe (ultrasound Doppler probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
artery. The ultrasound Doppler probe uses ultrasound waves to measure blood flow in 
these arteries. The femoral artery will be studied for 10 minutes before you exercise 
and for two hours after you exercise.  
10. Before and after the exercise session, a small probe (laser-Dopper probe) will be 
placed on the skin of your left and right thigh (quadriceps). This probe uses a laser 
beam to non-invasively determine skin blood flow.  
11. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit or the study visit. 
Some examples of discomfort include back pain, shortness of breath, light-
headedness, and nausea.  
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How long will I be in the study?  
You will be in the study for four days (initial visit and three study visits). The initial visit 
will last one hour. Each study visit will last four hours. You will need to refrain from 
eating for two hours prior to the initial visit and each study visit.  
What are the risks of the study?  
There is some minor discomfort associated with the initial exercise test and exercise 
sessions, including temporary fatigue and muscle soreness. These sensations resolve 
within minutes after the test is completed. There is the possibility of some residual 
muscle soreness in the few days following the initial exercise test and each exercise 
session. Vitamin C has been infused intravenously without any unfavorable side effects 
into young and older healthy subjects as well as patients with chronic cardiovascular 
diseases. However administration of concentrated Vitamin C may cause irritation to the 
area local to the infusion. In order to reduce this risk we will dilute the infusion of 
Vitamin C in a saline (sterile water) solution. There are no known risks of intravenous 
administration of Vitamin C at the doses proposed for the present study. There are no 
known risks associated with the oral administration of fexofenadine (brand name Allegra) 
or ranitidine hydrochloride (brand name Zantac) at this time. The only risk associated 
with the laser-Doppler probe is that you may have some slight skin irritation (redness) to 
the adhesive tape used to hold the probe on your skin. There are no major risks associated 
with this device. 
The study may include risks that are unknown at this time. 
May I participate if I am pregnant or breast-feeding?  
This study may be harmful to an unborn or breast-fed child. There is not enough medical 
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information to know what the risks might be to a breast-fed infant or to an unborn child 
in a woman who takes part in this study. Breast-feeding mothers are not able to take part 
in this study. Women who can still become pregnant must have a negative pregnancy test 
no more than 24 hours prior to the day on which they might receive study drugs. If the 
pregnancy test is positive (meaning that you are pregnant), you will not be able to take 
part in the study. There is no cost for the pregnancy test. 
Are there benefits to taking part in this study?  
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. The results will not be reviewed by a 
physician. However, if results fall outside of the normal range, you will be informed that 
you should consult your primary care physician for additional medical evaluation. The 
purpose of this study is to provide more information on what causes blood flow increases 
to occur after exercise. In this pilot study we are exploring whether Vitamin C, an 
antioxidant, reduces muscle blood flow responses after exercise. Our hope is that by 
better understanding the physiology of how the human body responds to exercise, we will 
be better able to use exercise in the prevention and treatment of diseases such as 
hypertension (high blood pressure) and other forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study?  
This study is only being done to gather information. You may choose not to take part in 
this study.  
What are the costs of tests and procedures?  
You will not pay for any tests or procedures that are done just for this research study. 
You will get $150 for participating in this study. This money is for the inconvenience and 
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time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $10 per hour that you 
complete.  
Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
346-5425. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study.  
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury.  
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If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel    Office of Human Subjects Compliance 
Office of the President   5237 University of Oregon 
1226 University of Oregon   Eugene, OR 97403-5237 
Eugene, OR 97403-1226   (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area.  
The Office for Responsible Conduct of Research and/or authorized representatives of the 
Food and Drug Administration (FDA) or National Institute of Health (NIH) may need to 
review records of individual subjects. As a result, they may see your name, but they are 
bound by rules of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
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will be destroyed when study results are published or 24 months after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study.  
If you have questions regarding your rights as a research subject, contact Office for 
Protection of Human Subjects, 5237 University of Oregon, Eugene, OR 97403, (541) 
346-2510. 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
 ______________________________________________ 
(Signature of Participant)     (Date) 
 
______________________________________________ 
(Printed Name of Participant)    (Date) 
 
 ______________________________________________ 
(Signature of Individual Obtaining Consent)  (Date) 
Chapter IV: Follow-up Study 
TITLE: Exercise, histamine, receptors, and vascular function (Experiment 2 - n-
acetylcysteine project) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
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This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? When humans exercise, there is an increase in 
blood flow to the skeletal muscle. This increase in blood flow lasts for several hours after 
exercise but we do not understand all the mechanisms that cause this increase in blood 
flow or why it happens. The purpose of this study is to provide more information on what 
causes blood flow increases to occur after exercise. This protocol will explore whether n-
acetylcysteine (Acetadote), an antioxidant, reduces muscle blood flow responses after 
exercise. This topic is both clinically and scientific important. As such, this study is 
currently funded by the National Institutes of Health. You have been asked to participate 
in this study because you are a young healthy individual who is recreationally active, free 
from any know cardiovascular disease, and has no history of an allergic or anaphylactic 
reaction to N-acetylcysteine.  
What will happen in the study? 
Initial Visit  
7. You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately one hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
laboratory, and to read this form. Your height and weight and resting blood pressure 
will be measured, and you will be asked questions about your health history. You will 
be given a physical activity questionnaire, which will allow investigators to determine 
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your activity level. The questionnaire will take approximately 15 minutes to 
complete. You will need to wear a t-shirt and refrain from eating for two hours prior 
to arrival.  
8. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the initial visit (and again during the study visit). For this test, 
you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center. 
9. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. 
10. During the initial visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm.  
11. You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
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minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose threshold or 
specific value that participants need to achieve; participants simply need to do their 
best. While you exercise you will be wearing a mouth piece and nose clip. The total 
time for either test (including initial height and weight measurements, completion of 
the survey, placement of electrodes on your skin, warm-up, exercise, and cool-down) 
is approximately one hour.  
12. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness.  
13. This session will serve to familiarize you with the procedures to be used on the study 
days. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study days. 
Study Visits  
12. You will then return to Dr. Halliwill’s laboratory to participate in the two study visits, 
one of which will be between 7 and 10 days after the initial visit and the other will be 
between 7 and 10 days after that. These two testing session will take approximately 4 
hours each.  
13. You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine (for example, 
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for 12 
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hours prior to the study and abstain from alcohol or exercise for 24 hours prior to the 
study. If you use oral contraceptives, you should take this when you normally do so.  
14. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visits.  
15. During the study visits, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a blood pressure cuff around your 
arm. The electrical activity of the muscle in your legs will also be monitored by 
electromyogram electrodes on the skin of the back and front of your leg.  
16. You will have one small flexible needle (“intravenous catheter”) placed into a vein 
near your elbow before the exercise protocol. The skin will be sterilized before this 
procedure. This catheter will remain in your skin throughout the three hour study. 
After the study, we will remove the flexible needle in your vein and a bandage will be 
placed over that area of skin.  
17. Before you exercise, we will administer a sterile solution containing Acetadote 
through the intravenous catheter in two stages. First we will infuse a large dose over 
20 minutes. Then, we will continue to infuse a smaller dose over 1 hour while you 
perform one-legged knee extension exercise at a moderate intensity. You will only 
receive Acetadote on one of the study visits. On the other study visit, you will receive 
a similar volume of sterile solution, but it will not contain Acetadote. 
18. During each study visit, you will perform one-legged knee extension exercise while 
seated on an exercise machine that measures how hard you are working. During these 
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exercise sessions you will be asked to maintain a selected kicking rate for 60 minutes.  
19. Before and after the exercise session, a small probe (ultrasound Doppler probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
artery. The ultrasound Doppler probe uses ultrasound waves to measure blood flow in 
these arteries. The femoral artery will be studied for 10 minutes before you exercise 
and for two hours after you exercise.  
20. Before and after the exercise session, a small probe (laser-Doppler probe) will be 
placed on the skin of your left and right thigh (quadriceps). This probe uses a laser 
beam to non-invasively determine skin blood flow.  
21. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit or the study visit. 
Some examples of discomfort include back pain, shortness of breath, light-
headedness, and nausea.  
How long will I be in the study?  
You will be in the study for three days (initial visit and two study visits). The initial visit 
will last one hour. Each study visit will last four hours. You will need to refrain from 
eating for two hours prior to the initial visit and each study visit.  
What are the risks of the study?  
There is some minor discomfort associated with the initial exercise test and exercise 
sessions, including temporary fatigue and muscle soreness. These sensations resolve 
within minutes after the test is completed. There is the possibility of some residual 
muscle soreness in the few days following the initial exercise test and each exercise 
session. Intravenous administration of Acetadote at the doses used for the present study 
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does not usually produce any side effects. However, an allergic (or anaphylactic) reaction 
to this drug is possible. Symptoms of an allergic reaction include rash, itching, swelling, 
severe dizziness, and trouble breathing. The only risk associated with the laser-Doppler 
probe is that you may have some slight skin irritation (redness) to the adhesive tape used 
to hold the probe on your skin. There are no major risks associated with this device. 
Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is less 
than a tablespoon. The samples will be used for DNA analysis to determine which 
versions of specific genes you have related to the processing of histamine. There may 
exist potential risks of insurability, employability, and social discrimination if the results 
of individual DNA were to be made known to others. To safeguard against this risk, your 
DNA will be stored by an ID number only and your name or other personally identifiable 
information will not be included with any data shared with other investigators. We will 
not reveal any genetic data to your physicians, or any other health care provider. The 
genetic data, without any personally identifiable information, may be used in other 
research and by other parties studying the human genetics of histamine in collaboration 
with this study. Any data that may be published in scientific journals will not reveal the 
identity of the participants. Since the implications of our research are unknown, you will 
not be told the results, even if there might be some potential benefit to you. You have the 
right to withdraw your samples from research in the future should you decide to do so. If 
you decided not to participate in the DNA sampling aspects of this research protocol, it 
will not compromise your ability to participate in the other aspects of the research. 
Samples will be kept for five years. After the five years, the samples will be destroyed by 
discarding them into a biohazard waste container to be collected and destroyed by the 
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Environmental Hazard and Safety department at the University of Oregon. Any excess 
samples will be discarded and destroyed in the same manner. A new Federal law, called 
the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for 
health insurance companies, group health plans, and most employers to discriminate 
against you based on your genetic information. Be aware that this new Federal law does 
not protect you against genetic discrimination by companies that sell life insurance, 
disability insurance, or long-term care insurance. GINA also does not protect you against 
discrimination if you have already been diagnosed with the genetic disease being tested. 
Although we have made every effort to protect your identity, there is a small risk of loss 
of confidentiality. If the results of these studies of your genetic makeup were to be 
accidentally released, it might be possible that the information we will gather about you 
as part of this study could become available to an insurer or an employer, or a relative, or 
someone else outside the study. Even though there are discrimination protections in both 
Oregon law and Federal law, there is still a small chance that you could be harmed if a 
release occurred. 
The study may include risks that are unknown at this time. 
May I participate if I am pregnant or breast-feeding?  
This study may be harmful to an unborn or breast-fed child. There is not enough medical 
information to know what the risks might be to a breast-fed infant or to an unborn child 
in a woman who takes part in this study. Breast-feeding mothers are not able to take part 
in this study. Women who can still become pregnant must have a negative pregnancy test 
no more than 24 hours prior to the day on which they might receive study drugs. If the 
pregnancy test is positive (meaning that you are pregnant), you will not be able to take 
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part in the study. There is no cost for the pregnancy test. 
Are there benefits to taking part in this study?  
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. The results will not be reviewed by a 
physician. However, if results fall outside of the normal range, you will be informed that 
you should consult your primary care physician for additional medical evaluation. The 
purpose of this study is to provide more information on what causes blood flow increases 
to occur after exercise. In this pilot study we are exploring whether Acetadote, an 
antioxidant, reduces muscle blood flow responses after exercise. Our hope is that by 
better understanding the physiology of how the human body responds to exercise, we will 
be better able to use exercise in the prevention and treatment of diseases such as 
hypertension (high blood pressure) and other forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study?  
This study is only being done to gather information. You may choose not to take part in 
this study.  
What are the costs of tests and procedures?  
You will not pay for any tests or procedures that are done just for this research study. 
You will get $150 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
complete.  
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Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
346-5425. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury.  
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
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General Counsel     Research Compliance Services 
Office of the President    5237 University of Oregon 
1226 University of Oregon    Eugene, OR 97403-5237 
Eugene, OR 97403-1226    (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area.  
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 24 months after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
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which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study.  
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-
2510.Your signature indicates that you have read and understand the information 
provided above, that you willingly agree to participate, that you may withdraw your 
consent at any time and discontinue participation without penalty, that you will receive a 
copy of this form, and that you are not waiving any legal claims, rights or remedies. 
 
Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty.  
______________________________________________ 
(Initial of Participant)    (Date) 
If you would chose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you chose to abstain, and you will still be able to 
participate in all other aspects of the study. 
______________________________________________ 
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(Initial of Participant)    (Date) 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
 
______________________________________________ 
(Signature of Participant)     (Date) 
 
______________________________________________ 
(Signature of Individual Obtaining Consent)  (Date) 
 
Chapter V 
TITLE:  Exercise, histamine receptors, and vascular function (Experiment 1) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? 
When humans exercise, there is an increase in blood flow to the skeletal muscle. This 
increase in blood flow lasts for several hours after exercise but we do not understand all 
the mechanisms that cause this increase in blood flow or why it happens. The purpose of 
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this study is to provide more information on what causes blood flow increases to occur. 
This topic is both clinically and scientific important. As such, this study is currently 
funded by the National Institutes of Health. You have been asked to participate in this 
study because you are a young healthy individual, who is recreationally active and free 
from any know cardiovascular disease. 
What will happen in the study? 
Initial visit 
1) You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately one hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
laboratory, and to read this form. Your height and weight and resting blood pressure 
will be measured, and you will be asked questions about your health history. You will 
be given a physical activity questionnaire, which will allow investigators to determine 
your activity level. The questionnaire will take approximately 15 minutes to 
complete. You will need to wear a t-shirt and refrain from eating for two hours prior 
to arrival.  
2) If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the initial visit (and again during the study visit). For this test, 
you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center. 
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3) A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. 
4) During the initial visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm.  
5) You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose threshold or 
specific value that participants need to achieve; participants simply need to do their 
best. While you exercise you will be wearing a mouth piece and nose clip. The total 
time for either test (including initial height and weight measurements, completion of 
the survey, placement of electrodes on your skin, warm-up, exercise, and cool-down) 
is approximately one hour.  
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6) You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness.  
7) This session will serve to familiarize you with the procedures to be used on the study 
days. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study day. 
Study visit 
1) You will then return to Dr. Halliwill’s laboratory to participate in one study visit. This 
testing session will take approximately five hours.  
2) You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine (for example, 
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for 12 
hours prior to the study and abstain from alcohol or exercise for 24 hours prior to the 
study. If you use oral contraceptives, you should take this when you normally do so.  
3) If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visits.  
4) During the study visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a blood pressure cuff around your 
arm.  
5) You will undergo the following procedures: 
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  Microdialysis fibers in muscle: You will have 4 small probes (these are called 
“microdialysis fibers”) placed into the vastus lateralus (outer thigh). First, the area 
of skin where the probes will enter and exit will be numbed with a local anesthetic 
(lidocaine/xylocaine with epinephrine). Then a small needle will be placed 
through the skin and through the muscle, exiting back out about 2-3 inches from 
where it entered your skin and muscle. The small probe will be passed through the 
needle, and then the needle will be withdrawn, leaving the small probe passing 
through your muscle. This process of inserting a small needle through the skin 
and muscle to place a probe will be repeated 4 times, once for each of the probes 
that are placed. The probes will be separated by about 1 inch. These will remain 
in place throughout the rest of the study. There may be some discomfort during 
the insertion of the small probes into your muscle. We will use a local anesthetic 
to numb skin where the probes will be inserted to minimize this discomfort, but 
you may feel pressure or a dull ache in the muscle as the needle moves through 
the muscle. The infusions through the fiber should not be painful, and there 
should only be minor swelling at the sites. We will put small doses of several 
drugs through the small probes in your muscle. The drugs you will receive include 
the following:  
Microdialysis infusions: We will put small doses of several drugs through the 
small probes in your muscle. The drugs you may receive include the following: 
a) Pyrilamine (a common ingredient in over the counter cold remedies). This 
drug blocks the effects of histamine and will prevent blood vessels in the 
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muscle from opening up if histamine is present. You should not feel anything 
when this drug infuses into your muscle. 
b) Cimetidine (brand name Tagamet). This drug blocks the effects of histamine 
and will prevent blood vessels in the muscle from opening up if histamine is 
present. You should not feel anything when this drug infuses into your 
muscle. 
c) Ethanol alcohol. This is used to determine how much blood flow muscle 
receives. You should not feel anything when this drug is infused into your 
muscle. 
d) Alpha-fluoromethylhistidine. This drug prevents your body from producing 
histamine in the local area around the probe. You should not feel anything 
when this drug infuses into your muscle. 
e) Histamine. This substance is naturally produced by your body and will cause 
blood vessels to open in the local area of muscles around the probe. You 
should not feel anything when this drugs is infused into your muscle. 
f) Compound 48/80. This is a substance that releases histamine, which is 
naturally produced by your body, which will cause blood vessels in that local 
area of muscles to open. You should not feel anything when this drug infuses 
into your muscles. 
g) Radioactive nuclide. Tritium is a radioactive form of hydrogen (known as a 
radioactive nuclide) that is produced naturally in the upper atmosphere or 
produced commercially for various uses. In this study, a small quantity of 
tritium will be infused through the microdialysis probe. This is being done to 
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assess the function of the microdialysis probes. You should not feel anything 
when this drug infuses into your muscle. Some of the tritium will be absorbed 
by your body and so you will be exposed to some radiation. This radiation 
exposure is not necessary for your medical care and is for research purposes 
only. The risk associated with this exposure is described below. 
6) During the study visit, you will perform one-legged knee extension exercise while 
seated on an exercise machine that measures how hard you are working. During this 
exercise session you will be asked to maintain a selected kicking rate for 60 minutes. 
The microdialysis fibers will be in place while you exercise but should not cause any 
discomfort during exercise. 
7) Before and after the exercise session, a small probe (ultrasound Doppler probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
artery. The ultrasound Doppler probe uses ultrasound waves to measure blood flow in 
these arteries. The femoral artery will be studied for 10 minutes before you exercise 
and for two hours after you exercise. 
8) At the end of the study visit, the fibers will be withdrawn from your leg and a sterile 
dressing will be applied. Any swelling or redness after the study should be gone a few 
hours after completion of the study, but you may feel some muscle soreness for 
several days. You will be given some ibuprofen (e.g. Advil or Motrin) to relieve some 
of the initial soreness. Although the small probes are sterile, there is a slight risk of 
infection at the sites where the probes were placed. You will be instructed on how to 
keep the area clean for a day or two following the study and will need to inform the 
researchers immediately if you have any redness or swelling in the area.  
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9) You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit or the study visit. 
Some examples of discomfort include back pain, shortness of breath, light-
headedness, and nausea.  
How long will I be in the study? 
You will be in the study for 2 days (initial visit and study visit). The initial visit will last 
one hour. The study visit will last five hours. You will need to refrain from eating for two 
hours prior to the initial visit and the study visit. 
What are the risks of the study? 
1. Microdialysis: There may be some discomfort during the insertion of the small probes 
into your muscle. We will use a local anesthetic to numb skin where the probes will 
be inserted to minimize this discomfort, but you may feel pressure or a dull ache in 
the muscle as the needle moves through the muscle. The infusions through the fiber 
should not be painful, and there should only be minor swelling at the sites. At the end 
of the study, the fibers will be withdrawn and a sterile dressing will be applied. Any 
swelling or redness after the study should be gone a few hours after completion of the 
study, but you may feel some muscle soreness for several days. You will be given 
some ibuprofen (e.g. Advil or Motrin) to relieve some of the initial soreness. 
Although the small probes are sterile, there is a slight risk of infection at the sites 
where the probes were placed. You will be instructed on how to keep the area clean 
for a day or two following the study and will need to inform the researchers 
immediately if you have any redness or swelling in the area. The researchers will also 
ask you to return to the lab the day after the study visit so they can see how the sites 
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are healing. 
2. Infusions: We will be infusing very small doses of each drug and only into a very 
small area of your muscle or skin. You will not have any systemic (whole body) 
effects of these drugs in the doses given in this study, unless you have an allergic 
reaction. There is a minimal risk that you are allergic to one of the drugs being 
infused during this study; however, an allergic reaction to the drug could include 
changes in blood pressure and difficulty breathing. Symptoms of an allergic reaction 
include: rash, itching, swelling, severe dizziness and trouble breathing. 
3. Radioactive nuclide: This research study involves exposure to radiation from tritium, 
a radioactive label used to assess the function of the microdialysis probes. This 
radiation exposure is not necessary for your medical care and is for research purposes 
only. The total amount of radiation that you will receive in this study is equivalent to 
a uniform whole body exposure of less than 1 day of exposure to natural background 
radiation. For comparison, the amount of radiation you would receive from a chest X-
ray is equivalent to 5 days of exposure and the amount of radiation you would receive 
from a dental X-ray is equivalent to 11 days of exposure. This use involves minimal 
risk and is necessary to obtain the research information desired.  
4. Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is 
less than a tablespoon. The samples will be used for DNA analysis to determine 
which versions of specific genes you have related to the processing of histamine. 
There may exist potential risks of insurability, employability, and social 
discrimination if the results of individual DNA were to be made known to others. To 
safeguard against this risk, your DNA will be stored by an ID number only and your 
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name or other personally identifiable information will not be included with any data 
shared with other investigators. We will not reveal any genetic data to your 
physicians, or any other health care provider. The genetic data, without any 
personally identifiable information, may be used in other research and by other 
parties studying the human genetics of histamine in collaboration with this study. Any 
data that may be published in scientific journals will not reveal the identity of the 
participants. Since the implications of our research are unknown, you will not be told 
the results, even if there might be some potential benefit to you. You have the right to 
withdraw your samples from research in the future should you decide to do so. If you 
decided not to participate in the DNA sampling aspects of this research protocol, it 
will not compromise your ability to participate in the other aspects of the research. 
Samples will be kept for five years. After the five years, the samples will be 
destroyed by discarding them into a biohazard waste container to be collected and 
destroyed by the Environmental Hazard and Safety department at the University of 
Oregon. Any excess samples will be discarded and destroyed in the same manner. A 
new Federal law, called the Genetic Information Nondiscrimination Act (GINA), 
generally makes it illegal for health insurance companies, group health plans, and 
most employers to discriminate against you based on your genetic information. Be 
aware that this new Federal law does not protect you against genetic discrimination 
by companies that sell life insurance, disability insurance, or long-term care 
insurance. GINA also does not protect you against discrimination if you have already 
been diagnosed with the genetic disease being tested. Although we have made every 
effort to protect your identity, there is a small risk of loss of confidentiality. If the 
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results of these studies of your genetic makeup were to be accidentally released, it 
might be possible that the information we will gather about you as part of this study 
could become available to an insurer or an employer, or a relative, or someone else 
outside the study. Even though there are discrimination protections in both Oregon 
law and Federal law, there is still a small chance that you could be harmed if a release 
occurred. 
5. The study may include risks that are unknown at this time. 
May I participate if I am pregnant or breast-feeding? 
This study may be harmful to an unborn or breast-fed child. There is not enough medical 
information to know what the risks might be to a breast-fed infant or to an unborn child 
in a woman who takes part in this study. Breast-feeding mothers are not able to take part 
in this study. Women who can still become pregnant must have a negative pregnancy test 
no more than 24 hours before taking part in the study visit. If the pregnancy test is 
positive (meaning that you are pregnant), you will not be able to take part in the study. 
There is no cost for the pregnancy test. 
Are there benefits to taking part in this study? 
This study will not make your health better. Fluid samples collected from microdialysis 
are not being collected for diagnostic purposes. The results will not be reviewed by a 
physician and no action will be taken if a laboratory result falls outside of the normal 
range. This study will help researchers understand the factors that control blood flow 
during recovery from exercise. Our hope is that by better understanding the physiology of 
how the human body responds to exercise, we will be better able to use exercise in the 
     
 163
prevention and treatment of diseases such as hypertension (high blood pressure) and other 
forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information. You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this research 
study. You will get $105 for participating in this study. This money is for the 
inconvenience and time you spent in this study. If you start the study but stop before the 
study has ended, the amount of money you receive will be pro-rated at a rate of $15 per 
hour of the study you complete.  
Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
346-5425. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
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The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury.  
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel     Research Compliance Services 
Office of the President    5237 University of Oregon 
1226 University of Oregon    Eugene, OR 97403-5237 
Eugene, OR 97403-1226    (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
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number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area.  
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 24 months after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study.  
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services,. 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
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Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty.  
______________________________________________ 
(Initial of Participant)    (Date) 
If you would chose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you chose to abstain, and you will still be able to 
participate in all other aspects of the study. 
______________________________________________ 
(Initial of Participant)    (Date) 
 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
 
______________________________________________ 
(Signature of Participant)     (Date) 
 
______________________________________________ 
(Signature of Individual Obtaining Consent)  (Date) 
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Chapter VI 
TITLE: Exercise, histamine, receptors, and vascular function (Experiment 6) 
 
INVESTIGATOR: Dr. John Halliwill, Dr. Hans Dreyer, and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? The purpose of the current study is to examine 
the cellular changes that occur in skeletal muscle following aerobic exercise. In 
particular, we are interested in whether or not activation of histamine-receptor in 
response to exercise promotes the generation of certain cellular factors that eventually 
lead to the growth of new blood vessels within the skeletal muscle. Specifically, this 
research study is investigating the effects of a single bout of exercise on certain factors 
that are known to influence the growth of new blood vessels, and whether they are 
affected by drugs used to block histamine receptors. For this study, exercise will be 
performed with the thigh muscles of just one leg. We anticipate that 40 individuals will 
participate in this research study. This topic is both clinically and scientific important. As 
such, this study is currently funded by the National Institutes of Health. You have been 
asked to participate in this study because you are a young healthy individual, who is 
recreationally active and free from any know cardiovascular disease.  
What will happen in the study? 
Initial Visit 
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1. You will arrive at Dr. Dreyer’s laboratory on the Second Floor of the Center for 
Medical Education and Research (CMER Building) for an initial visit. This initial 
visit will take approximately one hour. 
2. You will meet with one of the investigators of the study to discuss the project, to see 
the laboratory, and to read this form. Your height and weight and resting blood 
pressure will be measured, and you will be asked questions about your health history. 
You will be given a physical activity questionnaire, which will allow investigators to 
determine your activity level. The questionnaire will take approximately 15 minutes 
to complete. You will need to refrain from consuming caffeine, medications or 
vitamins in the 12 hours prior to the study and refrain from exercise or alcohol for 24 
hours prior to the study. You will need to wear a t-shirt, shorts, and refrain from 
eating at least two hours prior to arrival.  
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the initial visit (and again during the study visit). For this test, 
you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center.  
4. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. 
5. During the initial visit, your heart rate will be monitored by electrocardiogram 
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electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm.  
6. You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose thresh  or specific 
value that participants need to achieve; participants simply need to do their best. The 
total time for either test (including initial height and weight measurements, 
completion of the survey, placement of electrodes on your skin, warm-up, exercise, 
and cool-down) is approximately one hour.  
7. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness.  
8. This session will serve to familiarize you with the procedures to be used on the study 
visit. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study visit.  
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Study Visit  
1. You will then return to Dr. Dreyer’s laboratory to participate in the following 
protocol, which will be several days after the initial visit. This study visit will take 
approximately 5 hours.  
2. You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine, (for 
example, coffee, tea, Coke, RedBull) or medications (except oral contraceptives) for 
24 hours prior to the study and will need to refrain from alcohol or exercise for 24 
hours prior to the study. If you take oral contraceptives, you should take them when 
you normally would. If you are a women who can still become pregnant you will be 
asked to undergo a pregnancy test before the study. 
3. During the study visits, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a women, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a cuff placed on your upper arm. 
The electrical activity of the muscle in your legs will also be monitored by 
electromyogram electrodes placed on the skin of the back and front of your legs. 
Before and after the exercise session, a small probe (Doppler ultrasound probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
aretery. The ultrasound probe uses sound waves to meaure blood flow in your femoral 
artery. We will take periodic measurements before exercise and for the three hours of 
exercise recovery. 
4. You will have one small flexible needle (“intravenous catheter”) placed into a vein 
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near your elbow before the exercise protocol. The skin will be sterilized before this 
procedure. The catheter will remain in your skin throughout the three hour study. 
After the study, we will remove the flexible needle in your vein and a bandage will be 
placed over that area of skin. The catheter will be used to obtain samples of your 
blood. The amount that will be obtained is equal to about 6 tablespoons. 
5. We will take one muscle biopsies from your non-dominant leg. This biopsy will be 
performed through a single incision and involves taking a small piece of muscle from 
your leg. First, a small patch of hair is removed (if needed) from your thigh and the 
skin is cleaned and sterilized. Next, the skin and tissue below are injected with a local 
anesthetic (numbing medicine) to eliminate pain. This medicine is similar to what 
dentists use to numb your mouth. After your leg is numb we will make a small 
incision about the size of this dash “____” at approximately mid-thigh. Through this 
incision a needle about the size of the letter “O” will be advanced into the muscle. A 
single piece of thigh muscle will then be removed with the needle, the skin closed 
with a single stitch and light dressing will be applied.  
6.  If this box is checked, you will be given a 540 mg dose of fexofenadine 
hydrochloride (brand name Allegra) and a 300 mg dose of ranitidine hydrochloride 
(brand name Zantac) with a glass or water after the first biopsy. If the box is not 
checked, you will not receive these drugs.  
7. You will be asked to perform one-legged knee extension exercise you’re your 
dominant leg while seated on an exercise machine that measures how hard you are 
working. During these exercise sessions you will be asked maintain a selected kicking 
rate for 60 minutes.  
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8. Next, we will take two muscle biopsies from your dominant leg. Each biopsy will be 
performed through a single incision and involves taking a small piece of muscle from 
your leg. First, a small patch of hair is removed (if needed) from your thigh and the 
skin is cleaned and sterilized. Next, the skin and tissue below are injected with a local 
anesthetic (numbing medicine) to eliminate pain. This medicine is similar to what 
dentists use to numb your mouth. After your leg is numb we will make a small 
incision about the size of this dash “____” at approximately mid-thigh. Through this 
incision a needle about the size of the letter “O” will be advanced into the muscle. A 
single piece of thigh muscle will then be removed with the needle, the skin will be 
temporarily closed with a bandage between muscle biopsies and light dressing will be 
applied. One sample will be obtained immediately after you stop exercise (or the end 
of seated rest if you did not exercise). The other biopsy sample will be obtained 3 
hours later from the same incision. Following the second biopsy from the same site 
we will close the incision site with a single stitch and dressing will be applied. 
9. After the experiment you will go over things that you must do to help minimize the 
risk of infection. We will also provide a hardcopy of these instructions for you to take 
home. The handout is titled “Things to Remember After Muscle Biopsy,” and must 
be taken seriously. We will also periodically contact you to see how the biopsy site is 
doing.  
10. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the study visit.  
Follow-up Visits 
We ask that you return to the Dreyer lab (for 20 minutes) 48 hours after the experiment to 
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allow us to inspect the biopsy site. You will return again at 7 days after the experiment to 
have your sutures removed and the biopsy site inspected. This will take about 20 minutes.  
How long will I be in the study?  
You may be in the study for up to 12 days. The initial visit will last for about 1 hour. The 
study visit will last 5 hours. Prior to the initial visit and study visit, you will need to 
refrain from eating for two hours, and refrain from consuming caffeine or medications for 
12 hours and abstain from alcohol or exercise for 24 hours. You must also refrain from 
exercise 72 hours after the study visit. Following the study visit you will return two more 
times for follow-up visits. The first follow-up visit will be 48 hours after the study visit 
and the second follow-up visit will be 7 days after the study visit. Each of the follow-up 
visits will take approximately 20 minutes.  
What are the risks of the study?  
1. There is some minor discomfort associated with the initial exercise test and exercise 
sessions, including temporary fatigue and muscle soreness. These sensations resolve 
within minutes after the test is completed. There is the possibility of some residual 
muscle soreness in the few days following the initial exercise test and each exercise 
session. There are no known risks associated with the oral administration of 
fexofenadine (brand name Allegra) or ranitidine (brand name Zantac) at this time.  
2. The muscle biopsy carries the potential risk of pain, bleeding, bruising, infection, and 
scar formation at the site of the biopsy. Careful sterile technique should reduce the 
likelihood of any of these complications. The risk of bleeding is about 0.2%; the risk 
of bruising or a blue-and-black mark is 1.4%; and infection is so small that the precise 
number is unknown. After the study you have a 50% chance of experiencing soreness 
     
 174
at the site of biopsy for 24 to 48 hours. However, over the counter medications such 
as Motrin or Advil are sufficient to control such discomfort. Additionally, you may 
experience numbness around the area of the biopsy site (2x2 inches), which will 
likely go away with time (sensation returns) but in very rare instances may never 
return. The risk that you experience numbness is less than 0.5% and the risk that the 
numbness never goes away is much less. The scar will be approximately as long as 
the dash “____”.  
3. Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is 
less than a tablespoon. The samples will be used for DNA analysis to determine 
which versions of specific genes you have related to the processing of histamine. 
There may exist potential risks of insurability, employability, and social 
discrimination if the results of individual DNA were to be made known to others. To 
safeguard against this risk, your DNA will be stored by an ID number only and your 
name or other personally identifiable information will not be included with any data 
shared with other investigators. We will not reveal any genetic data to your 
physicians, or any other health care provider. The genetic data, without any 
personally identifiable information, may be used in other research and by other 
parties studying the human genetics of histamine in collaboration with this study. Any 
data that may be published in scientific journals will not reveal the identity of the 
participants. Since the implications of our research are unknown, you will not be told 
the results, even if there might be some potential benefit to you. You have the right to 
withdraw your samples from research in the future should you decide to do so. If you 
decided not to participate in the DNA sampling aspects of this research protocol, it 
     
 175
will not compromise your ability to participate in the other aspects of the research. 
Samples will be kept for five years. After the five years, the samples will be 
destroyed by discarding them into a biohazard waste container to be collected and 
destroyed by the Environmental Hazard and Safety department at the University of 
Oregon. Any excess samples will be discarded and destroyed in the same manner. A 
new Federal law, called the Genetic Information Nondiscrimination Act (GINA), 
generally makes it illegal for health insurance companies, group health plans, and 
most employers to discriminate against you based on your genetic information. Be 
aware that this new Federal law does not protect you against genetic discrimination 
by companies that sell life insurance, disability insurance, or long-term care 
insurance. GINA also does not protect you against discrimination if you have already 
been diagnosed with the genetic disease being tested. Although we have made every 
effort to protect your identity, there is a small risk of loss of confidentiality. If the 
results of these studies of your genetic makeup were to be accidentally released, it 
might be possible that the information we will gather about you as part of this study 
could become available to an insurer or an employer, or a relative, or someone else 
outside the study. Even though there are discrimination protections in both Oregon 
law and Federal law, there is still a small chance that you could be harmed if a release 
occurred. 
4. The study may include risks that are unknown at this time. 
May I participate if I am pregnant or breast-feeding?  
Women who are pregnant or breastfeeding may not participate in this study. Women who 
can still become pregnant must have a negative pregnancy test no more than 24 hours 
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prior to the day on which they might receive study drugs. If the pregnancy test is positive 
(meaning that you are pregnant), you will not be able to take part in the study. There is no 
cost for the pregnancy test. 
Are there benefits to taking part in this study?  
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. The results will not be reviewed by a 
physician. However, if results fall outside of the normal range, you will be informed that 
you should consult your primary care physician for additional medical evaluation.  
What other choices do I have if I don’t take part in this study?  
This study is only being done to gather information. You may choose not to take part in 
this study.  
What are the costs of tests and procedures?  
You will not pay for any tests or procedures that are done just for this research study. 
You will get $105 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
complete.  
Who can answer my questions?  
You may talk to Dr. Hans Dreyer at any time about any questions you may have about 
this study. You may contact Dr. Dreyer by calling the Department of Human Physiology 
at (541) 346-5775. You can also reach Dr. Dreyer through email suing the following 
address hcdreyer@uoregon.edu. You may also talk to Dr. John Halliwill at any time 
about any question you have on this study. You may contact Dr. Halliwill by calling the 
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Department of Human Physiology at (541) 346-5425.  
What are my rights if I take part in this study?  
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon.  
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study.  
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury.  
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers:  
General Counsel      Research Compliance Services 
Office of the President     5237 University of Oregon  
1226 University of Oregon     Eugene, OR 97403-5237  
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Eugene, OR 97403-1226     (541) 346-2510 
(541) 346-3082  
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality?  
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area.  
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others.  
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 24 months after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
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which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study.  
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty.  
______________________________________________ 
(Initial of Participant)    (Date) 
If you would chose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you chose to abstain, and you will still be able to 
participate in all other aspects of the study. 
______________________________________________ 
(Initial of Participant)    (Date) 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
______________________________________________ 
(Signature of Participant)     (Date) 
______________________________________________ 
(Signature of Individual Obtaining Consent)  (Date) 
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APPENDIX B 
 ASSAY STANDARD OPERATING PROCEDURES 
Tryptase ELISA 
1. Determine wells for diluted calibrator, blank and sample. Prepare 7 wells for 
calibrator, 1 well for blank. Add 100 µL each of dilutions of calibrator (read Reagent 
Preparation), blank and samples (50ul) into the appropriate wells. Cover with the 
Plate sealer. Incubate for 2 hours at 37°C.  
2. Remove the liquid of each well, don’t wash.  
3. Add 100 µL of Detection Reagent A working solution to each well. Incubate for 1 
hour at 37°C after covering it with the Plate sealer.  
4. Aspirate the solution and wash with 350 µL of 1X Wash Solution to each well using a 
squirt bottle, multi-channel pipette, manifold dispenser or autowasher, and let it sit for 
1~2 minutes. Remove the remaining liquid from all wells completely by snapping the 
plate onto absorbent paper. Repeat 3 times. After the last wash, remove any 
remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against 
absorbent paper.  
5. Add 100 µL of Detection Reagent B working solution to each well. Incubate for 30 
minutes at 37°C after covering it with the Plate sealer.  
6. Repeat the aspiration/wash process for five times as conducted in step 4.  
7. Add 90 µL of Substrate Solution to each well. Cover with a new Plate sealer. 
Incubate for 15-25 minutes at 37°C (Don’t exceed 30 minutes). Protect from light. 
The liquid will turn blue by the addition of Substrate Solution.  
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8. Add 50 µL of Stop Solution to each well. The liquid will turn yellow by the addition 
of Stop solution. Mix the liquid by tapping the side of the plate. If color change does 
not appear uniform, gently tap the plate to ensure thorough mixing.  
9. Remove any drop of water and fingerprint on the bottom of the plate and confirm 
there is no bubble on the surface of the liquid. Then, run the microplate reader and 
conduct measurement at 450 nm immediately 
 
Histamine ELISA 
Sample preparation and acylation 
1. Pipette 25 µL of standards, 25 µL of controls, 25 µL of plasma samples, 10 µL of 
urine samples, or 50 µL of supernatant from the release test* into the respective wells 
of the Reaction Plate. 
2. Add 25 µL of Acylation Buffer to all wells. 
3. Add 25 µL of Acylation Reagent to all wells. 
4. Incubate for 45 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
5. Add 200 µL of distilled water to all wells. 
6. Incubate for 15 min. at RT (20-25°C) on a shaker (approx. 600 rpm). 
2. Take 25 µL of the prepared standards, controls and samples for the Histamine ELISA 
Histamine ELISA 
1. Pipette 25 µL of the acylated standards, controls and samples into the appropriate 
wells of the Histamine Microtiter Strips. 
2. Pipette 100 µL of the Histamine Antiserum into all wells and cover plate with 
Adhesive Foil. 
3. Incubate for 3 hours at RT (20-25°C) on a shaker (approx. 600 rpm). 
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4. Alternatively: shake the Histamine Microtiter Strips briefly by hand and incubate for 
15 – 20 hours at 2 – 8 °C. 
5. Remove the foil. Discard or aspirate the contents of the wells and wash each well 4 
times thoroughly with 300 µL Wash Buffer. Blot dry by tapping the inverted plate on 
absorbent material. 
6. Pipette 100 µL of the Enzyme Conjugate into all wells. 
7. Incubate for 30 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
8. Discard or aspirate the contents of the wells and wash each well 4 times thoroughly 
with 300 µL Wash Buffer. Blot dry by tapping the inverted plate on absorbent 
material. 
9. Pipette 100 µL of the Substrate into all wells and incubate for 20-30 min at RT (20-
25°C) on a shaker (approx. 600 rpm). Avoid exposure to direct sun light! 
10. Add 100 µL of the Stop Solution to each well and shake the microtiter plate to ensure 
a homogeneous distribution of the solution. 
11. Read the absorbance of the solution in the wells within 10 minutes, using a 
microplate reader set to 450 nm with a reference wavelength between 620 nm and 
650 nm. 
Ethanol Assay 
1. Make EtOH Standards (use 2ml microtubes): 
2. Make Sol’n A (NAD/EtOH Buffer) – light sensitive -> Falcon Tube wrapped in alum 
foil. Note - check pH of EtOH Buffer before each use – adjust with NaOH or HCl as 
appropriate. 50 µL NAD Sol’n per 10 mL EtOH Buffer (need 20 mL Sol’n A for 
entire plate). 
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3. Put 150 µL of Sol’n A into the appropriate wells (NUNC 96-well black plates, Fisher 
# 12-566-09). 
4. Add 2 µL of Standards / Samples to wells in duplicate by pipetting just below the 
fluid surface of Sol’n A (duplicates in horizontal config, consecutive samples in 
vertical config). 
5. Add 10 µL Solution B (ADH) to each well (use either multichannel or repeat pipette) 
6. Cover with a plate sealer and incubate for 1 Hr in plate wrapped with foil. 
7. Read on Biotek Plate Reader (Synergy HT) using “EtOH Protocol” Excitation  = 360 
Emission = 460 
Quant-iT Total Protein Assay 
1. Make working solution by diluting Quant-iT protein reagen 1:200 in Quant-iT protein 
Buffer 
2. Load 200 µL of the working solution to each well of the microplate. 
3. Add 10 µL of each BSA standard to separate wells and mix well. 
4. Add 1 - 20 µL of each unknown protein sample to separate wells and mix well. 
5. Measure fluorescence using a microplate reader (excitation 470, emission 570). 
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APPENDIX CC. 
 REAL-TIME POLYMERASE CHAIN REACTION 
Subsequent to RNA isolation detailed in chapter VI, the concentration of RNA 
was measured via fluorometry (Qubit fluorometer, Invitrogen, Carlsbad CA, USA). RNA 
was reverse transcribed to cDNA from 1 µg RNA using a real-time polymerase chain 
reaction system (CFX96, BIO-RAD, Hercules, CA, USA) and a commercially available 
cDNA synthesis mix (iScript™, BIO-RAD, Hercules, CA, USA). All cDNA samples 
were then stored at -80°C until analysis. mRNA expression levels were examined by 
analyzing cDNA via SYBR Green fluorescence (IQ SYBR Green Supermix; BIO-RAD, 
Hercules, CA, USA). Beacon design software was used to design oligonucleotide primers 
specific for the Bio-Rad CFX96 real-time polymerase chain reaction detection system 
and to our genes of interest. Each polymerase chain reaction was measured in triplicate 
and contained the following:12.5 µl SYBR Green, 9.5 µl of Diethylpyrocarbonate -
treated nuclease-free water, 0.5 µl of forward and reverse primers, and 2 ul cDNA 
template. cDNA was first denatured by an initial cycle at 95°C for 5 min. Thereafter, 50 
cycles of denaturing at 95°C for 10 sec and 30 sec of primer annealing at the optimized 
primer pair-annealing temperature were carried out. All cycles were followed by a melt 
curve analysis. All genes of interest were normalized to the housekeeping gene GAPDH. 
mRNA expression was presented as a fold change relative to the housekeeping gene 
using the Livak method (116). 
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